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ABSTRACT 
James E. Huckle: C2E2: An Orally Administered Radionuclide Decorporation Agent 
Under the direction of: Michael Jay 
 
The increasing threats of nuclear terrorism have made the development of medical 
countermeasures a priority for international security. Injectable formulations of 
diethylenetriaminepentaacetic acid (DTPA) have been approved by the FDA, however an 
oral formulation is more amenable in a situation involving mass casualties. The overall 
objective of this thesis is to synthesize and characterize the di-ethyl ester of DTPA, 
named C2E2, and assess the orally bioavailability and radionuclide decorporation 
efficacy. 
The first specific aim investigates the physiochemical properties of C2E2. The 
solubility, lipophilicity and pKa’s were determined. C2E2 was shown to have high 
aqueous solubility and lipophilicity was moderately increased over DTPA. The 
americium binding constant for C2E2 was also determined and shown to be higher than 
that of the plasma proteins, suggesting that C2E2 would retain the ability to chelate 
americium in the plasma despite having a lower coordination number than DTPA. 
Secondly, both the stability of C2E2 prior to absorption and within the plasma was 
investigated. Single dose pharmacokinetics in Sprague-Dawley rats demonstrated that 
C2E2 was the predominant form in plasma after administration along with lower levels of 
the mono-ester metabolite and DTPA. The oral bioavailability was determined as 29% in 
Sprague-Dawley rats compared to that of 5% for DTPA.
 iv 
The third aim evaluated both the toxicity and oral efficacy of C2E2 in rats and 
dogs. Oral dose-range finding toxicology studies were performed to identify no-
observed-adverse-effect-levels (NOAEL). Single and multiple dose decorporation 
efficiency of C2E2 was determined when administered 24 hours post-contamination in 
rats with an intramuscular wound model with 
241
Am–nitrate. A single dose decorporation 
efficiency study was performed in dogs with contamination of 
241
Am–nitrate via 
inhalation. 
Overall C2E2 was synthesized and shown to have improved oral absorption over 
DTPA and retained the ability to chelate americium from the plasma. Oral administration 
of C2E2 exhibited low toxicity, a simple metabolic pathway and enhanced 
241
Am 
decorporation over control. Based on this research this DTPA analog appears to be an 
effective orally-administered medical countermeasure for treating individuals 
contaminated with transuranic elements. 
 v 
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CHAPTER I 
 
INTRODUCTION 
 
1.1 The Hazards of Radioactivity 
The threat posed by radioactive materials is not new; naturally occurring isotopes, such as 
radium, continually expose us to low levels of radiation. In the United States the average 
background absorbed radiation dose is 360 mrem/y, which comes equally from both natural 
and manufactured sources
1
. Fortunately the consequences of background radiation are 
minimal as our cellular repair mechanisms are usually capable of responding to the effects of 
ionizing radiation. Therefore, chronic low-dose radiation is stochastic in nature, whereby 
some people may experience an effect from the exposure but the risk is low and cannot be 
attributed to radiation. Exposure to ionizing radiation at high-doses however leads to 
predictable effects that can be irreversible and often fatal. 
The existence of radioactivity was unknown until electrical discharges were first 
observed from Crooks tubes after application of a high voltage across the tubes. Thomson 
identified the light emitted from the gas as negatively charged particles which became known 
as electrons
2
. In 1895 Roentgen also working with cathode rays discovered that the 
florescence produced was penetrating radiation which he named X-rays
3
. In 1896 Henri 
Becquerel discovered that alpha particles, beta particles and gamma rays were released from 
uranium
4
. The same discovery was subsequently made by Marie Curie in 1898 with radon
 2 
and coined the term radioactivity
5
. The discovery of these new particles led to further 
investigations and in 1911 Rutherford identified the nucleus, making it possible to determine 
the mechanism of these particle emissions
6
. The discovery of the neutron in 1932
7
 by 
Chadwick while studying the beryllium nucleus completed the puzzle and major advances in 
nuclear research quickly followed: uranium fission and the possibility of releasing vast 
amounts of energy in 1939
8
, self-sustaining fission reactions in a reactor in 1942, explosion 
of nuclear fission devices in 1945, production of thermonuclear explosives and the first 
nuclear powered submarine in 1952
9
. Prior to the 1950s only naturally occurring 
radionuclides were generally available, however the investigations of Glenn Seaborg at the 
University of California, Berkeley spurred the discovery of ten new transuranic elements 
including plutonium, americium and curium
10
. In addition to the use of radioactivity for 
power and weapons, there are now hundreds of medical, industrial and academic 
applications
11
. The use of Technetium-99m generators within hospitals and the power of 
computers have revolutionized diagnostic imaging with techniques such as single-photon 
emission computed tomography (SPECT) and positron emission tomography (PET) in 
common use. Radiation therapy has treated countless cancer victims, including those with 
drug resistant tumors. The increase in use of radioactive isotopes however has resulted in a 
large supply of radioactive sources with millions distributed over the last fifty years, and 
hundreds of thousands are currently used and produced
12
. Even though there are hundreds of 
available radioisotopes, only seven are of particular concern with respect to nuclear terrorism 
due to their widespread use, radiotoxicity and long half-life: 
241
Am, 
242
Cf, 
137
Cs, 
60
Co, 
192
Ir, 
238
Pu and 
90
Sr
13
. 
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This widespread availability gives rise to potential terrorist threats, which since 
September 11, 2001 has become a national security priority
14
. The use of unconventional 
terrorist tactics such as the delivery of anthrax spores in mailboxes in New York, Washington 
and Florida during 2001
15
 illustrates the risk of attacks and there is an increased risk of 
further attacks that utilize biological, radiological or even nuclear weapons. The use of either 
radiological or nuclear weapons could result in significant numbers of individuals being 
exposed to ionizing radiation requiring urgent medical intervention. President Obama 
highlighted the importance of this threat in his first speech to the U.N. Security Council in 
New York, where he called nuclear terrorism one of the greatest threats to international 
security and stated that the consequences of such an attack would be enormous
16
. 
Terrorist acts could expose a population to radiation by contaminating food/water 
sources, placing radiation sources in a public location, detonating a radiological dispersal 
device (RDD, “dirty bomb”) or by attacking a nuclear power plant or storage facility. Finally 
there is also a possibility that a nuclear explosive device (atomic bomb) could be detonated 
which, in addition to causing major structural damage would also lead to mass contamination 
from radioactive “fallout”. Of these threats, the wide availability of radiological sources and 
ability to produce homemade bombs makes an RDD the most likely candidate for terrorists. 
An RDD is a device that causes dispersion of radioactive material without nuclear 
detonation. In 2013 there were 146 incidents confirmed in the Incident and Trafficking 
Database (ITDB), 6 of which were related to criminal activities, 47 involved loss and 95 
were unauthorized activities
17
. In addition, four of these incidents involved theft of 
International Atomic Energy Agency (IAEA) category 1-3 sources. (Sources are categorized 
from 1-5, where a category 1 source is the most dangerous with which an exposure time of a 
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couple of minutes could be fatal.) The loss of radioactive sources does not only occur 
overseas, for example nineteen tubes of 
137
Cs were stolen from a hospital in Greensboro, 
North Carolina and were never found
18
.  
The release of radioactivity can result in localized or whole-body exposure and both 
internal and external contamination with radioactive materials. Exposure to radioactivity 
occurs when radiation penetrates the body from an external source, whereas contamination 
occurs when material deposits on the surface of an object. In order to minimize exposure it is 
important to increase distance from the source, wear shielding and minimize the time of 
exposure.  
In the case of local exposures patients can often survive high absorbed doses
19
. 
Although burns and blistering may occur, the systemic manifestations are not as severe as at 
the local area of contamination. Patients should be treated against infection and given pain 
medication as required. The absorbed dose is measured in Grays (Gy) where one Gy is 
equivalent to one joule per kg. Whole body exposure is more lethal with exposure to doses 
above 2 Gy resulting in bone marrow suppression leading to hematopoietic syndrome. The 
associated reduction in lymphocyte count can be used to estimate the dose of radiation. Acute 
doses of 10 to 30 Gy cause GI damage due to the death of mucosal stem cells leading to rapid 
onset of nausea, vomiting and diarrhea. Following a latency period sepsis and electrolyte 
imbalances lead to death. At doses exceeding 30 Gy cardiovascular and central nervous 
system damage begins to occur with almost immediate nausea, vomiting, hypotension and 
convulsions and death may occur within several days
19
. As with local exposure there are 
limited treatment options. Amifostine has been FDA approved for patients undergoing 
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radiotherapy, however, it is only effective if given prophylactically and has numerous serious 
side effects
20
. Treatment of people exposed to radioactivity is thus mainly symptomatic.  
When a radioactive nucleus decays it emits ionizing radiation in the form of an -
particle, -particle, -rays, or a combination of these. Alpha particles consist of two protons 
and two neutrons. They can travel 2-3 cm in air, however they can only travel microns in 
tissue. They cannot penetrate paper, so are not an external hazard on skin, the outer layers of 
which are already dead. However, if ingested or inhaled alpha particles can cause serious 
damage to the adjacent tissues. Beta particles are high-energy electrons and can travel a 
meter in air and millimeters within tissue. They are an external hazard as they can penetrate 
the skin and can cause severe burns, if internalized they will also cause significant damage. 
Finally gamma rays are high-energy rays with short wavelengths that are very penetrating, 
having the ability to travel many centimeters through tissue
21
.  
Differences in tissue susceptibility to radiation were first identified by Bergonie and 
Tribondeau in 1906 who reported that immature, undifferentiated and actively dividing cells 
are more radiosensitive than those which are mature and are not actively dividing
22
. These 
differences are a result of the interactions between cells and ionizing radiation, which acts 
either directly or indirectly with cells. Direct interaction occurs when the cell’s 
macromolecules are hit by the ionizing radiation causing disruption to the whole cell, either 
leading to cell death or mutation of cellular DNA
23
. Direct hits can cause a wide range of 
cellular injury depending on the location of the damage. Generally the effects of ionization 
are not observed until higher doses of radiation are present causing cell replacement to 
cease
24
. Alternatively cellular damage can occur indirectly as radiation energy causes 
hydrolysis of cellular water leading to the formation of hydroxyl free radicals. Two hydroxyl 
 6 
ions can form unstable hydrogen peroxide resulting in the formation of a peroxide hydroxyl 
radical that can become stable by combining with organic compounds in the cell. The organic 
hydrogen peroxide can then interfere with essential enzymes leading to cell death.  
In addition to being exposed to penetrating radiation following a nuclear accident, 
some people are likely to become contaminated. External contamination of skin and clothes 
does not require special medical treatment; the contaminated items should be removed and 
contained to minimize the spread of activity. The patient can then wash the contaminated 
areas of skin with soap and water providing that there are no physical injuries. If the patient 
has not received a very high dose of external exposure and any medical emergencies, such as 
trauma, have been addressed, then the greatest concern is that of internal radiation 
contamination.   
 7 
1.2 Internalized Radionuclide Contamination 
There are four main routes by which internal contamination can occur (a) inhalation, 
(b) uptake via cuts, wounds, burns or contaminated shrapnel, (c) ingestion followed by oral 
absorption and (d) transdermal absorption. The risk of exposure to radioactive heavy metals 
via the last two routes is low due to poor oral and transdermal absorption. Accidental 
contaminations such as syringe pricks or puncture wounds can occur in industrial, hospital or 
research laboratory environments. After detonation of a nuclear device, inhalation of the 
radioactive plume and wound contamination from radioactive shrapnel are the most likely 
sources of internalized contamination.  
 There have been a number of radiological accidents leading to contamination. The 
Goiânia incident in Brazil during 1987 highlighted the dangers of unsecure nuclear 
materials
25
. A radiotherapy source was stolen from an abandoned hospital and sold to a local 
scrapyard. The source container was opened and the blue cesium-137 was passed among the 
owner’s family and friends. As members of the family began to fall ill, the contents were 
tested and found to be radioactive; ultimately 249 people had significant contamination on 
their body of which 129 also had internal contamination. There were four fatalities associated 
with the incident, all of whom worked at the scrapyard where the radioactive source became 
exposed. 
More recently in 2011 following a tsunami, three nuclear reactors at the Fukashima 
nuclear power plant in Japan underwent meltdown that led to the release of large quantities 
of iodine-131 and cesium-137 into the atmosphere resulting in the evacuation of 300,000 
people
26
. In addition in 2014 a leak occurred in a nuclear storage facility in New Mexico, 
USA causing contamination of 13 workers with americium and the release of americium and 
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plutonium into the atmosphere, though in this case the levels were deemed low enough to not 
require treatment
27
.  
The main focus of this doctoral research is the decontamination of americium and 
plutonium, which are -particle emitting radionuclides of the actinide series, with 
americium-241 being the radioisotope of primary interest. Each of these radionuclides has a 
unique biokinetic profile resulting in different patterns of tissue deposition. As such the 
disposition is also dependent on the route of contamination, the physio-chemical properties 
such as size and solubility of the ingested form, and the health status of the contaminated 
individual. Once internalized the tissues adjacent to the radionuclide are exposed to ionizing 
radiation until the contamination is removed either by excretion or treatment. The 
International Commission on Radiological Protection (ICRP) has summarized the 
distribution of americium and plutonium
28
. 
Plutonium-239 has a half-life of 24,000 years
29
 and is the primary fissile isotope of 
plutonium used in the production of nuclear weapons and is also one of the main isotopes 
used as fuel in nuclear reactors. Due to its widespread use, the biodistribution of plutonium 
has been extensively investigated. Once it leaves the blood 50 % of the material is deposited 
on bone surfaces, 30 % retained in the liver and only 20 % in other tissues. Removal of 
plutonium from the bone and liver occurs with half-lives of 8000 and 9 years, respectively
30
. 
Americium-241 is produced through the degradation of plutonium present in spent 
nuclear fuel. It is an alpha emitter with a 432-year half-life but also emits a small amount of 
-radiation. Due to its alpha emission it is found in smoke detectors making small quantities 
widely available. In the body americium exists only in the trivalent Am(III) oxidation state. It 
behaves in a similar fashion to plutonium, however it’s uptake and retention in the liver is 
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different with 50 % of the radionuclide depositing in the liver and 30 % on the bone. 
Americium clears from the liver faster than plutonium with a half-life of 2-3 years, however 
loss from the skeleton is no different
31
. Once the radionuclide is deposited in a tissue it may 
re-speciate by equilibrating with other ligands and metal ions present, redistributing via the 
blood stream to a secondary deposition site
32
. It is for this reason that the half-life of 
americium elimination from the liver begins to increase over time, as americium redistributes 
from its primary disposition sites to the liver. It is easy to see from the long biological half-
lives that internalized americium and plutonium can be expected to continue to irradiate the 
surrounding tissues for the remaining life of a contaminated individual in the absence of 
treatment to remove it. 
The distribution and elimination kinetics of americium influence many aspects of 
treatment. Although the rate of tissue distribution is dependent on the site of contamination 
and the solubility of the internalized form, once solubilized and absorbed into the plasma the 
distribution and elimination kinetics are predictable and independent on the route of 
contamination. Therefore, though unlikely to occur, IV 
241
Am administration has proved 
useful for investigating the fate of 
241
Am after uptake from contamination sites. Radionuclide 
contamination is most likely to occur through either inhalation or a contaminated wound site. 
Thus during efficacy studies both inhalation and IM contamination models are more suitable 
as they mimic the continuous uptake of radionuclide into the plasma. 
Upon entry into the plasma, americium can associate with a variety of plasma 
proteins and low molecular weight ligands. There is little difference between the plasma 
concentrations of electrolytes and plasma proteins across species and although there is a large 
change in body size, the plasma volume remains fairly consistent
33
 (Table 1.1). The main 
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difference between species is the plasma iron concentration and subsequently the transferrin 
saturation. In human plasma americium is predominantly associated with transferrin, with the 
remainder associated with other proteins such as albumin, - and -globulins or low 
molecular weight ligands
34
. The stability constants for low molecular weight ligand 
complexes of americium have been determined
35
 (Table 1.2). Based on the stability constants 
and concentrations in plasma, citrate and carbonate are likely to be the predominant low 
molecular weight species. Any americium present as a citrate complex is ultrafiltratable by 
the kidneys and will be excreted in the urine. 
The rate of radionuclide plasma clearance is largely dependent on its ability to form 
complexes with transferrin. Actinides that form more stable complexes, such as plutonium, 
are cleared more slowly than those with lower affinities such as americium. Animal 
physiology is therefore important with plasma 
241
Am retention being directly related to body 
size and inversely related with metabolic rate and renal filtration rate so that: 
Human > Dog > Baboon > Monkey > Rat > Mouse 
Plasma clearance of 
241
Am is fast with 90 % complete within 60 minutes and 99% complete 
in < 600 minutes (Figure 1.1). Only a small fraction is present in the urine at 24 hours and 
therefore the majority is deposited within the tissues.  
The initial distribution of americium has been investigated in six species following IV 
administration. The tissue distributions are similar across all species (Table 1.3). Entry of 
metal ions into the liver can occur through facilitated diffusion or receptor-mediated 
endocytosis. The liver cell internalizes more than 20 % of its volume each hour in a process 
known as membrane recycling. Through this process any metal with a high affinity for 
membrane-binding sites will be internalized
36
. Iron is predominantly absorbed through 
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receptor-mediated endocytosis involving the Tf-Fe complex and a cell surface Tf-receptor. 
Although both americium and plutonium bind with Tf, this seems to have a negative effect 
on hepatic uptake
37
. Therefore, hepatic uptake is related to the successful competition of 
hepatic cell binding sites for 
241
Am from plasma circulating complexes. Similarly skeletal 
binding sites, depending on their location, compete with 
241
Am-complexes present in the 
plasma or extracellular fluid. Generally there are three types of bone surface, those actively 
growing, resting, or resorbing and 
241
Am deposition is higher on resorbing and resting bone 
surfaces than those actively growing
38
. Ultimately there is continual competition between 
americium ions, plasma complexes and the tissues resulting in a dynamic equilibrium of 
species with a continual shift to the most stable complex. However actinides deposited within 
the bone are only released during limited structural remodeling. Therefore, once deposited 
within the bone the strong association prevents release back into the circulation even in the 
continued presence of chelating agents. 
The risk associated with this internalized contamination is dependent on the dose of 
radionuclide. As the harmfulness of each type of radiation is different, the absorbed dose 
measured in Grays is weighted and defined as equivalent dose, measured in Sieverts (Sv). 
Susceptibility to radiation is also tissue dependent and therefore the equivalent dose can be 
further weighted to give an effective dose also quantified in Sieverts
39
. The biological effects 
resulting from the dose of ionizing radiation can be described as either deterministic or 
stochastic. Deterministic effects have a threshold below which they are nonexistent, however, 
once the threshold is reached, the severity of the effect is proportional to the dose. 
Conversely stochastic effects involve long-term low-level exposures that can increase the 
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likelihood of cancer or DNA damage leading to genetic mutations. As there is no threshold, 
an exposure at any level carries a risk of stochastic effects.  
 Although any degree of contamination can lead to an increase of cancer, the increase 
in risk may be insignificant compared to other daily health risks. Hence the National 
Commission for Radiation Protection (NCRP) has suggested radiation levels below which 
treatment is often unwarranted. These levels are based on a conservative point, whereby 
treatment should start at the upper limit of radionuclide contamination permitted for radiation 
workers each year, known as an allowable level of intake (ALI). This ALI corresponds to an 
effective radiation dose of 5 rem (equivalent to 0.05 Sv), fifty times that of what is allowed 
for members of the general public, at which there is no measurable risk. For americium and 
plutonium treatment is indicated when one ALI is internalized which correlates to 0.8 Ci of 
ingested or 6 nCi of inhaled material
40
. For reference the average smoke detector contains 1 
Ci of americium.  
Treatment of internal contamination is known as decorporation therapy, and it is 
intended to minimize absorption and internal disposition and enhance elimination of the 
radionuclide, thus reducing the future risk of biological effects. Prompt intervention is crucial 
as some isotopes reach their terminal organ of disposition within hours or minutes of 
internalization from which removal is difficult.  
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Table 1.1 Plasma volume, protein and iron concentrations across species (Taken from 
33
). 
 Mouse Rat Beagle Monkey Human 
Body weight (kg) 0.035 0.25 10 6.2 70 
Plasma (mL kg
-1
) 50 36 49 36 43 
Serum Albumin (mM L
-1
) 0.56 0.60 0.52 0.64 0.65 
Serum Globulin (mM L
-1
) 0.14 0.22 0.19 0.25 0.21 
Transferrin (mM L
-1
) 0.036 0.033 0.032 0.040 0.027 
Serum Iron (mM L
-1
) 0.053 0.039 0.025 0.032 0.018 
Transferrin Saturation (%) 74 59 39 40 33 
 
 
Table 1.2  Concentrations of relevant low molecular weight ligands in plasma and their 
stability constants for both americium and plutonium (Adapted from 
35a
 and 
35b
). 
Biological Ligand Blood Serum 
Concentration (M) 
Stability constant (Log K) 
Americium Am
3+
 Plutonium Pu
4+
 
Carbonate (CO3
2-
) 2.5 x 10
-2
 8.0 - 
Citrate 1.6 x 10
-4
 8.6 15.3 
Chloride 9.0 x 10
-2
 1.1 1.8 
Glycine 2.6 x 10
-4*
 4.1 - 
*Concentration from 
41 
 
 
Table 1.3. Comparison of the initial distribution of injected americium in various tissues 
across species. 
Species Mass 
Injected 
Days Fraction of injected americium (%) 
Tissues Excreta 
   Skeleton Liver Kidney Other Urine Feces 
Mouse 0.23 1 27 50 1 6 14 3 
Rat 0.12 4 35 42 - 3 10 10 
Dog 0.54 1 31 52 0.7 5 10 1 
Monkey 0.12 8 25 56 0.6 7 9 2 
Baboon 0.06 1 35 31 0.7 22 10 1 
Man 0.04 4 31 69 - - - - 
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Figure 1.1 Clearance of IV‐injected 241Am3þ from the plasma volume of animals: rat 
(Turner and Taylor, 1968a); mouse (P. W. Durbin and B. Kullgren, unpublished data); beagle 
(Stevens and Bruenger, 1972); monkey (Durbin, 1973); baboon (Guilmette et al., 1980). 
Figure from 
33
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1.3 Decontamination of Internalized Radinuclides 
Fortunately the dangers of plutonium and other actinide elements were perceived during 
early investigations, so decorporation methods were sought out by the health group of the 
Manhattan Project as early as 1947
42
. For those who become internally contaminated, there 
are five decontamination treatment options, the use of which depends on the internalized 
radionuclide. The underlying hypothesis for all five treatments is that accelerating the natural 
rate of elimination of the radionuclide will reduce the amount of activity remaining in the 
body and thus reduce the dose received by sensitive tissues and the risk of radiation effects
31
. 
The currently available oral and IV decorporation treatments are listed in Table 1.4. 
The first method is to surgically remove the contaminated area. This method may be 
employed in situations where wounds are contaminated with a long-lived isotope, such as 
plutonium, in order to prevent systemic uptake. A second simple measure is to administer 
large volumes of oral fluids, which help to dilute the radionuclides and increase urinary 
excretion. For example, treatment with 5-10 L/day of fluid for one week is indicated for 
tritium contamination
43
. The use of diuretics will also help to further enhance urinary 
elimination.  
For radionuclides that are ingested, gastric absorption can be limited by stomach lavage 
and/or the use of emetics, however this carries the risk of aspiration. Instead absorption 
blockers can be used to help minimize uptake without this risk. In addition they may also be 
effective after inhalation contamination, where a fraction of the dose may become ingested 
due to mucociliary clearance. Alternatively, the use of fast acting laxatives is the simplest 
form of absorption prevention by minimizing the time a radionuclide has to be absorbed from 
the GI tract. An example of an enteral binding agent is ferric hexacyanoferrate (Prussian 
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Blue), which is insoluble and binds cesium-137 and isotopes of thallium with high affinity, 
preventing their absorption. In addition to preventing absorption of ingested cesium-137, 
Prussian blue can play a role in decorporation of patients systemically contaminated with 
cesium-137 by interfering with its entero-hepatic circulation
44
. In 2003 it received US Food 
and Drug Administration (FDA) approval for treatment of internal contamination
45
. Other 
examples of binding agents include barium sulfate, a radiographic contrast agent, and 
aluminum and magnesium salts, all of which can bind to strontium and radium to decrease 
absorption
46
.  
Once a radionuclide is absorbed into the systemic circulation, the first three 
decontamination methods have limited use. The radionuclide must now be removed by 
enhancing its elimination either through blocking uptake into the target organ or through the 
use of a chelating agent. Uptake into target organs can be blocked by supersaturating 
radionuclide binding sites thereby preventing accumulation and enhancing elimination. 
Potassium iodide has been approved by the FDA since 2002 for prevention of radioactive 
iodine sequestration by the thyroid
47
. Calcium gluconate and calcium chloride act in a similar 
fashion, limiting the incorporation of radioactive strontium or calcium into the bone. 
Mobilizing agents can be used to help remove deposited radionuclides. Sodium bicarbonate 
can be used to remove uranium from the kidney and ammonium chloride can help to increase 
elimination of internalized radiostrontium. Both of these agents work by altering the pH at 
their target site. 
Chelating compounds are organic ligands that are able to exchange less firmly bound 
inorganic ions for other more favorable ion complexes. The strength of binding for a 
particular metal varies for each chelator, and, although they are able to form chelates with a 
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range of cations, some are bound with a higher affinity leading to preferential chelation of the 
most tightly bound cation. Once bound the cation is part of a stable complex and no longer 
acts as a free ion, allowing for excretion by the kidney. This basic principle was first reported 
in 1942 by Kety
48
 and has been applied to decorporation therapy since the 1950s. Chelator 
selectivity for a particular ion is determined by a number of properties including the number 
of vacant coordination sites, the distance between these sites and the size of the ion to be 
bound. If the affinity of the chelator for essential metals such as Mg
2+
 is higher than that of 
the plasma proteins toxicity can occur due to depletion of essential metals. 
Chelation therapy is most effective when administered immediately after contamination, 
while the radionuclide is in the plasma and before deposition within the tissues has occurred. 
Although the highest decorporation effect is seen with the initial dose, as a large proportion 
of the radionuclide is in the plasma, chelators are still effective at eliminating radionuclides 
albeit at lower levels with sustained treatment. The continual benefit of chelation therapy 
may be due to metabolic recycling of the radionuclide into the extracellular fluid or in some 
cases be due to intracellular chelation. After exposure via the lung or a wound, the 
radionuclide will continue to slowly diffuse into the plasma and redistribute from the 
contamination site to other tissues such as the bone. In these instances chronic chelation 
therapy may be indicated to continue fostering elimination, reducing the total dose and 
residual disposition in the bone and liver. Ultimately, the duration of treatment will be guided 
by the biokinetics of the radionuclide and the degree of contamination. 
Chelating agents for radionuclide decorporation have been under investigation since the 
early 1950s when the dangers of accidental exposure were recognized. Early efforts involved 
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the use of common carboxylic acids and complexing agents and showed limited efficacy. A 
good chelating agent should possess the following properties:  
 Chelating moieties should be deprotonated at physiological pH  
 High number of chelate rings to increase stability of the complex 
 Actinide-ligand complex behaves differently from actinide-biological complex 
 High affinity for actinides and low selectivity for essential metals 
 Low toxicity 
 Avoid degradation to metabolites that no longer bind the metal  
 High oral bioavailability is desirable35b 
There are currently 11 FDA approved chelators (Table 1.5) available for the treatment of 
poisoning with various metals
49
. British-Anti-Lewisite (BAL) or dimercaprol contains two 
sulfhydryl groups that form stable non-toxic five-membered heterocyclic rings with heavy 
metals
50
. It was initially used to sequester arsenic during the Second World War and in 1946 
received FDA approval for the decorporation of arsenic, mercury and gold
51
. D-
Penicillamine and N-Acetyl-D-Penicillamine are degradation products of penicillin and have 
been used for copper
52
, lead
53
, gold
54
, mercury
55
 and zinc
56
. Deferoxamine is a trihydroxamic 
acid secreted by the Streptomyces polosus fungus, which has a high affinity for iron and low 
affinity for other essential metals. Therefore it is used for treatment of acute iron toxicity or 
chronic iron overload
57
. Two synthetic polyaminopolycarboxylic acids are also used for 
chelation. Ethylenediaminetetraacetic acid (EDTA) was the first polyaminopolycarboxylic 
acid used in humans and has received FDA approval for the treatment of lead poisoning. 
Diethylenetriaminepentaacetic acid (DTPA) can be considered an expanded version of 
EDTA with an extra amine and carboxylic acid group. The addition of these two extra 
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chelation sites results in a 100-fold increase in binding affinity for various metals compared 
to EDTA. In 2004 two forms of DTPA, namely the pentetate calcium trisodium injection 
(Ca-DTPA) and pentetate zinc trisodium injection (Zn-DTPA), received FDA approval for 
treatment of internal contamination with plutonium, americium or curium
58
. 
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Table 1.4 Overview of Decorporation Treatments (Modified from
43
)  
Decorporation Agent Route Dosage Radionuclide 
Ammonium Chloride Oral 1-2 g q.i.d for 6 days Strontium 
Ca-DTPA, Zn-DTPA i.v. 1 g in 250 ml saline over an 
hour 
Americium, 
Plutonium, Curium 
Calcium Oral Generous doses Radium, 
Strontium, Barium 
Calcium gluconate i.v. 2.5 g administered in 0.5 L 
over 4h. Daily for 6 days 
Strontium 
D-Penicillamine Oral 250 mg daily between meals 
and bedtime up to 4-5g daily 
Cobalt, Indium, 
Palladium 
Potassium Iodide Oral 130 mg daily Iodine 
Potassium Phosphate Oral 250-500 mg q.d.s. Phosphorous 
Propylthiouracil Oral 100 mg t.d.s. for 8 days Iodine 
Prussian blue Oral 1 g t.d.s for up to three weeks Cesium, Thallium, 
Rubidium 
Sodium alginate Oral 10 g add water and drink Strontium 
Sodium bicarbonate i.v. - Uranium 
 
 
Table 1.5 Chelators currently approved by the FDA 
Chelator Target Radionuclide(s) 
Deferasirox 
Deferiprone 
Deferoxamine mesylate 
Dimercaprol (BAL) 
Edetate calcium disodium (Calcium EDTA) 
Penicillamine 
Pentetate calcium trisodium (Ca-DTPA) 
Pentetate zinc trisodium (Zn-DTPA) 
Prussian blue 
Succimer (DMSA) 
Trientine hydrochloride 
Iron 
Iron 
Iron 
Arsenic, Gold, Mercury 
Lead 
Copper 
Americium, Plutonium, Curium 
Americium, Plutonium, Curium 
Caesium, Thallium 
Lead 
Copper 
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1.4 DTPA 
Diethylenetriaminepentaacetic acid (DTPA) is a polyaminopolycarboxylic acid chelating 
agent that was originally synthesized in 1954 as an alternative EDTA ligand with the aim of 
increasing the affinity towards multivalent cations
59
. The additional nitrogen and carboxylic 
acid on DTPA provide eight potential metal coordination sites that allow binding to a wide 
range of metals with high affinity
60
 (Table 1.6). The additional binding sites improve the 
stability of metal chelates compared to EDTA, while the coordination of Ca ions remains 
similar therefore the / ratio is enhanced resulting in increased efficacy. Due to 
having a lower affinity for calcium compared to zinc, the Ca-DTPA salt is used preferentially 
within the first 24 hours after contamination where it is ten times more effective at actinide 
elimination than the Zn-DTPA salt
61
. After the initial 24-hour period both salts are equally 
effective, however Zn-DTPA is preferred due to zinc’s stronger affinity for DTPA, which 
minimizes toxicity by limiting the loss of essential traces metals. 
Due to its hydrophilic nature DTPA is poorly absorbed from the GI tract (3-5%)
62
, 
however when administered intraperitoneally or intramuscularly it is completely and rapidly 
absorbed
63
. Following IV injection DTPA rapidly distributes in the plasma and extracellular 
fluid, though its hydrophilicity prevents it acting intracellularly. The plasma concentration in 
humans can be described by three exponential components with half-lives of 1.4, 14.5 and 
94.4 minutes. DTPA is rapidly cleared by glomerular filtration into the urine (t½ 19 min); 99 
% of the administered dose is excreted in the urine within 24 hours, with the remaining 
DTPA being slowly excreted over the following days
64
. This remaining fraction of the DTPA 
dose (< 1%) may remain in excess of radionuclide due to the minute quantities present and be 
responsible for enhanced urinary elimination of the radionuclide after 24 hours.  
KML
M KCaL
Ca
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Historically DTPA been used for the treatment of lead poisoning and in the paper 
industry for chelation of metals in pulp. In addition, Gd-DTPA is used medically as an MRI 
contrast agent. Its efficacy for radionuclide decorporation was established through animal 
studies and accidental human contaminations
65
.  
The efficacy of DTPA has been extensively demonstrated in animal studies using mouse, 
rat and dog models for evaluation of decorporation. The experimental conditions used for 
efficacy studies have varied widely, though overall they demonstrate that chelation therapy 
can reduce radiation damage, increase tumor latency and survival
66
. In rats, the efficacy of 
241
Am decorporation has been investigated using both Ca- and Zn-DTPA salts over a series 
of concentrations and after a range of treatment delays. Administration of a single 30 
µmol/kg IV Ca-DTPA dose, 1.5 minutes after IV contamination with 
241
Am-citrate, the liver 
burden was reduced from 43 to 7 % and skeletal burden from 22 to 5 % compared to 
untreated controls
61
. Increasing the dose of chelating agent up to 300 µmol/kg continues to 
improve efficacy, however there is a diminishing return. This is due to the chelator levels 
being in excess of mobilized 
241
Am even at low doses. The influence of treatment delay on 
241
Am retention in the liver and skeleton is shown in Figure 1.2. As the time interval between 
contamination and treatment increases, the effect of DTPA diminishes
61
. The effect of 
treatment delay is more distinct when the rate of radionuclide translocation is high 
(americium and curium) and when binding to the target site is strong, such as on the bone 
surface
67
. The effect is not as pronounced for liver disposition as the actinide remains 
available for a longer period of time as demonstrated by the removal of americium from the 
liver with DTPA in both beagles
68
 and man
69
. 
In beagles contaminated by IV administration of 
241
Am-citrate, a single 30 µmol/kg IV 
 23 
Ca-DTPA dose administered 30 minutes after contamination resulted in significant increases 
in elimination. After seven days, urinary elimination was increased from 10 to 70 % of the 
 total injected dose and fecal elimination from 1.3 to 9.8 %. In addition the liver disposition 
was significantly reduced from 47 to 9.7 %
70
. The relationship between efficacy and initial 
dose was established in beagles to justify a 30 µmol/kg human initial dose. Body retention of 
241
Am was inversely proportional to the dose, with a linear relationship seen over doses up to 
300 µmol/kg. The 30 µmol/kg dose human dose was selected as doubling the dose resulted in 
< 25 % change in total body burden after seven days
71
.  
In addition to animal studies there have been many cases of accidental exposure to 
actinides in the workplace, however there are very limited numbers of incidents in which 
detailed in vivo measurements have been recorded
72
. The 1976 Hanford incident resulted in 
an exposure that was around 1000 times more severe than any previous incident, the patient 
was contaminated solely with 
241
Am and the case provides the best human evidence for the 
extended use of DTPA therapy
73
.  
The incident occurred at the plutonium finishing plant on the Hanford site in Washington. 
An ion exchange column containing around 100 g of 
241
Am exploded in a glove box and 
small shards of glass, nitric acid and the contents of the column were projected onto a 
radiation worker, especially his face which was uncovered. The explosion caused the worker 
to be contaminated with 1-5 Ci of 
241
Am, of which 6 mCi still remained after de-clothing and 
initial external decontamination before transport to the hospital. The thermoluminescent 
dosimetry badge indicated that he had been exposed to 500 mrem (5 mSv) during the 
explosion
74
. On arrival at the hospital the first dose of Ca-DTPA was administered by i.v. 
injection (1g over 3-5 min), however it is estimated that due to the high solubility of 
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Am(NO3)3 more than 20 and 40 Ci had already deposited in the bone and liver 
respectively
75
. 
As the 
241
Am was slowly absorbed into the blood stream this case was suited for 
chelation therapy. Over the course of the next 4.5 years the patient received a total of 584 g 
of DTPA. For the first 25 days up to three 1 g doses were given per day, this was followed by 
daily injections until day 332 where injections were administered 2-3 times per week. When 
treatment was suspended for a year, 
241
Am excretion in the urine dropped and biweekly 
DTPA therapy was resumed as liver retention was seen to be increasing
69
. In total 
approximately 900 Ci was eliminated via the urine, 59 % of which was removed in the first 
6 days. If left untreated only 10 % of the activity would be expected to be eliminated 
naturally with the remainder being deposited in the liver and bone
76
. The administration of 
DTPA ensured that after 5.3 years only 1% of the 
241
Am that reached the plasma was 
retained in the bone and liver, demonstrating that in this case DTPA blocked 99 % of the 
241
Am predicted to deposit in the tissues
69
. 
Due to the slow absorption of 
241
Am from the skin to the bloodstream the majority was 
prevented from depositing in the tissues. The only effects of radiation seen were depressed 
leukocyte, neutrophil and lymphocyte counts in the blood, which had no observable health 
effects. Due to the contamination at age 64, the threat of tumor development was low due to 
the latency period exceeding the patient’s life expectancy. In addition after intensive and 
extended therapy, 
241
Am deposited within the bone was not effectively removed. Therefore 
this corroborates the fact that therapy should be initiated as early as possible after exposure.  
DTPA toxicity has been investigated in mice, rats, dogs, baboons and humans. The 
calcium salt of DTPA is more toxic than the zinc salt due to the weaker association of 
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calcium resulting in increased depletion of natural metals such as zinc and magnesium. When 
examined in vivo, the differences in toxicities were less pronounced in non-dividing cells. In 
proliferating Chinese hamster cells the Zn-DTPA was non-toxic whereas Ca-DTPA resulted 
in significant toxicity, suggesting that it interferes with protein or DNA synthesis by altering 
the composition of the extracellular metal ions of the culture media. In mice, the zinc salt was 
2.5 times less toxic than the calcium salt
77
. The LD50 values for mice administered a single IP 
Zn-DTPA dose a is 12.5 mmol/kg (6484 mg/kg)
63
, which is 1.4 times higher than that of 
EDTA. In general DTPA can lead to histopathological lesions in the kidneys and similarly to 
EDTA can be considered nephrotoxic
78
.  
The doses at which toxicity was noted during animal studies are significantly higher than 
the 30 µmol/kg used in humans, and therefore it is unsurprising that in all human cases of 
prolonged DTPA administration, no severe side effects have been observed. The Atomic 
Energy and Alternative Energies Commission (CEA) in France has administered 1158 
injections to 469 people from 1970 to 2003, with over 70 of these cases involving multiple 
injections. From all these exposures the one-single adverse event was an allergic skin 
reaction that resolved with no long-term effect
79
. In addition the Oak Ridge Associated 
Universities (ORAU) maintain a DTPA registry and between the period of 1958 – 1987 
reported that 3077 doses of DTPA were administered to 485 patients, with the temporary loss 
of some essential elements being the only reported effects
80
.  
The FDA approval of DTPA was granted as part of a government initiative to increase 
the number of therapeutic agents available in the Strategic National Stockpile. Although no 
formal efficacy studies were conducted, extensive animal studies had been conducted and 
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evidence of enhanced elimination and lack of toxicity obtained during unlicensed use in 
accidental contamination cases was used to support regulatory approval.  
As DTPA is only available for treatment via IV infusion or nebulization, both of which 
require a health care professional. This is a severe limitation in a mass casualty situation 
during which a large population of patients may require decorporation therapy, in addition to 
those who have more acute trauma requiring immediate attention. Treatment of internal 
contamination is likely to be initially deprioritized as it results in a more chronic risk than the 
acute risk from trauma injuries. These delays in chelation therapy will limit treatment 
effectiveness, therefore there is a need to develop formulations that can be self-administered 
and rapidly distributed. In addition there is likely to be a significant population of “worried 
well” who, although do not need chelation treatment, may receive a benefit. A safe non-toxic 
oral formulation that has limited strain on medical resources may therefore help to calm the 
panic of this population of patients. Overall an oral product is more amenable to a mass 
casualty situation and will aid in minimizing treatment delays, which as shown previously 
will enhance decorporation. 
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Table 1.6 DTPA Binding Constants 
Element Log KM 
Americium 22.9 
Berkelium 22.8 
Californium 22.6 
Curium 23.0 
Neptunium 23.6 
Plutonium 23.4 
 
 
 
 
Figure 1.2 Retention of 
241
Am in rats after various treatment delays between 
contamination and administration of either Ca- or Zn-DTPA. Tissue concentration was 
assessed 7 days after DTPA treatment (n = 6)
61
. 
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1.5 Pro-drugs 
A drug’s bioavailability (F) is the fraction of unchanged drug that reaches the systemic 
circulation. In the case of an IV this is 100% of the administered dose and therefore its 
bioavailability is 1. In all other cases of drug delivery, a drug must first overcome a cellular 
barrier during absorption and only a fraction of the unchanged drug reaches the systemic 
circulation. The composition of this barrier and the difficulty in achieving permeation varies 
depending on the delivery route. In order to be absorbed, the drug molecule must first be in 
solution. Consequently the physiochemical properties of the molecule that affect both 
solubility and lipophilicity play a critical role in determining its bioavailability. 
Although drug absorption is predominately considered to be affected by both the 
solubility and permeability of the drug molecule, there are additional factors that play an 
important role in defining the bioavailability. The presence of efflux pumps such as P-gp on 
the basolateral membrane
81
 and first-pass metabolism also contribute to a reduction in the 
fraction of unchanged drug reaching the circulation. 
There are a variety of methods used to improve oral bioavailability, including formation 
of salts
82
, use of novel formulations
83,84,85
 and prodrugs
86,87
 all of which have been 
thoroughly reviewed. Prodrugs are biologically inactive versions of a drug that must undergo 
a chemical transformation in order to release the pharmacologically active drug. They have 
been used for many years to overcome drug delivery challenges such as poor solubility, poor 
permeability or rapid metabolism. In the majority of cases a prodrug only requires one or two 
metabolic steps to yield the active form. The central hypothesis of this dissertation is that 
synthesis of a DTPA prodrug will enhance the oral bioavailability of DTPA due to both 
increased lipophilicity and consequential reduction in charge. 
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Although effective at binding radionuclides in the plasma, the majority of chelators are 
highly hydrophilic, restricting entry into cells and limiting efficacy. Lipophilic prodrug 
chelators have previously been investigated in hope of removing radionuclides deposited 
within the tissues such as the liver and bone. Markley
88
 was the first to produce a DTPA pro-
drug with the aim of promoting intracellular penetration. Esterification was chosen to allow 
intracellular hydrolysis, restoration of the carboxylic acids and therefore chelation sites
89
. 
Markley chose the penta-ethyl ester of DTPA so that toxicity from the liberated alcohol 
would be minimized. The results indicated that although the penta-ethyl ester was no better 
than DTPA at removing plutonium from the liver alone, when given in combination with 
DTPA there was an additive effect suggesting that there were two mechanisms of removal 
and that the penta-ethyl ester was acting intracellularly. 
Although able to act intracellularly the penta-ethyl ester was far more toxic than DTPA, 
possibly due to chelation of natural metals within the cells
88
. Therefore partially esterified 
DTPA analogues were investigated for their potential to remove intracellular plutonium
90
. 
The effect on plutonium deposition in mice was investigated using di-methyl, -ethyl, -butyl 
and –octyl esters given five days after contamination. None of the esters showed benefit in 
terms of liver burden, however the methyl and ethyl esters did show a reduction in skeletal 
burden compared with untreated controls. The study also confirmed that in general the 
toxicity of esters increased as chain length increased, the exception being that the ethyl ester 
was less toxic than the methyl ester. All were significantly less toxic than the penta-ethyl 
ester, which suggests that toxicity is affected primarily by lipophilicity. 
More recently the prodrug concept has been applied to the enhancement of oral 
bioavailability. Triethylenetetraaminehexaacetic acid (TTHA) is a further extension of the 
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DTPA molecule containing an additional nitrogen and carboxylic acid increasing its 
coordination number to 10. TTHA molecules have been esterified with chain lengths varying 
from C8-C22 in order to both improve their oral absorption and traverse cellular barriers. 
These chelators were designed to increase removal americium or plutonium retained within 
the tissues and efficacy was assessed in rats contaminated with 
239
Pu and 
241
Am by IV 
injection. The chelators were administered fourteen days after administration of activity to 
allow deposition in tissues. For 30 days, rats received 80-85 mg of the C22-TTHA ligand 
orally, DTPA control rats were administered an equimolar concentration of DTPA by S.C. 
injection twice a week. At completion of the study the activity of 
239
Pu and 
241
Am in all 
tissues and bones was no better than DTPA therapy
91
. Interestingly the prodrug is 
predominantly excreted via the fecal route, suggesting a biliary excretion pathway, less 
lipophilic prodrugs however result in a larger fraction of urinary excretion
92
. Preliminary 
toxicity studies indicated that there was no apparent toxicity following 10 daily 200 mg/kg 
(200 µmol/kg) doses of the C22-TTHA ligand
93
. 
Similarly to the TTHA prodrugs, a range of penta-ester substituted DTPA analogues has 
previously been investigated with the penta-ethyl ester selected due to its lower potential 
toxicity due to the liberation of ethanol and to keep the molecular weight close to 500 as per 
lipinski’s rules. Although previously studied for removal of intracellular plutonium, the 
improvement in oral bioavailability remained uninvestigated. The penta-ethyl ester was 
highly absorbed
94,95
 and in rats contaminated with 
241
Am-Citrate (IV) the elimination of 
241
Am was doubled compared to untreated controls when a 75 µmol/kg oral dose was 
administered one hour after contamination. Unfortunately the penta-ethyl ester was not fully 
metabolized to DTPA in the plasma and the tetra- and di-ethyl esters were the predominant 
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circulating forms
95
. The increased lipophilicity resulted in efficient membrane transport, 
which may be a contributing factor to the high toxicity. Although successful the oral penta-
ethyl ester research ceased due to a complex metabolic profile involving ten potential 
metabolites and due to the high toxicity. The penta-ethyl ester prodrug has also been 
examined topically with the aim of establishing sustained delivery of chelator to eliminate 
the continual release of radionuclide from the contamination site
96
. Topical administration 
and subsequent metabolism by skin esterases was also hypothesized to limit the fraction of 
lipophilic metabolites reaching the plasma resulting in reduced toxicity and improved 
efficacy. In rats contaminated with Am-nitrate (IM) and treated with a 1120 µmol/kg topical 
gel applied over a 6 cm
2
 area 24 hours after contamination, statistically significant increases 
in elimination of 
241
Am were observed
97
. Liver and skeletal burdens were also reduced 
compared to untreated control animals, demonstrating that the transdermal route may be a 
feasible option for chelation therapies. 
Though there has been much research into alternatives for DTPA over the past fifty years 
there are still no new products in medical use. This may have been due to the lack of funding 
for a product with a limited patient population and the lack of animal rule pathway for 
regulatory approval.  
. 
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1.6 Approval of Medical Countermeasures 
In late 2001 the National Institutes of Health (NIH) and National Institute of Allergy and 
Infectious Disease (NIAID) began to formulate a comprehensive biodefense research 
program, which culminated with the publication of a strategic plan for medical 
countermeasures against radiological and nuclear threats in 2005. One of the aims outlined in 
this plan was to promote research of new decorporation products that can be easily 
administered, safe for repeated dosing, have a long shelf life and be easy to manufacture
98
. In 
addition to the creation of a biodefense research program, the FDA introduced a new 
pathway for drug approval to accelerate the development of medical countermeasures 
(MCM) known as the “Animal Rule”99. Prior to the introduction of this rule there was no 
pathway for approval for these MCMs where the patient population is too small to conduct 
well-controlled clinical trials and it is unethical to contaminate healthy individuals in order to 
determine the efficacy. 
In order to gain regulatory approval via the animal rule the product must meet the 
following criteria
100
: 
1. A detailed understanding exists regarding the pathophysiological mechanism for toxicity 
of the agent in humans and also regarding the mechanism by which the proposed product 
reduces or prevents adverse effects in humans. 
2. The prophylactic or therapeutic effect of the product is demonstrated in more than one 
animal species, unless the effect is demonstrated in a single animal species that represents 
a sufficiently well characterized animal model for predicting human response. 
3. The animal study end points correlate to increased survivability or prevention of 
significant morbidity in humans in the face of lethal challenge. 
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4. Pharmacokinetic and pharmacodynamics data for the proposed product are available and 
can be used to select an effective dose in humans. 
For radionuclides the mechanism of toxicity is established and extensively detailed in 
published data. The kinetics of americium and plutonium distribution have predominantly 
been investigated in rats and dogs. Not only is the choice of animal important but the route of 
contamination must also be considered, as the animal model must mimic the effects of 
contamination in humans. In addition to selecting the most appropriate contamination 
models, the timing of treatment administration should mimic that which will be used in 
humans. A single model is unlikely to simulate the human response and two species can help 
to increase the confidence in the animal models response
101
. The development of a 
pharmacokinetic-pharmacodynamic model will help to identify the dose range likely to be 
effective in humans. 
Currently five products have received FDA approval through the animal rule. The first 
two products to be approved, pyridostigmine bromide (PB) and Cyanokit, both contained 
drugs that had previously received approval for alternative uses. PB was approved in 2003, 
only seven months after the introduction of the animal rule, for use by the army for 
prophylaxis against soman toxicity
99
. Cyanokit contains hydroxocobalamin and is used as an 
antidote for cyanide poisoning. It was approved in 2006, based on a single placebo-controlled 
study in dogs
102
. There was a six-year lull before the approval of additional products, though 
three products achieved approval during 2012-13, namely Levaquin, raxibacumab and 
botulism antitoxin. Interestingly raxibacumab was the first completely novel product to gain 
approval solely via the animal rule, demonstrating the changing regulatory environment over 
the last decade
103
 and is promising for the future approval of novel medical countermeasures.  
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1.7 Perspective 
In response to the NIH/NIAID call for improvements of DTPA formulation, three 
research groups received funding, including SRI International (Menlo Park, CA), 
Nanotherapeutics Incorporated (Alachua, FL) and the lab of Dr. Jay at the University of 
Kentucky
51
. SRI has developed orally bioavailable formulations of DTPA by incorporating 
permeation enhancers into an oral capsule. Various permeation enhancers have been 
evaluated in vitro and the oral absorption of DTPA has been shown to increase from 5 to 12 
% in rats
104
. The toxicity and efficacy of this novel oral formulation has also been 
investigated. The Nanotherapeutics approach involves the development of an orally 
administered nanoparticle formulation. Preclinical studies of this oral ‘NanoDTPA™ capsule 
formulation have demonstrated good pharmacokinetic and safety profiles in rodent and dog 
models
105
 and the product received additional funding from Biomedical Advanced Research 
and Development Authority (BARDA)
106
. For a more detailed discussion on the results of 
these studies in relation to the current work the reader is referred to chapter VII. 
The research presented herein is an extension of the DTPA prodrug research initiated at 
the University of Kentucky. As described previously the research in Dr. Jay’s lab has focused 
on two novel DTPA products. Both the oral and topical formulations were based on the 
penta-ethyl ester of DTPA, named C2E5. C2E5 was shown to effectively decorporate 
241
Am 
in a wound-contamination animal model
94-95
, but its unfavorable pharmaceutical properties 
and concerns related to its hepatotoxicity caused us to focus our efforts on the di-ethyl ester 
of DTPA, named C2E2. 
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1.8 Specific Aims  
Specific Aim 1: To synthesize and characterize the di-ethyl ester pro-drug of DTPA, 
C2E2, and its major metabolite the mono-ethyl ester C2E1. In order to study C2E2 as a 
potential DTPA pro-drug and to determine its pharmacokinetics, the compounds of interest 
must be synthesized. Both C2E2 and its primary metabolite C2E1 have previously been 
described in the literature, however their use as an oral pro-drug of DTPA is novel. Once 
synthesized the compounds will be characterized by NMR, MS, HPLC, DSC, XRPD, 
elemental analysis and water content to determine their purity. The majority of active 
pharmaceutical ingredients (APIs) are administered as a solid dosage form. Regulatory 
agencies place a heavy emphasis on safety and efficacy; therefore the chemical purity of 
solids is often the primary focus. However the physical aspects of the dosage form such as 
stability are equally important. The measurement of pKa, solubility and lipophilicity are an 
integral part of lead compound profiling. Properties to be investigated include solubility, 
pKa, stability constants, Log P and metal binding kinetics. 
Specific Aim 2: To investigate the metabolism of C2E2 in vitro. The stability of C2E2 will 
be determined in simulated intestinal and gastric fluids to ensure the esters are not 
hydrolyzed prior to absorption. Plasma binding, and stability will be determined using 
human, beagle dog and rat plasma. The metabolism of C2E2 by human, beagle dog and 
Sprague-Dawley rat S9 fractions will be evaluated to determine the conversion of C2E2 to 
it’s metabolites C2E1 and DTPA. 
Specific Aim 3: Determine the pharmacokinetics and decorporation efficiency of C2E2, 
C2E1 and DTPA in vivo using a Sprague-Dawley rat and Beagle Dog models. The 
pharmacokinetics of C2E2 and its metabolites C2E1 and DTPA will be determined in both 
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Sprague-Dawley rat and Beagle dog models. The parameters obtained such as the CMax and 
AUC can be incorporated into a pharmacokinetic model. The bioavailability and 
decorporation efficiency of C2E2 will also be determined. Tissue accumulation will also be 
performed.  
The successful completion of these specific aims is expected to lead to a greater 
understanding of the efficacy and pharmacokinetics of C2E2 which, combined can assist in 
the development of a physiologically based pharmacokinetic model for the oral 
decorporation efficacy of C2E2. Due to the complexity of the dual pro-drug and the fact that 
C2E2 and C2E1 in addition to DTPA are expected to have some metal chelating activity, it 
would be helpful to predict the therapeutic outcome before large scale lengthy and expensive 
pre-clinical and clinical trials are performed. A pharmacokinetic-pharmacodynamic model 
combines a model that describes drug concentration vs time (PK) with a model describing the 
relationship of effect vs concentration and a statistical model describing intra and inter 
individual variability of the PK/PD models. The parameters investigated above can be 
incorporated into a pharmacokinetic-pharmacodynamic model. The in vitro species 
dependent metabolism can then potentially be used to predict the human metabolism based 
on interspecies scaling calculations. Binding constants for C2E2 and its metabolites can be 
incorporated into the model in order to correlate the exposure of each compound with the 
observed effect. The ultimate aim is to produce a model that is capable of predicting the 
human dose required to produce the desired decorporation as human efficacy studies are not 
possible for decorporation agents. 
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CHAPTER II 
 
C2E2: A DI-ETHYL ESTER PRODRUG OF DTPA AS AN ORALLY 
BIOAVAILABLE RADIONUCLIDE DECORPORATION AGENT 
 
2.1. Introduction 
Diethylenetriaminepentaacetic acid (DTPA) is a chelating agent with eight 
coordination sites making it effective at binding a wide range of metals with high affinity. It 
is available as both calcium and zinc tri-sodium salts (Ca-/Zn-DTPA) for intravenous 
injection both of which have been approved by the FDA for treatment of individuals 
internally contaminated with isotopes of the transuranic elements of americium (Am), curium 
(Cm) and plutonium (Pu)
58
. Once administered DTPA is rapidly distributed to the 
extracellular fluids where the calcium or zinc is exchanged for the higher affinity radioactive 
metals enhancing their elimination via urinary excretion. 
Americium, curium and plutonium are α-emitters which rapidly deposit on the bone 
surface where they irradiate the radiosensitive bone marrow causing increase the risk of 
cancer and leukemia in a dose dependent manner
107
. If left untreated the biological half-lives 
of radionuclides can be up to 50 years
28b
. DTPA is relatively ineffective at removing 
skeletally deposited radionuclides and therefore is most effective when given soon after
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exposure while the metal is in the circulation and soft tissue
43
. Any delay in treatment has a 
profound effect on the retention of americium (
241
Am). In beagles contaminated with IV 
241
Am citrate and treated with a single dose of IV Ca-DTPA, the percentage of 
241
Am 
retained increased from 3% after a 1 minute delay to 29, 58 and 73% after 30 minutes, 8 
hours and 1 day delays, respectively
108
. Similar effects have been shown with both plutonium 
and curium. The radionuclide deposition kinetics are dependent on the method of 
contamination, species, and chemical form of the heavy metal
33
. Contamination is most 
likely to occur via inhalation or wound sites and therefore the percentage decorporation 
achieved after a single dose is likely to be lower than that described above due to retention of 
the metal in the lung or wound site. For this reason it is not uncommon for DTPA to be given 
over a period of days or months and in extreme cases for years
73
. The efficacy of DTPA in 
humans has been investigated after unintentional contaminations such as during the Hanford 
Americium Accident
109
. Due to the increased threat of nuclear terrorism both forms of DTPA 
have been added to the United States Strategic National Stockpile as radiological 
countermeasures. 
DTPA is highly ionized and therefore poorly absorbed (~5%) 
110
, thus it is usually 
given by intravenous injection or infusion. Following inhalation exposure the solution may 
be given via a nebulizer, however this also is more expensive and requires specialized 
equipment. An orally administered DTPA product would offer an advantage over the current 
treatment. Health care professionals are required for administration of the IV product which 
is time consuming and costly. This is a limitation during emergency situations such as the 
release of radioactivity from a nuclear power (Fukushima) and waste facilities, or by 
terrorists using a radiological dispersal device or improvised nuclear device (“dirty bomb”) 
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where there may be mass contamination and casualties. During an emergency scenario 
delivery of oral dosage forms of DTPA would enable rapid distribution and cost-effective 
treatment saving resources for patients who need more urgent care. The ease of 
administration should also help to decrease the delay in receiving the first dose thereby 
improving decorporation and reducing the length of treatment required. In addition those 
who are severely contaminated may need months of treatment. Daily IV injections will 
reduce the patient’s quality of life, which would not be the case with an oral product.  
Prodrugs have frequently been used for bioavailability enhancement
111
, with ester 
groups frequently being employed to add lipophilic moieties or remove charge. The ideal 
prodrug would retain high solubility, enhance permeability, and be stable in the GI tract prior 
to absorption and subsequently metabolize to DTPA. The five carboxylic acids present on 
DTPA provide multiple sites for esterification. We therefore hypothesized that by reducing 
the net charge of DTPA through formation of esters using these free acid groups and 
concurrently increasing lipophilicity, the permeability limited absorption could be overcome. 
The use of ester prodrugs should allow subsequent metabolism in the plasma due to pH or 
esterases yielding DTPA. Ethyl groups were chosen to keep the molecular weight of the 
prodrug below 500 as per Lipinski’s rules112. In addition cleavage of larger aliphatic alcohols 
are generally more toxic
113
, whereas shorter chains such as ethanol although less 
hydrophobic also have less toxicity. The di-ester prodrug was chosen as previous studies in 
our lab with the penta-ethyl ester although exhibiting good efficacy had shown incomplete 
metabolism to DTPA with the majority of the metabolites remaining as the tetra-ethyl ester
95
.  
The following experiments were conducted to examine the physiochemical properties 
of the di-ethyl ester prodrug of DTPA in relation to oral delivery. In addition a preliminary 
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efficacy study has been performed to evaluate the prospect of DTPA di-ethyl ester as an oral 
decorporation agent. These studies will be used to identify suitable formulations based on 
both the physiochemical properties determined and the doses required to achieve 
decorporation. 
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2.2. Experimental Methods 
 
2.2.1 Synthesis & Identification 
The synthesis of C2E2 is a simple two-step procedure as depicted in Figure 2.1. 
Initially, diethylenetriaminepentaacetic bisanhydride (DTPA-BA) was synthesized in a 
method similar to that used by Raut et al.
114
. DTPA (3.93 g, 10 mmol) and acetic anhydride 
(5.72 g, 56.9 mmol) were added to 6.2 mL of pyridine and heated to reflux 65-70
o
C for 14 
hours. The resulting material was filtered through a Buchner funnel and rinsed with diethyl 
ether. An off-white powder (DTPA-BA, 1) was collected and dried overnight. The di-ethyl 
ester of DTPA (2, C2E2) was synthesized by reacting DTPA-BA (2.0 g, 5.6 mmol) with 
ethanol (0.97 ml 0.77 g, 16.7 mmol) in pyridine (1.33 ml 1.32 g, 16.7 mmol). The reaction 
was stirred under nitrogen at RT for 24 hours, the product precipitated in DCM (200 mL) at -
40
o
C, filtered and dried to give an off-white powder. The identity of the product was 
confirmed to be the di-ethyl ester by 
1
H NMR, mass spectrometry (MS) and elemental 
analysis. 
1
H NMR was performed using a Varian 400 MR NMR spectrometer (Agilent 
Technologies, Santa Clara, CA) operating at 400 MHz. MS was performed on a TSQ 
Quantum (Thermo Scientific, Waltham, MA) by direct injection of the C2E2 dissolved in 
acetonitrile. Electrospray ionization with nitrogen gas was used and the ion trap mass 
analyzer was operated in positive-ion scanning mode. Elemental analysis was performed for 
C, H, N and O elements by combustion and pyrolysis at ALS Environmental (Tuscon, AZ). 
A 25-minute HPLC method was developed to quantify C2E2 during pre-formulation 
experiments. Analysis was performed on a prominence HPLC (Shimadzu Corporation, 
Kyoto, Japan) equipped with a Corona Ultra charged anion detector (CAD) (Thermo 
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scientific, Sunnyvale, CA). A reverse phase gradient separation was performed using an 
Alltima C18 column 250 x 2.1 mm
2
 internal diameter with 5 µm particle size (Grace) at 40 
o
C and a flow rate of 0.25 mL/min. The mobile phases were composed of water with 0.1% 
trifluoroacetic acid (A), acetonitrile/isopropanol 2:1 (B). The mobile phase followed a linear 
gradient from 94:6 to 75:25 over 14 min, the gradient then increased for 0.5 min to achieve a 
flow of 0:100 for 3.5 minutes followed by re-equilibration of the system at 94:6 for 6 min. 
The CAD analysis was performed at 25 
o
C with nitrogen flow at 35.1 psi.  
 
2.2.2 Characterization of Solid C2E2 
Two thermal methods were used to characterize the DTPA di-ethyl ester. Differential 
scanning calorimetry (DSC) was performed using a Perkin Elmer heat flux DSC (Waltham, 
MA). This enabled determination of the melting point and can was also used to detect the 
presence of solvate species. Briefly a few mg of solid powder was weighed into aluminum 
pans placed in the DSC and heated to 145
o
C at 5
o
C/min followed by a 1 min hold at 145
o
C 
before cooling. Thermogravimetric analysis (TGA) was also performed using a Q5000 
Thermogravimetric Analyzer (TA Instruments, New Castle, DE). Briefly a few mg of solid 
was weighed into open aluminum pans placed on the TGA and was heated from 25 to 100
o
C 
at a rate of 10
o
C/min. An isothermal step was introduced at 100
o
C for 5 min to ensure all 
water loss had occurred, and then the temperature was further increased at 10
o
C/min to 170 
o
C. The experiment was stopped at 170
 o
C to avoid decomposition. In addition X-Ray 
powder diffraction was used to further characterize the solid and determine crystallinity. A 
Cu K radiation with a wavelength of 1.5405 Å at 45 kV and 40 mA from an X'Pert PRO 
diffractometer (PANalytical, Almelo, The Netherlands) was used. Samples were placed on 
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zero-background silicon plates and scanned from 2-50 2 with a step size of 0.016 and a 
time of 10 s per step. 
 
2.2.3 Solubility 
The apparent solubility of C2E2 was determined in deionized water. C2E2 was added 
to the water in excess and left to stir, at various time-points a sample of supernatant was 
taken and filtered to remove undissolved solid. The concentration of the supernatant was then 
determined by HPLC-CAD. The solubility was measured until two concurrent readings were 
achieved and the experiment repeated in triplicate.  
 
2.2.4 Lipophilicity 
The pH-dependent partition coefficients were calculated by measuring the partition of 
C2E2 between 1-octonol and aqueous buffers. Phosphate (pH 2, 3 and 7), Acetate (pH 4 and 
5), Succinate (pH 6), TRIS (pH 8 and 9) were prepared at 200mM concentrations (I=0.6, 
NaCl). Initial experiments were performed to determine the optimum octanol-aqueous buffer 
ratio of 10:1. Prior to combining the phases octanol solutions were pre-saturated with the 
corresponding aqueous buffer overnight. After the phases were combined, they were gently 
agitated at room temperature for 24 hours using a rotisserie-style shaker and upon completion 
were separated by centrifugation and the C2E2 content of aliquots from each phase was 
measured by HPLC-CAD with all samples were analyzed in triplicate. 
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2.2.5 Stability 
The stability of C2E2 was investigated in simulated gastric fluid (SGF) and simulated 
intestinal fluid (SIF). The simulated fluids were prepared as outlined in the United States 
Pharmacopeia using pepsin and pancreatin (Acros organics). C2E2 was dissolved in pre-
heated simulated fluids, and the reaction mixture retained at 37.5
o
C for the duration of the 
experiment. At various time-points and aliquot was taken and the concentration of C2E2 was 
determined by HPLC-CAD. In addition C2E2 capsules were evaluated under accelerated 
stability conditions at both 25
o
C/65%RH and 40
o
C/75%RH. Size 0 HPMC capsules were 
filled with 200 mg C2E2 and placed in HDPE bottles. At 0, 1, 2, 3 and 6 months the 
dissolution performance of the capsules was evaluated. The C2E2 content of the capsules 
was measured at each of the aforementioned time-points and at 12 months. Dissolution was 
performed in a using dissolution bath (Hansen) equipped with USP II paddle apparatus. 
Capsules were placed in 900 mL of 0.1N HCl solution with constant stirring at 50 rpm with 
all samples were analyzed in triplicate. 
 
2.2.6 Single Dose 
241
Am Decorporation 
In order to evaluate the potential of C2E2 as an oral decorporation agent, an efficacy 
study was performed in rats contaminated with 
241
Am. Male and female Sprague Dawley rats 
(32/gender) were contaminated with 
241
Am(NO3)3 (0.25 µCi) by intramuscular injection (0.1 
mL, 0.1 M HNO3) into the right hind leg while under isoflurane anesthesia. Immediately 
after injection, body weights were recorded and animals were placed in individual metabolic 
cages. Rats (n = 4/gender/group) received a single oral gavage dose of 0, 200, 600, or 1000 
mg/kg C2E2 (10% w/w solution in water) 24 hours after contamination. The study was 
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performed under both fed and fasted conditions to determine if there were any food effects. 
Approximately 16 hours before administration of C2E2, rats assigned to the fasted groups 
had access to food restricted with replacement occurring 1 hour after oral gavage treatment. 
At all other times all animals had ad libitum access to food. A treatment control group 
received a single intravenous dose of Ca-DTPA solution (13.3 mg/kg, 0.67 mL/kg) via a 
jugular vein catheter 24 hours after contamination under fed conditions. All animals were 
observed at least once daily for morbidity, mortality, and general appearance. 
Excreted urine and feces were collected daily. Feces were allowed to dry overnight 
before transfer to 20 mL scintillation vials and weighing. Following necropsy selected tissues 
were removed and weighed. The 
241
Am gamma activity was determined by quantifying the 
59.7 keV photons emitted by 
241
Am using a gamma counter (Wizard2 2480, Perkin Elmer). 
The total amount of 
241
Am administered to the animals was determined by counting duplicate 
aliquots (100 µL) of the injection solution. A counting window from 40 – 80 keV and a 60-
second counting time were used for acquisition and each reading was corrected for 
background at acquisition. All experimental tissues and samples were counted using the same 
gamma counter and protocol. For all samples, 
241
Am content was expressed as a percentage 
of the initial dose. The femur from the leg opposite to the injection site was scaled by a factor 
of 20 to estimate total skeletal 
241
Am burden. 
Statistical analysis was performed for final decorporation parameters; total 
decorporation, liver burden, wound retention and estimated skeletal burden. All animals 
treated with C2E2 were analyzed by ANOVA to evaluate the effects of gender, dose and fed 
state. Non-contributing effects were removed from the model and control data (untreated and 
Ca-DTPA treatment groups) were included for subsequent analysis. ANOVA was performed 
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and Least squares means calculated for all the groups in this model. Comparison of means 
was made using the Tukey-Kramer adjustment for multiple comparisons, with p < 0.05 
considered significant. 
The general procedures for animal care and housing were conducted in accordance 
with the National Research Council for the Care and Use of Laboratory Animals and the 
Animal Welfare Standards. All procedures and protocols used in animal studies were 
reviewed and approved by the Institutional Animal Care and Use Committee of The 
University of North Carolina at Chapel Hill and were performed in AAALAC accredited 
facilities. 
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Figure 2.1 Synthesis of DTPA di-ethyl ester (C2E2).  
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2.3. Results 
 
2.3.1 Synthesis & Identification 
The synthesis of DTPA-BA (1) resulted in a cream colored powder. Yield = 50 %; 
1
HNMR (400MHz, d6 DMSO) δ 3.65 (8H, s), 3.44 (2H, d), 2.74 (4H, t), 2.59 (4H, t). 
Addition of ethanol in the presence of pyridine yielded the DTPA diethyl ester (2), named 
C2E2. Yield =95.6 %; 
1
HNMR (400MHz, d6 DMSO) δ 4.07 (4H, q), 3.53 (4H, s), 3.45 (2H, 
s), 3.43 (4H, s), 2.89 (4H, d), 2.84 (4H, d), 1.19 (6H, t). MS, m/z calculated 450.2; found 
450.13. Elemental analysis: Predicted for C18H31N3O10 – C, 48.10; H, 6.95; N, 9.35; O, 
35.60; Actual – C, 47.59; H, 7.22; N, 8.67; O, 36.29. 
 
2.3.2 Solid Characterization 
DSC identified a single-phase transition for C2E2 at 115.8
o
C (Figure 2.2). The use of 
TGA confirmed that the transition observed during DSC studies was the melting point. There 
was a small loss in weight observed during TGA analysis, prior to decomposition (Figure 
2.2). The loss was gradual, not attributed to a specific temperature, and non-stoichiometric 
suggesting that surface/incorporated water was the cause. The XRPD chromatogram was 
obtained and confirmed that the synthesized C2E2 was crystalline (Figure 2.3). 
 
2.3.3 Solubility 
 The apparent solubility of C2E2 in water was measured after 2, 4, 6 and 24 hours at 
room temperature. There was no change in concentration observed after 4 hours. The 
apparent solubility was 149.3 ± 1.9 mg/mL at pH 2.4. In order to determine a pH-dependent 
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solubility profile a range of buffers were prepared however, due to the high solubility of 
C2E2 the buffer capacities were exceeded even at high buffer concentrations and so the pH 
dependent solubility profile could not be determined.  
 
2.3.4 Lipophilicity 
 The lipophilicity of C2E2 was determined by its partitioning between aqueous buffers 
of pH 2-9 and 1-octanol. The log D profile in Figure 2.4 shows that lipophilicity increases 
with decreasing pH. The Log D values ranged from -2.1 to -3.8. This is expected for C2E2, 
the three acids and bases have an isoelectric point at pH 2.74, therefore the highest 
lipophilicity would be expected at this point.  
 
2.3.5 Stability 
 In order to ensure that the ethyl-ester promoeities were not hydrolyzed prior to 
absorption their stability was determined in both simulated gastric (SGF) and intestinal fluids 
(SIF). Over a 24-hour period there was a 34 % reduction in C2E2 concentration in SGF and 
only a 5 % loss in SIF (Figure 2.5). Therefore, with gastric emptying occurring within 2 
hours in the average adult
115
, only a small fraction of the dose (~5 %) is expected to be lost to 
hydrolysis prior to absorption. 
 The stability of HPMC capsules containing C2E2 was assessed over 12 months under 
accelerated stability conditions. In addition to measuring the content of C2E2, dissolution 
performance was also monitored for the first 6 months. Under both 25
 o
C /65% RH and 40
 o
C 
/75 %RH conditions there was no loss of C2E2 over the 12 months. In addition there were no 
significant changes observed in the dissolution profiles of capsules stored under either 
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condition, with > 90 % release achieved in 15 minutes for all capsules tested (Figure 2.6), 
meeting FDA immediate release acceptance criteria under all the conditions tested
115
.  
 
2.3.6 Single Dose 
241
Am Decorporation 
Sixty-four rats completed the study, of these 61 rats (32 male and 29 female) were 
included in data analysis. Three fasted female rats (1x 600 mg/kg; 2x 1000 mg/kg) were 
excluded from the dataset as they did not receive a complete dose. C2E2 enhanced the 
elimination of americium in a dose dependent manner in male and female rats (Figure 2.7). 
Analysis of the total decorporation achieved in the seven days after contamination for all the 
rats treated with C2E2 showed significant effects for gender (F(1,44)= 17.54, p < 0.001) and 
C2E2 dose (F(2,44)= 40.71, p < 0.001) but not for the fed state at treatment (F(1,44)=1.51, p = 
0.23). Interactions between food and other main effects were not considered significant and 
therefore, for subsequent analysis ad libitum and fasted groups were combined. 
 In male rats the total decorporation was significantly increased compared to 
untreated controls at doses of 600 mg/kg and above (p < 0.001) and increasing the dose from 
600 mg/kg to 1000 mg/kg also significantly increased decorporation (p < 0.05). A similar 
trend was observed in female rats with doses ≥ 600 mg/kg inducing significantly enhanced 
decorporation (p < 0.001), the 1000 mg/kg dose appears to be more effective than the 600 
mg/kg dose although this did not reach statistical significance. 
 In both male and female rats, C2E2 reduced the americium burden in liver, skeleton, 
and at the wound site. In male rats, the liver burden was significantly reduced compared to 
untreated controls at doses of 200 mg/kg (p < 0.05) and 1000 mg/kg (p < 0.001). Although 
the liver burden following a 600 mg/kg C2E2 dose did not reach statistical significance (p = 
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0.056) it is consistent with the trend of C2E2 treatment reducing liver burden. A dose-
dependent reduction in 
241
Am liver burden was observed in female rats although, only the 
reduction following the 1000 mg/kg dose was statistically significant compared to untreated 
controls (p < 0.01).  
Estimated skeletal americium burden in male rats decreased in a C2E2 dose 
dependent manner with significant reduction compared to untreated control animals at doses 
of 600 mg/kg and above. Skeletal burden in female rats was lower than in male rats for all 
groups though was not significantly changed by C2E2 treatment (Figure 2.8).  
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Figure 2.2 Differential scanning calorimetry (DSC, Red) and thermogravimetic analysis 
(TGA, Blue) chromatograms of C2E2.  
 
 
 
 
Figure 2.3 X-Ray powder diffraction (XRPD) chromatograph depicting crystalline nature 
of C2E2. 
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Figure 2.4 Log D profile for C2E2. 
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Figure 2.5 Stability of C2E2 in simulated gastric and intestinal fluids. 
 
 
 
Figure 2.6 Dissolution profiles of HPMC C2E2 capsules after storage under accelerated 
stability conditions for six months. 
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Figure 2.7 C2E2 dose response curve showing total 
241
Am decorporation in male and 
female Sprague-Dawley rats seven days after contamination. 
 
 
 
Figure 2.8 C2E2 dose response curve showing 
241
Am liver (left) and skeletal (right) 
burdens in male and female Sprague-Dawley rats seven days after contamination. 
 
  
 56 
2.4. Discussion 
An oral product provides significant advantages in the case of decorporation therapy. 
The ability to rapidly distribute and administer the product soon after contamination will 
minimize deposition of radionuclides in the skeleton and liver from which they are hard to 
remove
61
. Additionally long term decorporation therapy may be prescribed for highly 
contaminated patients for whom the oral route is more acceptable and far less disrupting. 
Finally, after IV administration DTPA is rapidly eliminated with 90 % of the dose being 
cleared within the first 2 hours
116
. Oral dosing provides further therapeutic benefit by 
extending exposure due to the extended duration of absorption. 
Lipophilic prodrug chelators have previously been investigated in hope of removing 
radionuclides deposited within the tissues such as the liver and bone. Markley
88
 was the first 
to produce a DTPA pentaethyl ester pro-drug with the aim of promoting intracellular 
penetration. Although able to act intracellularly the pentaethyl ester was far more toxic that 
DTPA, possibly due to chelation of natural metals within the cells
88
. More recently the 
prodrug concept has been investigated for enhancing oral bioavailability. The pentaethyl 
ester was highly absorbed
94,95
 and in rats contaminated with 
241
Am-Citrate (IV) the 
elimination of 
241
Am was doubled compared to untreated controls when a 75 µmol/kg oral 
dose was administered one hour after contamination. Unfortunately the pentaethyl ester was 
not fully metabolized to DTPA in plasma and the tetra- and di-ethyl esters were the 
predominant circulating forms
95
. The increased lipophilicity resulted in efficient membrane 
transport, which may have been a contributing factor to the high toxicity. Although 
successful the oral pentaethyl ester research ceased due to a complex metabolic profile 
involving ten potential metabolites and due to the high toxicity. 
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C2E2 was chosen as an alternative to the penta-ethyl ester due to its simpler 
metabolic profile, ease of synthesis and solid form. It is an amphoteric molecule containing 
three carboxylic acids and three basic tertiary amines. As with most amphoteric molecules 
C2E2 will be charged across the physiological pH range. The presence of charge on the 
zwitterions means that the solubility of C2E2 is high however they correspondingly 
contribute to reduced oral absorption potential. The biopharmaceutics classification system 
(BCS) is used by the FDA to classify drugs based on their solubility and permeability. The 
high aqueous solubility and low permeability of C2E2, brands the molecule as BCS class III. 
This is similar to DTPA, however the permeability (Log P) has been increased from -2.90 
(Clog P) to -2.1 through the addition of two ethyl esters
117
. Formulations containing 
permeation enhancers or efflux blockers have previously been used to further enhance the 
permeation of class III compounds
118
. A novel formulation of DTPA containing permeation 
enhancers is under investigation by SRI International (Menlo Park, CA) with oral 
bioavailability increased from 5 to 12 % in rats
104
. Permeation enhancers may not be 
appropriate for decorporation therapy as absorption of inhaled radionuclides deposited in the 
GI tract through muccocillary clearance may increase. Furthermore, high doses of radiation 
can damage the intestinal mucosa that would be further exacerbated by permeation 
enhancers. 
To assess the oral potential of the prodrug a preliminary decorporation study was 
performed. The study demonstrated that compared to untreated controls 
241
Am retention 
could be significantly reduced orally using C2E2. There was a dose dependent increase in the 
percentage of 
241
Am eliminated primarily through the urinary route. This is consistent with 
other highly charged hydrophilic compounds such as DTPA and contrary to the more 
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hydrophilic polyaminocarboxylic acids (PACA), which are primarily eliminated through the 
fecal route
92
.  
For all of the tissues no statistical difference in americium burden was observed 
between rats with ad libitum access to food and rats fasted overnight prior to C2E2 treatment. 
This may be due to the fact that over the pH range 5-9 the net charge on C2E2 is constant. 
The ingestion of food is therefore unlikely to sufficiently change the pH of the intestinal 
absorption site, alter the charge on C2E2 and effect its passive diffusion. As C2E2 is highly 
soluble the fed state will not affect the dissolution rate. The log D pH-profile suggests that 
the predominant site of C2E2 absorption may be the upper small intestine, where the 
molecules net charge is closest to zero. Under these conditions a fraction of C2E2 will be 
present as a zwitterion and a small fraction present as the uncharged drug. The absorption of 
C2E2 is higher than expected for a hydrophilic molecule and may be due to the presence of 
transcellular drug transporters. Although no food effects were seen lower liver burdens were 
observed in male rats than females. In contrast skeletal burden was lower in female rats 
across all groups. As these differences were also observed in untreated controls, they were 
likely due to variation in americium biokinetics between each gender and not attributed to 
C2E2.  
Oral administration was less effective than the IV DTPA control group, this is to be 
expected as C2E2 must first cross the intestinal barrier and be metabolically activated to 
DTPA. Although doses of 600 mg/kg in rats were required to significantly increase 
americium elimination over control, this is expected to be higher than the doses necessary for 
treatment in humans based on renal clearance rates of DTPA between species. The 
effectiveness of DTPA has been shown to differ across species due to differences in 
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transferrin binding between species with beagles and humans requiring lower concentrations 
than rats
119
. Additionally administration of multiple doses will also enable to dose to be 
lowered and result in enhance efficacy.  
Although initially designed as a prodrug, C2E2 may retain the ability to bind 
241
Am 
albeit with an affinity lower than DTPA making it an active compound. After addition of two 
esters, six of DTPA’s metal coordination sites remain available for chelation. This may result 
in metal binding affinities on an order similar to ethylenediaminetetraacetic acid (EDTA) 
thereby eliminating the need for metabolic activation upon absorption. However any ester 
hydrolysis after absorption will increase the metal coordination number and enhance 
chelation of americium.  
Given that the DTPA is given intravenously at doses of 1 g per day it is unsurprising 
that large doses of C2E2 are required to achieve chelation. Due to large doses a formulation 
encompassing minimal excipients is desirable. Based on the determined physiological 
properties, C2E2 is suited towards an immediate release oral formulation. The high 
solubility, rapid dissolution and long-term stability of the powder assist in this goal. C2E2 
may be formulated as a capsule with minor excipient additions to aid processing. 
Alternatively, C2E2 could be formulated as a powder in a bottle and reconstituted upon 
administration. Other marketed products (sodium alginate for strontium decorporation
120
) 
have used a similar approach to overcome large oral doses.  
The absorption of both C2E2 and DTPA are limited by their charge, however 
masking of all five acids leads to increased toxicity due the increased intracellular absorption 
and chelation of essential metals. DTPA analogues with more than two ethyl esters exist in a 
liquid form at RT rather than in a solid form reducing aqueous solubility. Increasing the 
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length of the esters promoieties can also be used to increase lipophilicity, however once 
hydrolyzed long chain alcohols are more toxic than ethanol. Increased lipophilicity can also 
enhance cellular uptake resulting in chelation of essential metals and toxicity. Ultimately in 
the search for an oral DTPA prodrug a balance must be struck between increased absorption, 
stability and toxicity.  
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2.5. Conclusions 
 The physiochemical properties of C2E2 are more favorable for oral delivery than 
DTPA. Oral C2E2 solutions were shown to be effective when administered to rats 24-hours 
after contamination with 
241
Am-nitrate via i.m. injection. A single oral dose of C2E2 can 
induce significant improvement in total 
241
Am decorporation and reduction in 
241
Am liver 
and skeletal burden. Thus, this DTPA analog appears to be an effective orally administered 
medical countermeasure for treating individuals contaminated with transuranic elements. 
Based on the dose and stability profile, C2E2 may be formulated in either oral capsules or as 
a powder for reconstitution. The oral bioavailability, metabolism and efficacy in an 
additional species must be established to continue development of this drug. Additionally, the 
ability of C2E2 and its metabolite the mono-ethyl ester of DTPA to chelate 
241
Am must be 
investigated. Overall C2E2 is a promising candidate for oral decorporation of 
241
Am. 
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CHAPTER III 
 
SCALE-UP AND CHARACTERIZATION OF POLYMOPRHIC C2E2 
 
3.1. Introduction 
The experiments above were conducted using C2E2 synthesized at UNC as described 
in section 2.2. However once efficacy was established larger batch sizes were required in 
order to conduct additional studies. The synthesis was scaled-up by Synexsis Inc. (RTP, NC) 
producing batches on a kilogram scale. In order to aid the processing of larger batches, the 
synthesis method was altered. 
Diethylenetriamine pentaacetic acid (DTPA) (2029 g, 5.16 mole) was dissolved in 
acetonitrile (1100 mL) with agitation. Acetic anhydride (1450 mL, 15.3 mole) and pyridine 
(1660 ml, 20.5 mole) were added and the reaction was heated to 60°C for 4 hours. The 
reaction mixture was cooled to 22°C and t-butyl methyl ether (MTBE) (800 mL) was added. 
The reaction mixture was filtered and the solid obtained was washed with MTBE (3000 mL). 
The solid was dried in a vacuum oven at 40°C. Yield: 1792 g, 97%. The bis-anhydride (1792 
g, 5.02 mole) was slurried in absolute ethanol (9000 mL) and heated to reflux with agitation 
for 1.5 hour. The heated reaction mixture was filtered through Celite and cooled below 20°C. 
The resulting slurry was filtered and washed with cold ethanol (2800 mL) followed by 
MTBE (3500 mL). The Celite cake was slurried in ethanol (800 mL) and heated to 70°C and 
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filtered. On cooling, the slurry obtained was filtered and washed with ethanol and MTBE. 
The combined isolated solids were dried in a vacuum oven at room temperature. The 
resulting slurry was filtered and washed with cold ethanol (2800 mL) followed by MTBE 
(3500 mL). The Celite cake was slurried in ethanol (800 mL) and heated to 70°C and filtered. 
On cooling, the slurry obtained was filtered and washed with ethanol and MTBE. The 
combined isolated solids were dried in a vacuum oven at room temperature. Yield: 1488 g, 
66%. From this point forward, unless otherwise stated, all studies were conducted with C2E2 
synthesized at Synexsis. 
 Upon receiving the Synexsis material differences in solubility were seen. 
Precipitation of solutions occurred at concentrations below the previously identified 
solubility. Therefore in order to identify the cause of this problem the material was 
characterized in the same manner as the UNC material. In addition SEM images were taken 
of both batches. After identifying the cause of the solubility differences additional 
pharmaceutical characterization methods were employed to further improve our 
understanding of C2E2s properties. 
 The stability of C2E2 was previously determined in simulated gastric and intestinal 
fluids with no significant ester hydrolysis is expected to occur during gastric transit. To 
further understand the ester hydrolysis kinetics, a pH stability profile was obtained for C2E2 
over the pH range 2-9. The metabolic stability of C2E2 was also investigated using both 
intestinal and hepatic S9 fractions and plasma to understand species differences in 
metabolism. 
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3.2. Methods 
 
3.2.1 Solid Characterization 
The structure of C2E2 was confirmed by elemental analysis, 
1
H-NMR, 
13
C-NMR and 
mass spectroscopy. Differential scanning calorimetry (DSC), thermogravimetric analysis 
(TGA) and X-Ray powder diffraction were performed using the same methods as described 
in section 2.2. Additionally, scanning electron microscopy was performed on both solids. The 
solids were coated with a thin layer (5 nm) of metal using a sputter coater (Cressington 108) 
and images collected on a Hitachi S-4700 SEM. 
 
3.2.2 Buffer Stability 
 Buffers were prepared across a range of pH values at constant ionic strength (600 
mM). To determine the hydrolysis kinetics of C2E2 at each pH, approximately 9 mg of C2E2 
was weighed into a 7 mL vial and the desired buffer was added to achieve a concentration of 
3 mg/mL. The samples were stored at 40
o
C for the duration of the experiment. The pH of the 
samples was checked and an initial concentration determined by HPLC. At each time-point 
15 l of sample was withdrawn and diluted in 285 l of water and stored at 4oC until analysis 
by HPLC. The pH of the samples was checked periodically to ensure the samples were 
effectively buffered. All conditions were run in triplicate. 
 
3.2.3 In vitro Plasma Stability 
Pooled rat, beagle and human plasma (Xenotech) were used for stability testing of 
C2E2. Prior to the study a fraction of the plasma was inactivated for negative control 
samples. This was achieved by heating plasma at 56ºC for 1 hour. For each sample 975 µl of 
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plasma (Rat, Beagle and Human) was preheated to 37ºC in eppendorff tubes. The test 
compound (C2E2 or diltiazem) was prepared in DMSO (10 mg/ml). To initiate the study 25 
µl of the test solution was added to the pre-heated plasma and briefly vortexed to mix. At 0, 
15, 30, 60 and 120 minutes a 150 µl sample of plasma was taken and an equal volume of cold 
acetonitrile added and mixed to precipitate plasma proteins. The sample was then centrifuged 
at 4 ºC and 14,000 x g for 10 minutes to remove precipitated proteins, the supernatant 
collected and the concentration determined by HPLC-CAD (C2E2) or HPLC-UV (diltiazem). 
All conditions were performed in triplicate. Diltiazem was used as a positive control 
compound, and heat-inactivated plasma as the negative control. 
 
3.2.4 In vitro S9 Stability 
C2E2 (5 mM final concentration) and buffer (phosphate pH 7.9) were pre-incubated 
at 37
o
C for 5 minutes. S9 fractions (1 mg/mL final concentration) were added to the buffer 
and incubated at 37
o
C for 0, 5, 10, 15, 30, 60 or 120 minutes. Metabolism was terminated at 
each time point by the addition of 100 µl of ice-cold ACN. The samples were vortexed and 
kept on ice before being centrifuged at 14,000 x g for 10 minutes. The supernatant was 
collected and the concentration of C2E2 analyzed by HPLC. 
Reaction Conditions 
Hepatic S9 
Reagent Volume (l) 
S9 fraction 5 
C2E2 (50 mM) 10 
Buffer 85 
 
Intestinal S9 
Reagent Volume (l) 
S9 fraction 25 
C2E2 (50 mM) 10 
Buffer 65 
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3.3. Results 
 
3.3.1 Solid Characterization 
The identity of C2E2 was confirmed by 
1
H-NMR, 
13
C-NMR and mass spectroscopy 
with results consistent with the structure. Elemental analysis was performed with the 
following results found C: 48.23%; H: 6.81%; N: 9.25%. Theoretical C: 48.10%; H: 6.95%; 
N: 9.35%. As with the C2E2 synthesized at UNC, DSC identified a single-phase transition 
for C2E2. Although, the UNC synthesis method had a melting point of 115.8
o
C and the 
endothermic heat loss was 95.3 J/g compared to the Scynexsis batch with a melting point of 
133.5 
o
C and an endotherm of 86.3 J/g (Figure 3.1). The use of TGA, again confirmed the 
endotherms observed during DSC studies was the melting point as there is no significant 
weight changed observed on the TGA thermogram for either compound at the associated 
temperature, which is indicative of a phase change rather than decomposition or desolvation. 
Similarly there was a small loss in weight observed during TGA analysis, prior to 
decomposition (Figure 3.2). The loss was gradual, not attributed to a specific temperature, 
and non-stoichiometric suggesting that surface/incorporated water was the cause and that the 
difference in properties was not due to the present of a solvate. Both solids begin to 
decompose around 170
o
C as seen by the rapid weight loss. The differences in melting points 
however, suggest the presence of polymorphs. From this point forward the C2E2 produced at 
UNC will be designated polymorph I, and that synthesized by Scynexsis, polymorph II. In 
addition to being used for identification of solid phases, XRPD can be used to detect 
polymorphs. Figure 3.3 shows compares the XRPD patterns obtained for both solids. The 
results demonstrate that both solids are crystalline albeit with distinctive structures. 
Confirmation of the structural difference and the presence of two polymorphs was obtained 
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by SEM (Figure 3.4). Polymorph I is scaly in nature, as opposed to the divergent habit of 
polymorph II, which possesses a triclinic crystal form. The solid characterization data 
suggests that C2E2 has two polymorphic forms. The higher melting point and lower 
solubility (observed as precipitating out during storage in the refrigerator) suggests that 
polymorph II is the most stable. This was also confirmed by a competitive ripening 
experiment, where upon stirring of a mixed solution of the two forms overnight polymorph II 
is the resultant form. 
 
3.3.2 Buffer Stability 
 The pH-dependent stability of C2E2 was evaluated across the pH range 2-9. The loss 
of C2E2 followed pseudo-first order kinetics and the rate observed rate constants (Kobs) were 
calculated by least squares regression. Figure 3.5 shows the U-shaped pH-rate profile 
determined in 200 mM buffer with the greatest C2E2 stability observed between pH 5-6. 
Based on this profile the hydrolysis of C2E2 is anticipated to occur as depicted in Figure 3.6. 
Below pH 4 where the triprotic form and above exists acid-catalyzed hydrolysis (KH) is the 
predominant mechanism. The diprotic form is both acid (K
’
H) and base (K
’
OH) catalyzed and 
the monoprotic form undergoes base-catalyzed hydrolysis (K
’’
OH). The pKa values obtained 
in section 4.3 and nonlinear regression analysis was used to fit that data to the equation
121
: 
Kobs =
[H + ]4KH +[H
+ ]3K 'HKa1 +[H
+ ]K 'OHKa1Kw +K
''
OHKa1Ka2Kw
[H + ]3 +[H + ]2Ka1 +[H
+ ]K a1Ka2
 
The rate constants were calculated to be KH = 0.05 h
-1
 M
-1
, K
’
H = 2.39 h
-1
 M
-1
, K
’
OH = 2.62 h
-1
 
M
-1
 and K
’’
OH = 749.5 h
-1
 M
-1
. 
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3.3.3 Plasma Stability  
The stability of C2E2 was investigated using rat, beagle and human plasma in vitro. 
C2E2 is stable in plasma with no significant loss observed in both rat and beagle samples 
over two hours. Similarly in human plasma 90 % remained intact at the conclusion of the 
study. Degradation of the positive control (diltiazem) was seen across all species, with the rat 
producing the highest metabolism. The heat inactivation procedure for production of negative 
control data was unsuccessful as diltiazem was metabolized as efficiently in these samples. 
However degradation of both positive and negative control samples demonstrates that 
enzymes were functional.  
 
3.3.4 S9 Fraction Stability 
 The metabolism of C2E2 by rat and beagle hepatic and intestinal S9 fractions was 
determined in vitro. As with plasma samples no significant metabolism of C2E2 was 
observed. In general greater metabolism was seen with the intestinal S9 fractions. Although 
significant loss is seen in rats at 120 minutes this result does not follow the trend and is 
assumed to be due to poor sample processing. The lack of C2E2 metabolism in plasma and 
S9 fractions supports the fact that C2E2 is the most predominant form in the plasma after 
administration. 
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Figure 3.1  Differential scanning calorimetry chromatograph of polymorph I (red) and II 
(blue). 
 
 
 
 
 
 
 
Figure 3.2 Comparison of polymorph I (red) and II (blue) by thermogravimetric analysis. 
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Figure 3.3 X-Ray powder diffraction (XRPD) chromatographs for polymorphs I and II 
depicting the differences in crystal structure. 
 
 
 
 
Figure 3.4 Scanning electron microscopy images of polymorph I and II, displaying the 
different crystal habits of each form. 
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Figure 3.5 pH-rate stability profile of C2E2 at buffer concentrations of 200 mM with 
constant ionic strength (I = 0.6 M). 
 
 
 
 
 
 
Figure 3.6 Schematic of the proposed acid and base catalyzed hydrolysis pathways for 
C2E2. 
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Figure 3.7 Stability of C2E2 in rat, beagle and human plasma. 
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Figure 3.8 Metabolism of C2E2 by rat and beagle hepatic S9 fractions. Graph depicts 
mean of triplicate samples (+ SD). 
 
 
 
 
Figure 3.9 Metabolism of C2E2 by rat and beagle intestinal S9 fractions. Graph depicts 
mean of triplicate samples (+ SD). 
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3.4. Conclusion 
 
 The scaled-up synthesis of C2E2 led to the formation of a more stable polymorph. All 
the subsequent studies in this thesis were conducted with the most stable polymorph. The 
stability of C2E2 was also further characterized across the pH range with greatest stability 
observed between pH 5-6. In addition to being stable in simulated gastric and intestinal fluids 
metabolism of C2E2 by hepatic and intestinal S9 fractions is insignificant. Furthermore there 
is no significant hydrolysis of the esters in plasma. These results suggest that C2E2 is poorly 
metabolized and is likely to be the predominant species present in plasma after 
administration.  
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CHAPTER IV 
 
SPECIES-DEPENDENT CHELATION OF 
241
AM BY DTPA DI-ETHYL ESTER 
 
4.1. Introduction 
Recent nuclear accidents such as the meltdown at the Fukushima nuclear power plant 
in 2011 and the increasing threat of terrorism has spurred research interest in medical 
evaluation and treatment of contaminated individuals
51
. In the event of a public health 
emergency the US maintains a Strategic National Stockpile containing medical supplies used 
protect the public. Of particular interest is diethylenetriamine pentaacetic acid (DTPA), one 
of only three drugs with FDA approval for treatment of internal contamination. DTPA is an 
aminopolycarboxylic acid chelating agent with eight potential metal coordination sites that 
allow binding to a wide range of metals with high affinity
122
. Two forms of DTPA, namely 
the pentetate calcium trisodium injection (Ca-DTPA) and pentetate zinc trisodium injection 
(Zn-DTPA), received FDA approval for treatment of internal contamination with Plutonium, 
Americium or Curium. However, due to its poor bioavailability (~3%)
110
, DTPA requires 
intravenous administration by medical professionals, which would prevent timely distribution 
in a mass casualty scenario. Americium rapidly clears from the plasma to the tissues with > 
90 % cleared 60 min after an IV injection and only a small fraction is excreted in the urine
123
. 
Early access to treatment therefore improves decorporation by minimizing tissue deposition
 76 
 of the radioactive material. The loss of efficacy caused by treatment delay cannot be 
compensated for by increasing the cumulative dose
124
, therefore there is a need to develop 
patient-friendly formulations that can be easily distributed and self-administered. 
In order to improve the oral bioavailability of DTPA a number of novel formulation 
approaches have been investigated such as nanoDTPA capsules
105
 and permeation 
enhancers
104, 119
. Alternatively in our lab we have focused on the development of DTPA pro-
drugs
94, 125
. These penta-ethyl ester prodrugs of DTPA although highly absorbed are limited 
by their toxicity and the potential to form ten metabolites complicating their regulatory 
approval. Therefore, in order to avoid these difficulties the di-ethyl ester of DTPA, named 
C2E2, was selected for further development due to its cleaner metabolic profile and lower 
toxicity.  
In the case of all of these approaches there is an insufficient patient population to conduct 
well-controlled clinical trials. Furthermore, it is unethical to contaminate healthy individuals 
in order to determine efficacy. Therefore, to encourage the development of such products the 
FDA introduced the ‘Animal Efficacy Rule’ 21CFR(314.600), which provides a pathway for 
approval of a drug if its efficacy is demonstrated in more than one animal species in 
conjunction with safety data from animals and healthy human volunteers
126
. For this 
pathway, the mechanism of action needs to be understood and the animal models selected to 
establish efficacy must be demonstrated as appropriate. In order to fully understand the 
mechanism of action of these agents the binding affinities should be determined. 
Additionally, previous research with DTPA revealed that there are species differences in the 
plasma concentrations of DTPA required for chelation of 
241
Am
119, 120
. Consequently, to 
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justify the animal models used for efficacy studies the binding of novel prodrugs should also 
be evaluated in animal plasma to confirm the appropriateness of the species.  
Although C2E2 is designed to be a pro-drug of DTPA, due to its three free acids and 
three tertiary amines acting as metal coordination sites, it is also likely to act as a chelators 
itself. Similarly, its primary metabolite, the mono-ethyl ester of DTPA, named C2E1, is also 
expected to bind metals with affinities between those of DTPA and C2E2. The binding 
affinities of C2E2 and C2E1 for Am
3+
 are of significance, although they are expected to be 
lower than DTPA, as the presence of these ligands in plasma could contribute to the overall 
decorporation efficacy of C2E2 therapy. Furthermore, even if the binding affinities are lower 
than those of DTPA they may still be several orders of magnitude greater than those of the 
plasma proteins to which 
241
Am is bound. 
Below the ability of C2E2 and its metabolite C2E1 to chelate 
241
Am is investigated. The 
differences of plasma concentrations required for efficacy in rat, beagle and human plasma is 
also determined. The in vitro plasma concentrations are then combined with pharmacokinetic 
data from dogs to demonstrate the dose required to achieve efficacy and the likely duration of 
action.  This work will be used to support justification of animal model selection in future 
efficacy studies and aid development of a pharmacokinetic-pharmacodynamic model to help 
establish the required human efficacious dose.  
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4.2. Methods 
 
4.2.1 Materials 
The di- and mono-ethyl esters of DTPA were obtained from Synexsis Inc (Durham, NC). The 
synthesis of the diethylester was achieved by first synthesizing DTPA bis-anhydride 
followed by its subsequent reflux with ethanol as previously described
90
. The monoethyl 
ester of DTPA was obtained as an impurity during the synthesis and was separated using 
chromatography. The 
241
AmNO3 stock solution was obtained from Eckert & Ziegler Isotope 
Products (Valencia, CA). 
 
4.2.2 Ionization Constants 
 The protonation constants for C2E2/1 were determined by preparing a 5 mM solution 
of free ligand in 0.15 M KCl. The constants were calculated from three replicates, with each 
experiment consisting of a titration with acid, followed by a titration with base. After each 
addition of titrant, a 30 second equilibration time passed before pH measurement with a 
Seven Easy pH meter and (Ag/AgCl reference) glass electrode (Metler Tolledo). At the end 
of the titrations the presence of C2E2/1 was confirmed by HPLC-CAD.  
 
4.2.3 Solvent Extraction Studies 
The formation constant for the 
241
Am/C2E2 complex was determined by a solvent 
extraction method similar to that described previously
127
. The experiments conducted with 
tracer amounts of 
241
Am (16.7 MBq.L
-1
) using an organic phase of 0.1 M HDEHP in 
dodecane and aqueous phase consisting of 0.1 M NaCl at pH 1.3. The concentration of ligand 
in the aqueous phase ranged from 0.05 to 100 M. On addition of aqueous phase the samples 
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were vortexed and then maintained at 25°C for 60 minutes by means of thermomix automatic 
shaker. Following incubation the two phases were separated by centrifugation (10,000g, 10 
min) and a 100 μL sample of each phase was collected and the 241Am content in each sample 
fraction was measured by gamma scintillation counting (Perkin Elmer Model 2470 Gamma 
Counter). Background-corrected radioactivity was quantified over 30 min using a 40-80 keV 
energy window to measure the 59.7 keV photon emission associated with 
241
Am decay. 
Experiments were performed in triplicate. In addition to determining the distribution in the 
presence of C2E2, C2E1 or DTPA, the HDEHP solvent loaded with 
241
Am was contacted 
with a 0.1 M NaCl solution at pH 1.3, free of chelating ligand to determine Do. 
 
4.2.4 Competitive Binding Studies 
The ability of C2E2 and its primary metabolite C2E1 to chelate plasma bound 
241
Am 
in blood was investigated by in vitro experimentation using a method developed in our lab 
for DTPA
119, 120
. As previously described various concentrations of chelating ligand were 
combined with 
241
Am in rat, beagle or human plasma before separation and evaluation. All 
samples utilized 385 µl of plasma, 8 µl of ligand and 7 µl of 
241
Am solution. The ligand stock 
solutions were prepared in 10 mM sodium phosphate buffer at pH 7.4. The final 
concentrations of ligand used ranged from 0.5 to 750 µM in rat, beagle and human plasma 
for both C2E2 and C2E1. The 
241
Am stock solution was prepared by diluting 
241
AmNO3 in 1 
M hydrochloric acid. The resulting concentration of 
241
Am nitrate once combined with 
plasma and ligand was 3 nM. 
Once combined the samples were incubated for 60 minutes in a heating block at 37 
o
C with mild agitation before being transferred to an Amicon Ultra centrifugal filter with a 
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Ultracel 3K membrane (Milipore, Billerica, MA) and centrifuged at 14,000 x g for 30 min to 
extract the protein bound fraction. The filtrates were subsequently transferred to Pierce 
Strong Cation Exchange Spin Columns (Thermo Fisher Scientific, Rockford, IL) that had 
been conditioned with 0.8 M ammonium hydroxide and water to separate positively charged 
241
Am species from ligand-bound 
241
Am. Elution on the ligand-bound 
241
Am species was 
achieved by centrifuging at 2000 x g for 5 min. The positively charged 
241
Am species were 
collected by further centrifugation at 2000 x g with 1 M nitric acid. The 
241
Am content of 
each fraction was determined by gamma scintillation counting (Pelkin Elmer Model 2470 
Gamma Counter, Waltham, MA). Background corrected radioactivity was quantified over 30 
min using a 40-80 keV energy window to measure the 59.7 keV photon emission associated 
with 
241
Am decay.  
The dose-response curves were produced by calculating the fraction of total 
241
Am 
that was bound to C2E1, C2E2 or plasma proteins. The sigmoidal regression profiles were 
generated by Gauss-Newton non-linear least squares regression analysis using SAS 9.3 
(SAS, Cary, NC). The regression applied the logistic equation
128
; 
𝑦 =
𝑐
1 + 𝑒𝑎(𝑏−𝑥)
 
where; a describes the slope as the curve approaches the asymptote, b is the inflection point, 
c is the asymptote, and x is the log transformed concentration of C2E1 or C2E2 that 
corresponds to y, the fraction of bound 
241
Am. The EC50 values were determined by setting y 
equal to 50% of the c term and calculating for x. The same regression analysis was applied to 
the data for 
241
Am-protein binding; however, a transformation was applied to yprotein such 
that,  
𝑦′ = 100 − 𝑦𝑝𝑟𝑜𝑡𝑒𝑖𝑛 
 81 
where y’ was used for the regression analysis. Subsequent reversal of the transformation 
produced the final binding curves. 
 
4.2.5 Pharmacokinetics of C2E2 in Beagle Dogs 
Two male and two female beagle dogs were administered a single 100 mg/kg dose of 
C2E2 via oral gavage (12.05 mg/mL). The dogs were 8 to 10 months old, and their body 
weights were 11.4 and 12.0 kg for the males and 10.1 and 10.9 kg for the females. During the 
study they were housed individually and fasted overnight prior to dosing with food returned 
approximately 2 hours after dose administration. Blood (0.7 mL) was collected via a jugular 
vein pre-dose and at 0.5, 1, 2 4, 6, 8, 12 and 24 hours post dose in vacutainer tubes 
containing 5mg sodium fluoride and 4 mg potassium oxalate. The tubes were pre-chilled, 
once added the sample was inverted several times prior to centrifugation at 4 
o
C for 10 
minutes (1300 x g) within 15 minutes of collection. 125 µL of plasma was transferred to a 
micro centrifuge tube containing 125 µl of 20 % formic acid, vortexed and stored on dry ice 
prior to being stored in a freezer (-80
 o
C) until analysis was conducted.  
The plasma concentrations of C2E2 and its metabolites, C2E1 and DTPA were 
quantified using two LC/MS/MS methods. One method was used for C2E2 and C2E1 and 
another for DTPA. For C2E2, 100 µl of the acidified samples was treated with 400 µL 
acetonitrile containing internal standard (
13
C5-C2E5) followed by mixing and centrifugation. 
400 µL of the supernatant was subsequently removed, evaporated and reconstituted with 500 
µL water/acetonitrile/formic acid (85/15/0.1) for injection. The separation of the components 
was performed on a YMC ODS-AM (100 x 2.1 mm, 3.5 µm) column with a mobile phase 
gradient starting with 0.1% formic acid in water and ending with 0.1 % formic acid in 
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acetonitrile. The compounds were detected on a triple quadrapole mass spectrometer using 
heated electrospray ionization in the positive-ion mode. For DTPA, an excess of Fe(III) was 
utilized to ensure formation of an Fe(III)-DTPA complex for quantification. A 
13
C5-DTPA 
internal standard was used. 100 µl of the acidified samples was treated with 50 µL of 2 mM 
Fe(III)Cl2 and allowed to incubate for 90 minute. Acetonitrile (400 µL) containing internal 
standard was added. After mixing and centrifugation, 350 µL of the supernatant was 
removed, evaporated and reconstituted with 100 µL of mobile phase. Separation was 
performed using a Phenomenex Luna phenyl-hexyl (150 x 2mm, 3 µm) column with a 
mobile phase gradient starting with water/methanol (90/10) with 1 mM acetic acid and 1 mM 
tributylamine and ending with acetonitrile/methanol (50/50) with 1 mM acetic acid and 1 
mM tributylamine. The DTPA was detected on a triple quadrapole mass spectrometer using 
heated electrospray ionization in the negative-ion mode. 
Quantification of C2E2 and DTPA was based on the peak areas of analyte to their 
respective internal standards. The range of quantification was 100 to 100,000 ng/mL for 
C2E2, 5 to 1,000 ng/mL for C2E1 and 10 to 1,000 ng/mL for DTPA. The approximate 
precursor-product ion transitions and approximate retention times are described in Table 4.1. 
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4.3. Results 
4.3.1 Ionization Constants 
 Evaluation of the titration curve for C2E2 (Figure 4.1) identified 6 pKa values that 
correspond with the three tertiary amines and three carboxylic acids. The C2E2 molecule 
exhibits resistance to pH change over the region of 1.8 – 2.7 where the molecules 
overlapping pKa’s lie. In order to determine these overlapping values a Bjerrum plot was 
used where the average number of protons (nH) bound to the ligand at each pH was 
calculated and the pKa values occur at half integer values of nH. These plots have previously 
been utilized to establish the 6-pKa molecule, vancomycin or even the 30-pKa molecule, apo-
metallothionein
129
. The values determined from the Bjerrum plots were used as seed values 
for refinement in HYPERQUAD. The calculated ionization constants are shown in Table 4.2. 
The pKa’s determined for C2E2 are consistent with DTPA analogues previously investigated 
for use as MRI contrast agents with two carboxylic acids are functionalized such as DTPA-
BMA
130
 and DTPA-BBA
131
.  
 
4.3.2 Solvent Extraction Studies 
The formation constants of the Am(III)/ligand complex were determined using a 
solvent extraction method. Tracer levels of 
241
Am were combined with HDEHP diluted in the 
dodecane organic phase. Distribution ratios, D, were determined as a function of ligand 
concentration at constant pH (1.3). As expected when the concentration of competing ligand 
is increased the 
241
Am is chelated from the organic phase into the aqueous phase (Figure 4.2). 
The results indicate that C2E2 retains the ability to chelate 
241
Am albeit at higher 
concentrations than those of DTPA. In order to achieve the same degree of binding C2E2 
concentrations need to be approximately 20-fold higher than those of DTPA. In comparison 
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C2E1 retains a higher affinity for 
241
Am with only 5-fold increases in concentration required 
to match DTPA.   
  In order to quantify these differences in affinity for 
241
Am the conditional stability 
constants (lg cond) of the complexes were determined by linear fitting of the variations of 
(D/Do - 1) versus CLigand as described by Leguay et al.
127
 (where Do stands for the D value in 
the absence of ligand). The lg cond for C2E2, C2E1 and DTPA were 1.36, 2.46 and 2.70 
respectively. From the pKa values it is known that at pH 1.3, the predominant ligand species 
is in the protonated form and therefore the calculated formation constants are 19.6  0.2, 21.7 
 0.5 and 25.4  0.3 for C2E2, C2E1 and DTPA, respectively. These values indicate that the 
stability of the C2E2-
241
Am complex is 6 log units lower than that of the DTPA-
241
Am 
complex. The solvent extraction data determined for DTPA and the corresponding formation 
constant is consistent with that previously determined
127
. 
 
4.3.3 Competitive Binding Studies 
The suitability of this method for separation of both protein-bound 
241
Am and DTPA-
bound 
241
Am was previously determined by Sueda et al.
119
 At physiological pH 
241
Am in 
solution is present as the +3 oxidation state and DTPA exists in the -5 oxidation state. 
Therefore, DTPA-bound 
241
Am is results in a negatively charged complex, which is able to 
pass through the cationic filter. If the same logic is followed for C2E1 and C2E2 then the 
complexes with 
241
Am are expected to be negatively and neutrally charged. As with DTPA, 
preliminary studies were conducted to confirm C2E1/2-bound 
241
Am passed through the 
cation filter further confirming that the protein, ligand and free fractions could be adequately 
separated. In the previously performed studies the 
241
Am stock was a citrate salt however, for 
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the present work 
241
Am nitrate was used to ensure consistency between the in vitro 
characterization and planned in vivo studies. Reevaluation of DTPA binding with 
241
Am 
nitrate was therefore performed to help further characterize the model and enable 
comparisons between each ligand. The dose response curves for C2E2, C2E1 in rat, beagle 
and human plasma are shown in figure 4.3a-f. The binding of 
241
Am to either the ligand or 
plasma proteins follows a sigmoidal profile characteristic of a competitive binding 
relationship. The parameters obtained from the logistic regression analysis are show in Table 
4.3. There were minor losses of activity during transfer steps however there was > 95% 
recovery for all samples. A minor fraction < 10% of each sample was considered to be 
associated with either small organic or inorganic ligands present in the plasma with affinity 
for 
241
Am such as carbonates and citrates. Similarly to the solvent extraction study, C2E2 and 
C2E1 were able to chelate 
241
Am from the plasma, albeit at higher concentrations than 
required with DTPA. The efficiency with which each ligand bound 
241
Am varied between 
species. To permit comparisons between the different species and ligands the EC50 values for 
the each condition have been calculated. The maximum percentage of 
241
Am capable of 
being bound is 45-65 % in all species. The EC50 value represents the concentration of ligand 
at which 50 % of maximal chelation occurs. The concentrations of ligand to achieve similar 
levels of chelation were highest in rat plasma and lowest in beagle plasma. The 
concentrations required in human plasma lay between those of each species. This suggests 
that if used for approval via the animal rule, efficacy in the rat model may underestimate the 
human response whilst beagle efficacy studies may result in an overestimation.  
The EC50 for each ligand can be used to determine the dose of each ligand required to 
obtain chelation. In addition incorporation of the relative binding numbers into a 
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pharmacokinetic model will help to determine the contribution of each ligand to the overall 
efficacy of C2E2. 
 
4.3.4 Pharmacokinetics 
 The homogeneity and concentration of the dosing solution was confirmed by HPLC 
by taking two samples form the top, middle and bottom of prepared solution. The solution 
was homogeneous and was found to be 97.8  0.5 % of the target concentration. The 
concentration-time profile for C2E2 and its metabolites in beagle dogs is shown in Figure 
4.4. There was no significant difference between the AUC0-24 for each sex, so the data was 
combined into a single profile, though the lack of significance may be due to the small the 
size of each group. The data was modeled using a two-compartment model with elimination 
from the central compartment, along with first-order absorption. The use of a two 
compartment model is consistent with the elimination of DTPA from dogs
132
. C2E2 is 
rapidly absorbed reaching its peak concentration 1 hour after administration. Elimination 
occurs from the first compartment with a half-life of 0.69 hours and from the second 
compartment with a half-life of 6.66 hrs. Only a small fraction (~2%) of the absorbed dose 
was hydrolyzed to C2E1, or DTPA and the concentrations of both of these ligands are below 
those required to effectively chelate 
241
Am. By combining the in vitro competitive binding 
concentrations with the pharmacokinetic profile time for which plasma concentrations of 
C2E2 are above those necessary to achieve both 50 and 90 % of the maximal binding can be 
determined. The concentration of C2E2 is above the 90 % threshold for 3.8 hrs and above the 
50% threshold for 4.7 hrs. These results suggest that any efficacy observed in dogs at 100 
mg/kg doses is due to C2E2 and not its metabolites. 
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Table 4.1 The precursor  product ion transitions and retention times for C2E2, C2E1 
and DTPA used during LC/MS/MS quantification. 
Analyte Precursor  product Approx. retention time 
(min) 
Fe-DTPA m/z 445  m/z 313 3.7 
Fe-DTPA-IS m/z 450  m/z 350 3.7 
C2E1 m/z 442  m/z 160,188 1.0 
C2E2 m/z 450  m/z 188, 216 3.1 
C2E5-IS m/z 539  m/z 218 6.3 
  
 
Table 4.2 Acid dissociation constants determined for C2E2 and C2E1 compared to those 
known for DTPA. 
Ligand pKa7 pKa6 pKa5 pKa4 pKa3 pKa2 pKa1 
DTPA 1.45  
0.15 
1.60  
0.15 
1.80  
0.05 
2.55  
0.05 
4.31  
0.02 
8.54  
0.02 
10.51  
0.01 
C2E1 < 1.5 < 1.5 1.18  
0.45 
1.72  
1.5 
2.99  
0.05 
6.35  
0.38 
9.63  
0.03 
C2E2 - 1.45  
0.09 
1.76  
0.05  
1.87  
0.05  
3.52  
0.03  
4.68  
0.02  
9.40  
0.02 
 
 
Table 4.3 Logistic equation parameters and calculated EC50 and EC90 values for C2E2, 
C2E1 and DTPA binding with 
241
Am. 
Ligand Plasma 
Parameters for logistic equation  
(Estimate ± 95 % Conf. Interval) EC50 (µM) EC90 (µM) 
a b c 
C2E2 
Rat 0.04 ± 0.00 46.17 ± 3.43 54.62 ± 1.58 46.17 101.10 
Beagle 0.37 ± 0.02 4.91 ± 0.18 64.79 ± 0.50 4.91 10.85 
Human 0.23 ± 0.04 8.87 ± 0.80 60.29 ± 1.25 8.87 18.42 
C2E1 
Rat 0.06 ± 0.01 25.50 ± 3.36 45.74 ± 1.51  25.50 60.12 
Beagle 0.57 ± 0.13 2.02 ± 0.38 61.69 ± 1.4 2.02 5.87 
Human 0.16 ± 0.03 5.26 ± 0.74 55.22 ± 1.06 5.26 18.99 
DTPA 
Rat 0.31 ± 0.03 5.36 ± 0.43  35.69 ± 0.85 5.36 12.44 
Beagle 1.87 ± 0.69  1.08 ± 0.18  54.75 ± 2.16 1.08 2.25 
Human 0.98  ± 0.13 2.82 ± 0.30  55.88 ± 1.40  2.82 5.05 
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Figure 4.1 Titration of DTPA di-ethyl ester with 1 N potassium hydroxide. 
 
 
  
 89 
Figure 4.2 Distribution of 
241
Am as a function of total ligand concentration at I = 0.1 M 
(NaCl), T = 25 
o
C, pH = 1.3, and CHDEHP = 0.1 M in dodecane. 
 
 
  
Figure 4.3 The competitive binding of 3nM 
241
Am by C2E2 (a-c) and C2E1 (d-f) (solid line) and plasma proteins (dotted line) 
after 0.5 h incubation at 37 
o
C in rat (a, d), beagle(b, e) and human plasma (c, f).  
 
 
 
9
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Figure 4.4 The plasma concentrations of C2E2, C2E1 and DTPA after administration of 
a 100 mg kg
-1
 oral solution. The effective duration based on EC50 and EC90 values are 
indicated by dotted lines. 
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4.4. Discussion 
Due to the nature of internal radioactive contamination FDA approval of decorporation 
agents may proceed under the animal rule, whereby animal studies can be used to provide 
evidence for effectiveness. Under this rule the mechanism of action must be known and 
efficacy must be shown in more than one species and both should be shown to react with a 
response to similar to humans
133
. Exposure to americium is most likely to occur through 
either inhalation or wound sites from where redistribution to the primary sites of deposition 
such as the liver and bone will occur. This rate of distribution is based on many factors such 
as the site of deposition and the rate of solubilization and absorption of the internalized form 
into the plasma
134
. 
The primary site of action for C2E2 is the plasma during the redistribution of americium. 
Once in the plasma ~30 % of the total 
241
Am is bound to transferrin, ~30 % is associated with 
additional plasma proteins such as albumin and globulins and the remainder is bound to low 
molecular weight complexes such as citrate
34
. The americium-transferrin complex has a 
stability constant (log K1) of 10.4 and that of the citrate complex is 8.6
35b
. Thus even after 
removal of two of DTPA’s coordination sites, C2E2 retains the ability to bind americium at a 
strength nine orders of magnitude higher than that of the strongest ligand in the plasma. 
In addition to determining the affinity of C2E2 for 
241
Am, it is useful to determine the 
concentration required for effective chelation in plasma to aid justification of a specific dose. 
The data presented here confirms previous research suggesting that there are species 
differences in the effective concentrations required for chelation of 
241
Am between species
119
. 
This has implications for the choice of animal models used to demonstrate efficacy of 
decorporation agents. For the three ligands examined the concentrations required for 
chelation in rat plasma were higher than those needed in beagles and humans suggesting that 
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the efficacious human doses may be better approximated from beagle data. Plasma is a 
complex solution and the source of the species differences has not been determined. The 
concentration of transferrin, albumin and other serum globulins which are responsible for 
binding around 60 % of the 
241
Am are at similar concentrations across all three species, 
however the concentration of serum iron is higher in rat than beagle or human plasma. In the 
case of DTPA iron binds with a higher stability constant (Log K 28.0
135
) and will compete 
with 
241
Am, the extra iron present in rat plasma could be one cause for the higher 
concentrations required.  
Although predominantly in the plasma both C2E2 and 
241
Am also distribute into the 
interstitial fluid where the plasma protein concentration is lower (only 42 % of the plasma 
transferrin
136
). In this environment it is likely that the concentrations of C2E2 required to 
achieve binding are lower than those determined for plasma, therefore the duration of action 
may be longer than that predicted using effective ligand concentrations derived from plasma.  
The americium nitrate salt was used throughout these studies; this is in contrast to the 
previous studies with DTPA where the citrate salt was used. Comparison of concentrations 
required for effective DTPA chelation identified a difference between each salt. Differences 
in the plasma clearance of the citrate and nitrate complexes were reported
123
 with americium 
citrate clearing the plasma faster than the nitrate complex. This may be due to the low 
affinity of nitrate for americium (log K 1.3
137
) resulting in rapid binding to transferrin as 
opposed to citrate where the binding to transferrin may occur more slowly.  
The administration of chelation therapy via the oral route provides fast, economical and 
noninvasive access to treatment. In addition oral administration results in a lower CMax than 
IV treatments but causes an increase in the elimination half-life of the drug due to continued 
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absorption. Although, C2E2 was designed as a pro-drug there was limited hydrolysis of the 
esters and therefore low concentrations of C2E1 and DTPA. Though the lack of metabolism 
should not limit efficacy as after a 100 mg/kg oral dose the effective duration in dogs was 
increased by 2 hours (doubled) compared to the standard IV treatment. The administration of 
higher doses of C2E2 may result in further extension of the effective duration and increased 
concentrations of C2E1 and DTPA that may yield further increases in efficacy. 
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4.5 Conclusion 
Although the number of coordination sites available on the DTPA pro-drugs have been 
reduced compared with DTPA, C2E2, and its metabolite, C2E1, have maintained high 
affinity for 
241
Am. In addition to determining their binding constants relative to DTPA, the 
concentrations required to achieve binding in plasma have been investigated in vitro. As 
expected higher concentrations of C2E2 are required to achieve the same effect as DTPA. 
Species differences were noted in the concentrations of ligand required to achieve chelation 
with beagle plasma most representative of a human response. Oral administration of a 100 
mg/kg C2E2 dose to beagles demonstrated that the effective plasma concentrations could be 
reached. The binding constants and pharmacokinetic parameters determined as part of these 
studies can be combined with efficacy data into a pharmacokinetic-pharmacodynamic model 
with the aim of predicting decorporation efficacy from different dosages and dosing regimes.
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CHAPTER V 
 
C2E2 EFFICACY, TOXICITY & PHARMACOKINETICS IN RAT 
 
5.1. Introduction 
The following two chapters report on the efficacy of C2E2 in rats (Chapter V) and dogs 
(Chapter VI). Due to the nature of internal radionuclide contamination it is unethical to 
conduct human clinical efficacy trials. Furthermore, human contaminations are sporadic and 
inconsistent by nature so the patient population is too small to conduct well-controlled 
clinical trials. In order to overcome this problem a new pathway for drug approval was 
established by the FDA, known as the “animal rule”. This pathway allows drug approval in 
the absence of human efficacy trials if a sufficiently well characterized animal model for 
predicting human response. 
It is therefore imperative that the animal models used for demonstrating efficacy are 
carefully selected. The animal models chosen for this research were based on a range of 
criteria. Firstly the similarities in uptake, retention and clearance of radionuclides were 
considered. Unfortunately for americium, no single model accurately predicts the human 
biokinetics and two species can help to increase the confidence in the animal models 
response101. Therefore rat and dog models were chosen due to the availability of well-
established radionuclide pharmacokinetics studies in these species. 
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 Utilizing two animal models also serves an additional benefit, as efficacy can be 
investigated after different routes of radionuclide exposure. Both inhalation and wound site 
contaminations were selected as they are the most likely to occur in a mass casualty 
situation
138
. The choice of which species to contaminate via each route was based on 
literature precedent and ease of conducting the studies. On initiation of the project there were 
more than five published studies utilizing a rat inhalation contamination model or a rat 
wound model. For dogs, there were more than five articles using an inhalation model and 
only one using a wound model. 
Radionuclide clearance from the lung can be considered to occur via two competing 
pathways, either mechanical clearance or absorption into the blood
139
. The mechanical 
clearance of particles from the lung is species-dependent, in contrast dissolution and 
absorption to the blood is relatively independent
140
. The clearance half-life from the lungs of 
mice and rats, are typically on the order of 30-60 days. In comparison, long-term clearance 
halftimes of insoluble particles from the lungs of dogs, monkeys and humans are on the order 
of 900-1500 days
141
. Therefore, the biokinetics of inhaled aerosol particles in the dog’s 
respiratory tract would be most similar to that seen in humans. 
The National Council on Radiation Protection and Measurements (NCRP) has developed 
a biokinetic model based on experimental animal data for wound contamination
142
. The 
model was based predominantly on data obtained from studies in rats with smaller 
contributions from mice, rabbits and dogs. NCRP Report 156 concluded that the most 
important factors affecting the biokinetics of radionuclides in a wound site were the 
radionuclide and its chemical form, the deposited mass of radionuclide, the tendency of the 
radionuclide to hydrolyze at neutral physiological pH, and the type and magnitude of wound 
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injury (puncture, laceration, cut, burn)
143
. The effect of the species on the biokinetics was 
secondary to these factors, and as such, most experimental animal models were considered 
appropriate for interpreting human wound-site biokinetics and absorption rates to blood and 
lymph
142
. Therefore, for C2E2 studies the rat wound model and dog inhalation model was 
selected. This choice also allowed rat efficacy studies to be conducted at UNC, where 
contamination via inhalation is not possible.  
 Another important consideration during the design of efficacy trials was the treatment 
delay after contamination. For all the studies a delay of 24 hours was chosen, as this is a 
realistic time frame for delivery of the drug during a mass casualty situation. This also 
provides a conservative estimate of efficacy, with administration at earlier time-points likely 
to increase total decorporation and lower tissue retention. 
Overall the rat wound and beagle inhalation models are those that most closely 
resemble human contamination and have the largest volume of supporting data. 
Decorporation efficacy has been determined after administration of a single dose in both 
species and for rats multiple daily dosing was investigated for up to ten days. Additionally 
the bioavailability and pharmacokinetics have been investigated in rats. For both species the 
maximum tolerated dose has been determined for both a single dose and ten daily doses. The 
genetic toxicity potential of C2E2 was also evaluated using a standard battery approach 
including in vitro bacterial mutation assay, chromosomal aberration assay and micronucleus 
test (Chapter VI). 
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5.2 Methods 
 
5.2.1 Rat Am-Nitrate I.M. Contamination Model 
To prepare the injection solutions a 200 μL aliquot was withdrawn from a stock 
solution of 
241
Am nitrate (0.1 mCi in 5 mL 1 M HNO3)(Eckert & Ziegler Isotope Products, 
Valencia, CA), evaporated to dryness, dissolved in concentrated HNO3 (15 M, 5 mL) then 
evaporated to dryness and dissolved in dilute HNO3 (0.1 M, 8 mL) to form the injection 
solution. During efficacy studies each rat received 250 nCi of 
241
Am nitrate by intramuscular 
injection (0.1 mL, 0.1 M HNO3) into the right hind leg, under isoflurane anesthesia. In all 
studies there was a 24-hour delay from contamination to initiation of treatment in order to 
mimic a real life response time. The delay also allows the consistency of contamination 
between groups to be determined by comparison of the 
241
Am excreted within the first 24-
hours between each animal.  
 
5.2.2 C2E2 Multiple Dose Decorporation Efficacy in Rats 
Groups of 4 female Sprague-Dawley rats contaminated with 250 nCi of 
241
Am(NO3)3 
by IM injection were administered 7 daily oral doses of C2E2 by gavage at 84 or 200 mg/kg 
under ad lib feeding conditions utilizing a 10 % w/w solution of C2E2 in sterile water. 
Control groups with ad lib access to food and water were given 7 daily doses of medium 
chain triglyceride (MCT) (2 mL/kg) by oral gavage (MCT was the vehicle for another 
compound in the study). Treatment was initiated 1 day after contamination and was 
administered daily for 7 days. Animals were euthanized 12 days after contamination and the 
following tissues were collected: liver, both kidneys, both femurs as well as the ipsilateral 
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and the contralateral hind leg muscle tissue and pelt from the injection site. Urine and feces 
were collected from the time of contamination through euthanasia. Cage washings were also 
collected 24 hours after the last dose (Day 8) and at the end of the study (Day 12). Statistical 
analysis of endpoint data (total decorporation, liver burden, wound site retention and 
estimated skeletal burden) was by one-way ANOVA with Tukey’s post test. Effects were 
considered significant at p < 0.05. 
 
5.2.3 C2E2 Multiple Dose Decorporation Efficacy in Rats: 5 vs 10 Daily Treatments 
Sprague-Dawley rats (N = 8/gender/group) were contaminated with 250 nCi of 
241
Am(NO3)3 by intramuscular injection. Daily oral gavage treatment with C2E2 (600 mg/kg 
in water) was started 24 hours after contamination and continued for five (qd x 5 group) or 
ten days (qd x 10 group); a third group of untreated animals was included as a control. 
Excreta (urine, feces and cage washes) were collected daily until euthanasia 12 days after 
contamination at which time select organs were harvested. Statistical analysis of endpoint 
data (total decorporation, liver burden, wound site retention and estimated skeletal burden) 
was by one-way ANOVA with Tukey’s post test, and analysis of the effect of treatment on 
daily decorporation was by repeated- measures ANOVA with Tukey’s post test, in all 
analysis effects were considered significant at p < 0.05. 
 
5.2.4 Effect of Dosing Schedule on C2E2 Multiple Dose Efficacy in Rats 
Sprague-Dawley rats (N = 8/gender/group) were contaminated with 250 nCi of 
241
Am(NO3)3 by intramuscular injection. Immediately after injection, body weights were 
recorded (Day 0 weight) and animals placed in individual metabolic cages. The rats were 
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assigned to four groups; untreated control, 5 daily oral gavage doses of 600 mg/kg C2E2 
once daily, 5 twice daily oral gavage doses of 300 mg/kg C2E2 or 5 daily intravenous doses 
of Zn-DTPA solution (13.3 mg/kg) via a jugular vein catheter. The C2E2 dosing solution 
utilized was a 10% w/w solution in water. All animals were observed at least once daily for 
morbidity, mortality, and general appearance. Excreted urine and feces were collected at 2, 4, 
8, 10, 12, 14, 18, 20 and 24 hours after the first dose and daily for the remainder of the study. 
Statistical analysis of endpoint data (total decorporation, liver burden, wound site retention 
and estimated skeletal burden) was by one-way ANOVA with Tukey’s post test. Effects were 
considered significant at p < 0.05. 
 
5.2.5 Efficacy Studies: Tissue Collection and Processing 
All excreta were transferred to 20 mL scintillation vials, weighed and placed in a 
gamma counter (Wizard2 2480, Perkin Elmer) for detection of 
241
Am gamma activity. In 
addition following necropsy selected tissues were removed, weighed and placed in a gamma 
counter (Wizard2 2480, Perkin Elmer) for detection of 
241
Am gamma activity. The total 
amount of 
241
Am administered to the animals was determined by quantifying the 59.7 keV 
photons emitted by 
241
Am in duplicate aliquots (100 µL) of the injection solution using a 
gamma counter (wizard series, Perkin-Elmer). A counting window from 40 – 80 keV and a 
60-second counting time were used for acquisition and each reading was corrected for 
background at acquisition. All experimental tissues and samples were counted using the same 
gamma counter and protocol. For all the samples, 
241
Am content was expressed as a 
percentage of the initial dose. The femur from the leg opposite to the injection site was scaled 
by a factor of 20 to estimate total skeletal 
241
Am burden. 
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5.2.6 Acute Maximum Tolerated Dose of C2E2 in Rats 
Fifty Sprague-Dawley rats (Charles River Laboratories; 10–12 weeks) were housed 
individually with ad libitum access to food and water under a 12-hour light/dark cycle. The 
weights were 267 ± 23 mg and 188 ± 13 mg for the males and females respectively. C2E2 
was dissolved in DI water and each rat received 8 mL/kg of dosing solution. Rats (n = 
5/sex/dose) were administered vehicle control or C2E2 at 200, 600, 1000 or 2000 mg/kg by 
oral gavage. The dose was escalated depending upon tolerability of the previous dose based 
upon clinical signs and clinical chemistry. Clinical observations were conducted pre-dose, 
approximately 0.5, 1, 2 and 4 hours post dose and twice daily on non-dosing days. Four days 
after receiving C2E2, rats were euthanized by CO2 asphyxiation followed by thoracotomy. 
Blood was collected at necropsy via cardiac puncture and serum chemistry (alanine 
aminotransferase, aspartate aminotransferase, blood urea nitrogen, creatinine) was evaluated. 
Study endpoints were evaluated for normality followed by an ANOVA (p<0.05) and, if 
significant, groups were compared using the Holm-Sidak test.  If treatment groups failed the 
normality test, a Kruskal-Wallis ANOVA (p<0.05) on ranks with post hoc Dunn’s 
comparison to the control group was made. 
 
5.2.7 Ten Day Oral Dose Range Finding Study of C2E2 in Rats 
Male and female Sprague-Dawley rats (200-400 g; 10-11 weeks of age) were divided 
into groups of 5 rats/sex each and administered 0 (reverse osmosis water) or 200, 400, 800, 
or 2000 mg/kg C2E2 utilizing a dose volume of 8.3 mL/kg for up to 10 consecutive days.  
Parameters evaluated included clinical observations, body weight, food consumption, 
toxicokinetics, hematology, clinical chemistry, coagulation, urinalysis, trace elements 
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(blood), gross pathology, organ weights, and histopathology of selected tissues. Satellite rats 
(n = 3 for control animals; n = 6 per test article group) were used for toxicokinetic (TK) 
evaluations. The TK animals had blood collected via the jugular vein on Day 1 and Day 10 at 
0.25, 1, 3, 6, 12, and 24 hours post dose. A pre-dose sample was collected on Day 10 only. 
The TK time points for the two cohorts of C2E2-treated rats and the time points selected for 
the vehicle control animals are summarized in Table 5.1. Blood samples were rapidly 
transferred to vacutainer tubes (containing 5 mg sodium fluoride; 4 mg potassium oxalate). 
These tubes were inverted several times to ensure proper mixing and were maintained on wet 
ice or chilled cryorack. Samples were then centrifuged at 1,300 x g for 10 minutes at 4 °C 
within 15 minutes of collection. Aliquots (125 μL) of plasma were split into two chilled 2.0 
mL microcentrifuge tubes containing 125 μL 20% formic acid and were frozen on dry ice 
and stored at -80 °C until analysis. Analytical evaluation was performed by the UNC GLP 
Bioanalytical Facility as described in Chapter III (Calculated concentrations: C2E2, DTPA; 
Estimated concentrations: C2E3, C2E1). Pharmacokinetic parameters were derived by non-
compartmental methods for C2E2, C2E1, and DTPA using WinNonlin® Professional 
Version 6.2.1 (Pharsight Corp.).  
 
5.2.8 Determination of Oral Bioavailability in Rats 
A single dose pharmacokinetic study of C2E2 in Female Sprague-Dawley rats was 
performed. Jugular-cannulated Sprague-Dawley rats (226-250 g; n = 3 per time point) were 
divided into two groups and administered either a single IV (16.9 mg/kg; caudal vein) or PO 
(84 mg/kg) dose of C2E2 (water) under ad lib conditions. All rats had a pre-dose sample 
drawn on the day of dosing. Blood was collected from the jugular catheter (0.7 mL per draw; 
5 blood draws/animal) at 0.083, 0.25, 0.5, 1, 3, and 8 h post dose. Blood samples were 
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collected by syringe and immediately transferred to chilled vacutainer tubes containing 5 mg 
sodium fluoride and 4 mg potassium oxalate. These tubes were inverted to ensure proper 
mixing and placed on ice until centrifugation. Tubes were centrifuged at 1,300 x g for 10 
minutes at 4 °C within 5 minutes of collection. Aliquots of plasma were then divided into 
chilled 1.7 mL microcentrifuge tubes within 5 minutes of centrifugation. Analysis for C2E2, 
C2E1, and DTPA in plasma was performed at the UNC GLP Bioanalytical Facility. 
Pharmacokinetic parameters in plasma were determined from concentration-time profiles by 
established non-compartmental methods using WinNonlin® Version 5.2. 
 
5.2.9 Pharmacokinetics of 
14
C-C2E2 in Rats 
In order to further investigate the pharmacokinetics of C2E2, its metabolites and 
determine the fraction absorbed an additional single dose pharmacokinetic study in Male 
Sprague Dawley rats was performed using 
14
C-C2E2. Jugular- and portal-cannulated 
Sprague-Dawley rats (263-298 g; n = 3 per time point) were divided into four groups. Either 
a single IV (16.9 mg/kg; jugular or portal vein) or PO (600 mg/kg) dose of C2E2 (water) 
under ad lib conditions or fasted conditions. Blood was collected from the jugular catheter 
(0.7 mL per draw) at 0.083, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 h post dose. Blood samples were 
collected by syringe and immediately transferred to chilled vacutainer tubes containing 5 mg 
sodium fluoride and 4 mg potassium oxalate. These tubes were inverted to ensure proper 
mixing and placed on ice until centrifugation. Tubes were centrifuged at 1,300 x g for 10 
minutes at 4°C within 5 minutes of collection. Urine was collected at 2, 4, 8, 12 and 24 hours 
and feces were collected at 4, 8, 12 and 24 hours. 
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Analysis for C2E2, C2E1, and DTPA in plasma and urine was performed using a 
HPLC (Prominence UFLC; Shimadzu, Columbia, Maryland) with a flow-through 
radiochemical detector (Radiomatic 650TR; PerkinElmer). The HPLC method was the same 
as previously described for C2E2 analysis except detection and quantification occurred in a 
120 μL flow cell using standard measurement parameters for 14C rather than using the CAD 
detector. 
In addition total 
14
C content was analyzed by taking aliquots of plasma and urine, adding 
directly to 10 mL of scintillation cocktail (Ultima Gold; PerkinElmer, Waltham, 
Massachusetts) and analyzing by liquid scintillation counting (LSC; Tri-Carb 3110 TR, 
PerkinElmer). The LSC data were corrected for quenching using an external standard. Feces, 
were diluted with a 1:1 mixture of acetonitrile and pH 4, 25 mM citrate buffer and 
homogenized in polycarbonate vials containing steel grinding balls. The homogenization was 
performed by shaking the vials on the high throughput homogenizer (PowerGen; Thermo 
Fisher Scientific, Waltham, Massachusetts) for 5–8 min at high speeds. Approximately 200 
mg of each homogenate was sampled and combined with 1 mL of solvable (PerkinElmer) 
and heated in an oven at 60°C for 1–3 h until digestion was visibly complete. Once the 
samples were cooled, hydrogen peroxide (30% in water) was added in two aliquots of 100 μL 
to decolorize the sample. The samples were returned to the 60°C oven for an additional 1 h. 
After cooling, each sample was diluted with 10 mL of scintillation cocktail and analyzed by 
LSC. The radioactivity measured in each sample was weight-corrected to determine the total 
radioactivity in each whole tissue. 
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Table 5.1 Toxicokinetic Blood Collection Schedule. 
 
Group Set 
Day of 
Dosing  
Time Points
 
1 Three/sex 1, 10 1, 6, and 24 hours postdose 
2, 3, 4, 5 
1
st
 
three/sex/group 
1, 10 
0.25, 3, and 12 hours 
postdose 
2, 3, 4, 5 
2
nd
 
three/sex/group 
1 1, 6, and 24 hours postdose 
 
 
10 
Predose, 1, and 6 hours 
postdose 
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5.3. Results 
 
5.3.1 C2E2 Multiple Dose Decorporation Efficacy in Rats 
Extending the administration of C2E2 from a single dose to seven daily doses 
resulted in a significant enhancement in total 
241
Am elimination. Table 5.2 and Figure 5.1 
show total decorporation and residual liver burden at euthanasia after 7 daily oral doses of 
C2E2 compared to MCT control. Administration of seven daily doses of either 84 or 200 
mg/kg C2E2 to female rats, resulted in the total decorporation of 21.6  1.3 or 32.3  3.7% of 
the total injected dose, respectively. These results are similar to those achieved with a single 
600 mg/kg or 1000 mg/kg dose where total decorporation is 24.2  3.3% and 31.3  5.5%, 
respectively. Therefore, after 7 daily administrations, a 5-fold reduction in daily dose can 
achieve similar decorporation efficacy as a single dose. As with DTPA the enhancement in 
elimination was predominantly due to increased urinary clearance. 
 Liver retention of 
241
Am was significantly reduced (p<0.01) after multiple doses. The 
repeated administration of 84 mg/kg/day was as effective as a single 1000 mg/kg dose 
resulting in a liver burdens of 14.2  2.1%, and 13.7  1.3%, respectively. Skeletal burden 
was not significantly reduced by either dose. 
 Although increased decorporation was observed over control at both treatment levels, 
only the 200 mg/kg dose was significant (p <0.001) and administration of multiple IV DTPA 
doses further enhanced total decorporation and reduced liver burden compared to C2E2 
(Table 5.2 and Figure 5.1). 
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Table 5.2 Total 
241
Am Decorporation (Mean  SD), represented as percent of the 
administered 
241
Am dose, after treatment with increasing doses of orally administered C2E2 
or intravenously administered DTPA. Daily dosing began 24 h after contamination and 
continued for a total of 7 days. n = 4 for all groups. 
 
Drug Dose 
(mg/kg) 
Urine (%) Feces (%) Cage wash 
(%) 
Total 
Decorporation 
(% Injected) 
Liver 
burden (% 
Injected) 
Skeletal 
burden (% 
Injected) 
0 3.5  0.9 10.2  3.4 1.7  0.8 15.3  4.7 16.0  3.1 11.9  3.5 
84 8.8  1.9 9.1  1.1 3.8  1.3 21.6  1.3 14.2  2.1 13.0  1.7 
200 14.1  2.3 13.4  3.3 4.7  1.9 32.3  3.7 7.9  2.1 9.6  1.7 
14 (DTPA) 31.9  4.6 13.5  2.7 8.6  4.2  53.9  8.6 2.7  0.6 6.9  0.9 
 
 
 
Figure 5.1 Total 
241
Am Decorporation (Mean  SD), represented as percent of the 
administered 
241
Am dose, after treatment with increasing doses of orally administered C2E2 
or intravenously administered DTPA. Daily dosing began 24 h after contamination and 
continued for a total of 7 days. n = 4 for all groups. 
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5.3.2 Effect of Dosing Schedule on C2E2 Multiple Dose Efficacy in Rats 
The data obtained for male and female rats during this study have been separated due 
to differences previously observed in americium biokinetics (Chapter III), though the trends 
observed for C2E2 in this study are similar for both genders. In addition data from two rats 
(one qd x 5 and one qd x 10, both male), which died due to gavage error, were excluded from 
analyses. The radionuclide clearance was the same across the three treatment groups on Day 
1 before treatment commenced, indicating the contaminations were consistent across each 
group (Figure 5.2). 
Treatment with C2E2 at 600 mg/kg significantly increased decorporation in both 
male and female rats compared with untreated control animals (p<0.001) (Table 5.3). In both 
genders total decorporation was higher in the qd x 10 group compared to the qd x 5 group, 
although the increase was only statistically significant in the female animals. Figure 5.2 
clearly demonstrates that the first dose is most effective at enhancing elimination, with 
subsequent doses resulting in diminishing daily enhancement of 
241
Am elimination. During 
the first five days of C2E2 treatment, equivalent decorporation was obtained in animals in the 
qd x 5 and qd x 10, indicating consistent dose administration and additional treatment beyond 
five days resulted in a significant but decreasing benefit. In male rats, every dose of C2E2 in 
both the qd x 5 and qd x 10 arms resulted in a significant increase in decorporation compared 
with untreated controls. In female rats all doses of C2E2 except the ninth and tenth doses in 
the qd x 10 treatment group resulted in a significant increase in decorporation compared with 
untreated controls. In both sexes decorporation returned to levels equivalent to or lower than 
in untreated controls within 48 hours of the last administered dose.  
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 Both the liver (Table 5.4) and skeletal (Table 5.5) burdens were statistically lower 
following treatment with C2E2 at 600 mg/kg compared to control animals (p<0.001). 
Following ten daily treatments the mean liver burden appears lower than five daily 
treatments, however as with total decorporation the difference was only significant in female 
animals (p<0.05). Similarly, the skeletal burden is only reduced to a significant extent in 
female rats after when treatment is increased from five to ten daily doses (p<0.001).  
There is a clear benefit of repeated daily treatment with C2E2. This study suggests 
that there is an additional benefit to continuing C2E2 treatment beyond five days. The return, 
expressed as the additional radionuclide decorporation achieved for each additional dose 
administered, appears to decrease approximately linearly from the third dose onward and the 
data suggest little or no additional benefit would be observed for treatment beyond ten daily 
doses. 
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Figure 5.2  Daily Decorporation of 
241
Am from Female (A) and Male (B) Sprague-
Dawley Rats as a Percentage of the Injected Dose. The effects of treatment with C2E2 (600 
mg/kg) administered by daily oral gavage for five (C2E2 qd x 5; red) or ten (C2E2 qd x 10; 
green) days are compared with each other and with untreated controls (blue). Excreta were 
collected daily from animals contaminated with 
241
Am (250 nCi in 0.1 M HNO3) by 
intramuscular injection (0.1 mL). Animals were contaminated at Day 0 and C2E2 
administration began on Day 1. Therefore, the excreta collected in the 24 hours following the 
last C2E2 dose is reported on Day 6 for the qd x 5 group and on Day 11 for the qd x 10 
group. Data shown are the means ± standard deviation from 7 – 8 animals per group. A 
repeated-measures ANOVA with Tukey’s post test was performed to probe differences 
between the treatments at each time point with differences considered significant at p < 0.05. 
* indicates a comparison with the untreated group and † indicates a comparison between the 
qd x 5 group and qd x 10 groups. The level of confidence for the comparisons is indicated by 
the number of symbols, e.g. * p < 0.05, ** p < 0.01 and *** p < 0.001. 
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Figure 5: Daily Decorporation of 
241
Am from Female (A) and Male ) Sprague-Dawley 
Rats as a Percentage of th  Injected Dose.  The effects of treatment with C2   mg/kg) 
administere  by daily or l gavage for five (C2E2 qd x 5; r ) r ten (C2E2 qd x 10; green) days 
are compared ith each other and with untreated controls (blue).  Excreta were collected daily 
from animals contaminated with 
241
Am (250 nCi in 0.1 M HNO3) by intramuscular injection 
(0.1 mL).  Animals were contaminated at Day 0 and C2E2 administration began on Day 1.  
Therefore, the excreta collected in the 24 hours following the last C2E2 dose is reported on Day 
6 for the qd x 5 group and on Day 11 for the qd x 10 group.  Data shown are the means ± 
standard deviation from 7 – 8 animals per group.  A repeated-measures ANOVA with Tukey’s 
post test was performed to probe differences between the treatments at each time point with 
differences considered significant at p < 0.05.  * indicates a comparison with the untreated 
group and † indicates a comparison between the qd x 5 group and qd x 10 groups.  The level of 
confidence for the comparisons is indicated by the number of symbols, e.g. * p < 0.05, ** p < 
0.01 and *** p < 0.001. 
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Table 5.3 Total 
241
Am decorporation 12 days after contamination
1
 
 
Group Male Female 
Mean ± SD n p Mean ± SD n p 
Untreated 23.4 ± 3.1 8 - 20.1 ±3.0 8 - 
C2E2 600 mg.kg qd x 5 44.1 ± 6.2 7 <0.001 38.1 ± 4.0 8 <0.001 
C2E2 600 mg.kg qd x 10 50.1 ± 4.2 7 <0.001 43.9 ± 5.8 8 <0.001* 
1
As a percentage of the administerd dose. Statistical analysis was by one-way ANOVA with 
Tukey’s post test. Differences considered significant (p < 0.05) are reported for comparison 
with untreated control groups. 
*indicates a significant difference also between the qd x 5 and qd x 10 groups (p < 0.05). 
 
 
Table 5.4 Total 
241
Am liver burden 12 days after contamination
1
 
 
Group Male Female 
Mean ± SD n p Mean ± SD n p 
Untreated 12.5 ± 3.0 8 - 19.5 ± 1.9 8 - 
C2E2 600 mg.kg qd x 5 5.9 ± 1.1 7 <0.001 12.0 ± 2.0 8 <0.001 
C2E2 600 mg.kg qd x 10 3.9 ± 1.1 7 <0.001 9.2 ± 2.4 8 <0.001* 
1
As a percentage of the administerd dose. Statistical analysis was by one-way ANOVA with 
Tukey’s post test. Differences considered significant (p < 0.05) are reported for comparison 
with untreated control groups. 
*indicates a significant difference also between the qd x 5 and qd x 10 groups (p < 0.05). 
 
 
Table 5.5 Total 
241
Am skeletal burden 12 days after contamination
12
 
 
Group Male Female 
Mean ± SD n p Mean ± SD n p 
Untreated 27.7 ± 4.4 8 - 23.4 ± 2.5 8 - 
C2E2 600 mg.kg qd x 5 13.4 ± 1.7 7 <0.001 14.5 ± 1.1 8 <0.001 
C2E2 600 mg.kg qd x 10 11.6 ± 1.5 7 <0.001 10.8 ± 1.1 8 <0.001*** 
1
As a percentage of the administerd dose. Skeletal burden is estimated by multiplying the 
burden detected in the femur of the leg contralateral to the americium injection by a factor of 
20. 
2
Statistical analysis was by one-way ANOVA with Tukey’s post test. Differences considered 
significant (p < 0.05) are reported for comparison with untreated control groups. 
***indicates a significant difference also between the qd x 5 and qd x 10 groups (p < 0.001). 
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5.3.3 C2E2 Multiple Dose Decorporation Efficacy in Rats: QD vs BID Administration 
All sixteen male and female rats completed the study. The elimination of americium 
was significantly enhanced in all treatment groups compared to the untreated control 
(p<0.001). Dividing the C2E2 dose in half and administering twelve-hourly did not 
significantly alter total decorporation (Table 5.6). The americium tissue burden in select 
tissues is shown in Figure 5.3 and Figure 5.4 for male and female rats, respectively.  
In addition to examining total decorporation and tissue burden, the urinary 
elimination profile of americium over time was obtained. Figure 5.5 shows the profiles of 
urinary decorporation after once and twice daily treatment with C2E2 in male rats. By 
looking at the first 24-hours after administration of the initial C2E2 dose, the increase in 
urinary americium elimination over control is clear. When a divided dose was given every 12 
hours, americium elimination was initially enhanced the effect was smaller than that of the 
single dose. A second elimination peak was observed after 14 hours following administration 
of the second daily dose. This peak was also larger than the first, which suggests that C2E2 
was still present from first dose. However, as urine was not manually expressed in this study 
the time of day and the activity of the animals may also affect the profile. Over each 24-hour 
period of the study, the QD and BID groups result in very similar profiles of daily urinary 
elimination; consistent with the hypothesis that drug AUC is the best indicator of efficacy in 
the rat. 
Division of the C2E2 dose into two equal doses resulted in no significant difference 
in efficacy (p<0.05) compared to a single dose for both male and female rats. This approach 
may therefore be used to lower the dose required for each administration and increase the 
therapeutic window for C2E2. 
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Table 5.6 Total 
241
Am decorporation 12 days after contamination following five days of 
a 600 mg/kg C2E2 dose administered either once daily or divided between two equal doses
1
.  
 
Group Male Female 
Mean ± SD n p Mean ± SD n p 
Untreated 17.8 ± 2.4 4 - 15.9 ± 0.8 3 - 
Daily C2E2 39.7 ± 3.0 4 p < 0.01 34.8 ± 6.0 4 p < 0.01 
Twice Daily C2E2 43.6 ± 1.8 4 p < 0.01 28.9 ± 1.5 4 p < 0.01 
IV DTPA 54.0 ± 4.5 4 p < 0.01 51.3 ± 2.3 4 p < 0.01 
1
As a percentage of the administered dose. Statistical analysis was performed by one-way 
ANOVA with Tukey’s post test. Differences considered significant (p < 0.05) are reported 
for comparison with untreated control groups. 
 
 
 
Figure 5.3 Total 
241
Am Decorporation (Mean  SD), represented as percent of the 
administered 
241
Am dose, after treatment with either once or twice daily orally administered 
C2E2 or intravenously administered DTPA to male SD rats. Daily dosing began 24 h after 
contamination and continued for a total of 12 days. n = 4 for all groups. Statistical analysis 
was performed by one-way ANOVA with Tukey’s post test. * (p < 0.01 compared to 
control), Ŧ (p < 0.01 compared to C2E2 BD) 
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Figure 5.4 Total 
241
Am Decorporation (Mean  SD), represented as percent of the 
administered 
241
Am dose, after treatment with either once or twice daily orally administered 
C2E2 or intravenously administered DTPA to female SD rats. Daily dosing began 24 h after 
contamination and continued for a total of 12 days. n = 4 for all groups. Statistical analysis 
was performed by one-way ANOVA with Tukey’s post test. * (p < 0.01 compared to 
control), ** (p < 0.01 compared to C2E2 Once and Twice Daily), *** (p < 0.05 compared to 
C2E2 Once Daily) 
 
 
 
Figure 5.5 Percentage of initial americium injection eliminated in the urine per hour in 
male rats. A) 
241
Am concentration in urine excreted over the duration of the study. B) 
Expanded view starting 24 hours after americium contamination as the first C2E2 dose was 
administered. The percent decorporation per hour at time zero reflects the average hourly 
decorporation over the first 24 hours of the study. Blue - Untreated control, Red – C2E2 600 
mg/kg QD, Green - C2E2 300 mg/kg BID.  
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5.3.4 Acute Maximum Tolerated Dose of C2E2 in Rats 
After a single dose of C2E2, no mortality or test article-related clinical observations 
for male or female rats were identified at any dose level. Additionally, there were no 
significant changes in the clinical chemistry endpoints at any dose levels. No abnormal gross 
pathological findings were identified following macroscopic examinations performed at 
necropsy in rats receiving doses ≤ 600 mg/kg. At ≥ 1000 mg/kg, there was a small incidence of 
pale lesions in the jejunum, stomach or spleen, however, due to the lack of dose-response for 
each observation, they were not considered to be test-article related. The single-dose no-
observed-adverse-effect-level (NOAEL) was determined to be 2000 mg/kg in rats. 
 
5.3.5 10 Day Maximum Tolerated Dose of C2E2 in Rats 
No test article-related clinical observations occurred in rats given  800 mg/kg/day. 
Rats in the highest dose group, receiving 2000 mg/kg/day were sacrificed on day 4 of the 
dosing phase due to clinical observations indicating declining health characterized by fecal 
abnormalities (few, liquid, mucoid, or nonformed), poor food consumption, and hypoactivity. 
Based on microscopic examination, the cause of morbidity was gastrointestinal lesions 
present in 4/5 males and 1/5 females. Specifically, elevation/loss of the keratinized layer of 
the nonglandular stomach, blunting/fusion of duodenal villi, attenuated cecal mucosa, and 
congested cecal mucosa was present in some rats given 2000 mg/kg. Microscopic individual 
cell degeneration in the mucosal epithelium of gastrointestinal tract was also noted in females 
given ≥ 800 mg/kg and males given ≥ 400 mg/kg however, these findings were not 
considered adverse due to the minimal severity of changes, which were only slightly greater 
than a normal background observation, and the absence of clinical signs. In addition to 
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gastrointestinal lesions rats given 2000 mg/kg/day also had degeneration of acinar cells of the 
pancreas and tubules of the kidneys. C2E2-related clinical pathology effects for animals 
administered 2000 mg/kg were small and did not indicate specific target organ toxicity. 
Notable effects included: minimally higher absolute red blood cell count, hemoglobin, and 
hematocrit (males only); mildly lower absolute reticulocyte and lymphocyte counts; and 
mildly higher glucose, albumin and total protein levels. The findings for red blood cell mass 
and serum proteins were consistent with hemoconcentration and likely related to the fecal 
abnormalities observed clinically. Other findings were likely associated with poor condition, 
poor food consumption, or a stress (endogenous corticosteroid) response. Below 2000 
mg/kg/day C2E2-related clinical pathology effects were limited to mildly lower urea nitrogen 
in animals administered 800 mg/kg/day and mildly higher albumin in females administered 
>400 mg/kg/day. The exact mechanism for these minor effects was not determined; however 
they were not considered toxicologically important or indicative of specific target organ 
toxicity. A preliminary toxicokinetic (TK) analysis was performed on mean C2E2, C2E1, 
and DTPA concentration-time data determined at each time point for each sex. A plasma 
sample was not collected at 24 hours post dose on Day 10; for TK analysis, concentrations at 
this time point were assigned the Day 10 pre-dose concentration, based on an assumption that 
steady-state conditions had been achieved. TK parameters for all analytes are reported in 
Tables 5.7 to 5.8. C2E2 was the predominant compound observed in the systemic circulation. 
In general, C2E2 Cmax and AUC values increased with C2E2 dose in both sexes. C2E2 
exposures at 400 mg/kg and above were greater in female than in male rats on Day 1. On 
Day 10, there was little difference between sexes in C2E2 exposures at any dose level except 
for the 400 mg/kg group, in which C2E2 Cmax in males was about one-fourth that in females.  
  
Table 5.7 C2E2 toxicokinetic parameters in Sprague-Dawley rats after oral gavage doses of C2E2 for 10 days (based on mean 
concentrations from 3 animals/sex at each time point). 
Day Dose (mg/kg) Sex 
Cmax 
(ng/mL) 
Cmax/Dose 
(ng/mL)/(mg/kg) 
Tmax 
(hr) 
AUC(0-tlast)  
(hr*ng/mL) 
AUC(0-tlast)/Dose 
(hr*ng/mL)/(mg/kg) 
1 
200 F 906 4.53 0.25 2280 11.4 
M 857 4.29 1.00 3230 16.2 
400 F 17,500 43.8 0.25 22,000 55.0 
M 1820 4.55 0.25 7740 19.4 
800 F 14,800 18.5 1.00 38,100 47.6 
M 5670 7.09 1.00 18,300 22.9 
2000 F 43,000 21.5 0.25 139,000 69.5 
M 24,100 12.1 1.00 94,000 47.0 
10 
200 F 2770 13.9 0.25 3580 17.9 
M 2970 14.9 0.25 4140 20.7 
400 F 6320 15.8 0.25 10,300 25.8 
M 1550 3.88 0.25 6240 15.6 
800 F 23,700 29.6 0.25 28,000 35.0 
M 18,600 23.3 0.25 35,100 43.9 
2000 F ND ND ND ND ND 
 M ND ND ND ND ND 
NA – Not applicable 
ND – No data 
 
  
1
1
8
 
  
Table 5.8 C2E1 toxicokinetic parameters in Sprague-Dawley rats after oral gavage doses of C2E2 for 10 days (based on mean 
concentrations from 3 animals/sex at each time point). 
Day Dose (mg/kg) Sex 
Cmax 
(ng/mL) 
Cmax/Dose 
(ng/mL)/(mg/kg) 
Tmax 
(hr) 
AUC(0-tlast)  
(hr*ng/mL) 
AUC(0-tlast)/Dose 
(hr*ng/mL)/(mg/kg) 
1 
200 F 0 0.0000 NA 0 0.0000 
M 0 0.0000 NA 0 0.0000 
400 F 127 0.3175 0.25 81.3 0.2033 
M 19.2 0.0480 0.25 15.9 0.0398 
800 F 65.7 0.0821 1.00 204 0.2550 
M 57.6 0.0720 1.00 184 0.2300 
2000 F 364 0.1820 0.25 1250 0.6250 
M 235 0.1175 1.00 1280 0.6400 
10 
200 F 18.3 0.0915 0.25 NC NC 
M 20.8 0.1040 0.25 NC NC 
400 F 66.4 0.1660 0.25 56.0 0.1400 
M 36.0 0.0900 0.25 30.9 0.0773 
800 F 124 0.1550 0.25 223 0.2788 
M 253 0.3163 0.25 464 0.5800 
2000 F ND ND ND ND ND 
 M ND ND ND ND ND 
NA – Not applicable 
NC – Could not be calculated; only one measurable data point in curve 
ND – No data 
 
 
 
 
 
1
1
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5.3.6 Determination of Oral Bioavailability in Rats 
Following both oral and IV administration, the parent molecule C2E2 was the most 
abundant circulating analyte in rats. C2E1 and DTPA were observed in plasma at 
substantially lower levels than C2E2. The synthetic impurity, C2E3, was also observed in 
plasma of rats at very low levels after an IV dose of C2E2 (C2E3 was not detected after the 
oral C2E2 dose). Peak concentrations were attained at 0.033 hours (tmax) for C2E1, C2E2, 
C2E3, and DTPA following IV administration and 0.25 hours for C2E1, C2E2, and DTPA 
following oral administration. The terminal half-life for C2E2 was estimated to be 0.35 and 
1.1 hours following the IV and oral doses, respectively, although these may underestimate 
the true half-life values, as sampling was only performed through 8 hours post dose. For 
example, C2E2 concentrations were measurable through 24 hours post dose in rats after a 
single dose and after 10 days of once-daily oral administration during the dose-range finding 
toxicity study. During the toxicity study oral doses had terminal half-lives of 0.25-1 hour. 
Oral bioavailability was calculated from the area under the plasma concentration vs. time 
curve (AUC) values of C2E2 and under these experimental conditions the absolute oral 
bioavailability of C2E2 in female Sprague-Dawley rats was 29%. 
 
4.3.7 Pharmacokinetics of 14C-C2E2 in Rats 
All sixteen rats successfully completed the study. The inability to synthesize large 
quantities of 
14
C-C2E2 resulted in low plasma 
14
C concentrations and HPLC could not be 
used to determine the species present. The samples were therefore analyzed by liquid 
scintillation counting, however the plasma 
14
C concentrations were still too low to determine 
concentration time profiles over 24 hours. High 
14
C concentrations were observed in the 
 121 
urine and the 
14
C content must arise from C2E2 absorbed prior to elimination. During the 
study oral groups were administered a 600 mg dose containing 50 mg of 
14
C-C2E2 and IV 
groups received 50 mg of pure 
14
C-C2E2. Assuming that 99% of the dose is eliminated 
within 24 hours, then a comparison between the total quantity of 
14
C observed in the urine of 
IV and oral groups can be used to approximate the fraction of C2E2 absorbed. For fed and ad 
lib rats the fraction of 
14
C material seen in the urine compared to the IV group was 0.42 and 
0.48, respectively. This suggests that oral absorption was greater than 40% after 
administration of a 600 mg dose. This is higher that the fraction noted in the previous 
pharmacokinetic study that utilized an oral dose of 84 mg/mL and supports evidence of non-
linear exposure seen with C2E2 in toxicokinetic studies. 
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5.4 Discussion 
The efficacy of orally administered C2E2 after a single dose was previously discussed in 
Chapter 1. The study demonstrated that compared to untreated controls 
241
Am retention could 
be significantly reduced orally using C2E2 in a dose dependent manner (Tables 5.9 and 
5.10). The increased elimination of 
241
Am was primarily due to enhanced urinary excretion 
consistent with other highly charged hydrophilic compounds such as DTPA. Although 
americium elimination was enhanced over control, large doses were required and IV DTPA 
therapy remained superior. In addition to demonstrating oral efficacy, no statistical difference 
in americium burden was observed between rats with ad libitum access to food and rats 
fasted overnight prior to C2E2 treatment. Therefore food effects were not investigated during 
future studies. 
Oral decorporation therapy, in addition to increasing the promptness at which therapy can 
be given in a mass casualty situation, is also more conveniently administered over multiple 
doses than IV therapy. Administration of multiple daily IV DTPA doses has previously been 
used to enhance decorporation. We hypothesized that radionuclide decorporation provided by 
C2E2 could similarly be enhanced with multiple administrations and that the daily dose 
could be lowered reducing the pill burden. Therefore a multiple dose study was conducted 
over twelve days with C2E2 administered for seven consecutive days.  
 C2E2 was administered at doses of 84 and 200 mg/kg with total decorporation 
significantly higher than untreated control animals at 200 mg/kg with 32.3  3.7 % of the 
injected dose eliminated. In comparison total decorporation from a single 200 mg/kg C2E2 
dose in female rats after 7 days was 14.4  0.7 %. This confirms that the additional doses 
further enhance americium elimination. Although mainly due to C2E2, the multiple dose 
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study was conducted over an additional five days, which also contributed to the increased 
decorporation as control animals eliminated 11.2  2.1 % and 15.3  4.7 % for 7 and 12 days, 
respectively. Furthermore, after 7 daily 200 mg/kg doses of C2E2, total decorporation begins 
to approach that of a single 14 mg/kg IV DTPA treatment (36.1  4.6 %) and liver burden is 
reduced from 12.3  1.2 % to 7.9  2.1 % suggesting that an extended oral regimen may be 
able to replace the single IV DTPA dose in a mass casualty situation. By comparison, total 
decorporation following administration of C2E5 was 8.4  1.0 %, 14.8  4.2 % and 18.5  
4.4 % following single doses of 40, 100 and 200 mg/kg to rats contaminated by IM injection 
of 
241
Am-nitrate
125
. These decorporation values are lower than expected, with the control 
animals eliminating only 7.1  1.4 % of the injected americium after 7 days. This may be due 
to use of a slightly different injection site in early studies conducted in our lab. Therefore to 
more accurately compare single dose C2E2 to C2E5 the percentage increase in elimination 
over control was considered (Table 5.11). This demonstrates that C2E2 is less effective that 
C2E5, with approximately a six fold increase in dose required to achieve the same effect. 
Further increases in efficacy are obtained with multiple doses of C2E5 and to achieve the 
same effect, the C2E2 dose must be approximately 2.5-3.5 fold higher than that of C2E5 
(Table 5.12).  
While, the multiple dose study successfully demonstrated that repeated dosing 
enhances decorporation, it also promoted further questions regarding the duration of therapy. 
In the majority of cases DTPA has been given as a single dose; in severe cases multiple doses 
have been administered. In these cases the urinary americium levels are monitored to ensure 
therapy continues to provide a benefit. In order to investigate the effects of treatment 
duration on C2E2 efficacy the study protocols were modified to include daily cage washes in 
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place of every three days. This minimized the variation observed in daily excretion data and 
allowed inter-day comparisons of americium elimination to be made.  
The 600 mg/kg dose was selected for additional efficacy studies in rats based on data 
obtained during the single dose decorporation and toxicology studies. Following 
administration of five daily doses total decorporation was 44.1  6.2 % and 38.1  4.0 % in 
male and female rats, respectively. Similarly to the previous multiple dose study, repeat 
dosing showed a clear benefit over a single dose in which total decorporation was 26.4  1.4 
% and 23.6  2.3 % for male and female rats, respectively. Prolonging the duration from five 
to ten days further increased the total decorporation to 50.1  4.2 % and 43.9  5.8 % in male 
and female rats, however this increase was not statistically significant. 
Figure 5.2 clearly shows that the greatest elimination is achieved after the first dose 
with subsequent doses yielding successively smaller returns. Upon contamination, a fraction 
of the radionuclide administered rapidly distributes from the wound site into the plasma 
resulting in initially high plasma levels. This can be seen in control animals excretion 
profiles, where approximately 4.5% of the administered dose is eliminated within the first 
24-hours. Thereafter, only a small percentage (~2%) is released each day. Consequently, 
initially there is a large fraction of translocating radionuclide available for chelation and 
elimination as shown by the large percentage of decorporation in the initial days (7-8 %/day). 
After wound contamination in rats, americium rapidly distributes to the liver over 12 hours 
followed by slower uptake until day 4 when constant elimination begins to occur
138
. 
Distribution to the skeleton is also fast with the majority of deposition occurring within 4 
hours, however translocation continues to deposit material within the skeleton and steady 
state is not reached until 4 days
138
. Therefore, as each day progresses not only does the total 
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amount of americium remaining decrease, the percentage deposited within the skeleton 
increases, thereby lowering the fraction available for elimination. 
Although increasing the duration from five to ten days did not result in a significant 
increase in total decorporation overall, each additional day resulted in a significant increase 
in decorporation over control. Therefore extending therapy for ten days is beneficial and as 
ionizing radiation causes cancer through stochastic effects, any enhancement in elimination is 
beneficial and thus therapy should be given until no significant increase in daily 
decorporation is seen over control. 
Ultimately treatment duration should be determined by a number of factors, including 
route of contamination, amount of radionuclide deposited and age of the patient at time of 
contamination. A balance must be struck between the risk posed from additional chelation 
treatment and the benefit of removing another fraction of radionuclide. Furthermore as the 
duration of therapy is extended, the daily dose must be reduced to minimize toxicity, thereby 
reducing the benefit of treatment at early time-points where tissue disposition is greatest. The 
use of a shorter time course is therefore preferable.  
 The pharmacokinetics of C2E2 was determined in female rats after administration of 
C2E2 via both the oral and IV routes. Oral absorption was fast with tmax achieved in 15 
minutes. With a half-life of 1.1 hours, the C2E2 duration of action is longer than with IV 
DTPA, as expected of an oral product, although the majority of the drug will be cleared 
within 6 hours. During toxicokinetic studies C2E2 exposure increased with increasing dose 
level from 200 to 2000 mg/kg. The increase in Cmax and AUC0-24 however was greater than 
dose proportional. There were no significant differences between genders and no 
accumulation of the dose was observed after multiple dosing. The bioavailability of C2E2 
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was calculated from the dose normalized AUCs of both the oral and IV doses. The oral 
bioavailability of DTPA was increased from 5% to 29% through the addition of two ethyl 
esters. Although oral absorption of greater than 90% is required to classify a drug as highly 
permeable, C2E2 has sufficient bioavailability to be delivered orally and further 
enhancement maybe possible through modification of the formulation. 
 In order to further investigate the oral absorption of C2E2 a second pharmacokinetic 
study was performed using 
14
C-C2E2. The purpose of the study was two fold; to determine 
the oral bioavailability at the higher dose of 600 mg/kg and to determine if C2E2 or its 
metabolites were the predominant species in urine. C2E2 was administered orally, via the 
jugular vein and via the portal vein in order to determine the total oral bioavailability, the 
fraction absorbed and fraction metabolized during the first pass. Unfortunately the 
14
C-C2E2 
sample concentrations were insufficient to enable speciation via HPLC and so the total 
14
C 
content was determined by scintillation counting. Although unable to provide exact 
speciation data an approximation of the fraction absorbed can be determined by comparing 
the total 
14
C content excreted in the urine over the duration of the study. The results 
suggested that the fraction absorbed was > 40% supporting toxicokinetic studies in which 
larger doses result in greater exposure.  
 In hope of further enhancing decorporation or lowering the pill burden the daily dose 
was split evenly into two 12-hourly doses. The aim was to help maintain plasma levels of 
C2E2 so that chelation could occur for longer over each 24-hour period. After five days 
treatment there was no significant difference in total decorporation between each group in 
either male of female rats. However liver burden was lower in the single daily dose group 
than those receiving the split dose. As the AUCs for both treatments are equal, these results 
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suggest that decorporation is linked to AUC and not Cmax. Though, a high Cmax may 
contribute to lower 
241
Am liver burden as both a single dose, and IV DTPA treatments result 
in enhanced decorporation. In addition to assessing decorporation, the rate of americium 
elimination in urine were studied during the first 24 hours to determine differences between 
each group. The urinary excretion profiles (Figure 5.5) showed that the majority of the effect 
of C2E2 occurs within the first 2-4 hours after administration. For the twice-daily dose, a 
second peak in excreted americium is observed after administration of the second dose, 
interestingly this peak is higher than the first, suggesting that urinary elimination is yet to 
reach background levels 12 hours after administration of the first dose. After 24 hours no 
C2E2 accumulation was observed in the 10 day toxicokinetic analysis; accumulation may be 
possible with dose intervals of 12 hours. For DTPA even though approximately 60% of the 
dose is eliminated in 1.4 min, a small fraction (~0.5%) remains in the plasma after 24 hours 
with small amounts continuing to be excreted over 7 days
64
. Although small, this fraction 
may be responsible for the increase in americium elimination seen for a number or days 
following a single dose. For C2E2 a small faction may also be present but not detectable. 
Urine was also collected for the 24 hours after contamination prior to treatment 
delivery. The urinary elimination profile for untreated controls follows second order kinetics 
with rapid elimination of 
241
Am occurring over the first 4-8 hours, followed by a gradual 
decline over the remainder of the study. Four days after contamination natural excretion is 
less than 0.02 % ID/hour. If the 
241
Am elimination profile is assumed to be proportional to 
free circulating 
241
Am it is easy to see why chelation efficacy is reduced over time, and why 
early access to treatment will enhance decorporation. 
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 In addition to demonstrating efficacy in well-characterized animal models, 
radionuclide decorporation agents must still comply with all the standard FDA toxicological 
requirements. In order to conduct human clinical trials, non-clinical safety studies must 
initially be performed. These non-clinical studies generally encompass toxicity studies, 
nonclinical pharmacokinetics, reproduction toxicity and genotoxic studies. For toxicity 
studies both MTD and repeated dose studies are conducted in two mammalian species (one 
nonrodent). The duration of the repeated dose study relates to the duration of proposed 
clinical trials. For C2E2, toxicity was assessed in both rats and dogs (Chapter VI). For both 
species in addition to determining the MTD, multiple dose toxicity was assessed for 10 days 
based on the fact that little additional therapeutic benefit is likely to be achieved with 
additional doses. 
Dose escalating toxicity studies were conducted to evaluate the acute toxicity of 
C2E2 and the data was used to support dose level selection for subsequent repeat-dose 
toxicity testing. The NOAEL established in rats indicates that large doses of C2E2 are well 
tolerated. After single doses no adverse effects were noted and the maximum tolerated dose 
was therefore set at the highest dose tested (2000 mg/kg). The toxicity of C2E2 was then 
evaluated for 10 days. Again no organs were identified as the targets of toxicity, however 
gastrointestinal lesions caused morbidity at doses of 2000 mg/kg/day. After 10 consecutive 
daily doses the NOAEL for C2E2 was 800 mg/kg. This is higher than the doses used during 
all multiple dose studies.  
In comparison, a dose escalation study performed with C2E5 used doses of 0, 20, 
200, 600 or 1000 mg/kg in 300 mM acetic acid, pH 4.3. Mortality occurred at doses of 1000 
mg/kg and weight loss (up to 16%) was noted at doses of 600 mg/kg. Following 10 days 
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studies abnormal posture, urine staining, mortality was seen at doses > 250 mg/kg. In 
addition increased ALT, AST, total bilirubin and creatinine levels were also seen at doses > 
250 mg/kg. The NOAEL was determined to be 114 mg/kg/day for the 10 day study.  
Overall, orally administered C2E2 is not as efficacious as IV DTPA therapy in rats. 
Though after administration of seven daily 200 mg/kg doses total decorporation approaches 
that of a single IV dose of DTPA. Furthermore, after five days of C2E2 treatment at 600 
mg/kg/day total decorporation is higher than a single dose of C2E2. As the majority of 
patients contaminated receive only a single dose of DTPA, a short course of C2E2 may be a 
viable substitute in a mass casualty situation. 
In order to achieve effective decorporation in rats large doses are required. Based on 
the differences in plasma binding data described in chapter IV, the rat may not be the best 
model for predicting human dose levels. For both C2E2 and DTPA higher concentrations of 
ligand are required in rat plasma to achieve the same degree of 
241
Am chelation as human 
plasma. The data also suggests that C2E2 efficacy may be further underestimated compared 
to that of DTPA. For DTPA the ligand concentration must be 1.9 times higher in rats to 
achieve the same effect as in humans, whereas for C2E2 a 5.2 fold increase is required. 
Therefore C2E2 efficacy is expected to be greater in the beagle model and the doses required 
more representative of those required in humans.  
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Table 5.9 Mean ( SD) 241Am Decorporation 7 Days after IM Contamination in Male 
SD Rats: Treatment with a Single Oral Dose of C2E2 24 h after Contamination 
 
C2E2 Dose 
(mg/kg) 
Urine (%) Feces (%) Cage 
Wash 
(%) 
Total Decorporation 
(%) 
Liver Burden 
(%) 
0 5.8  1.4 6.6  2.4 2.3  0.8 14.6  2.1 17.2  2.8 
200 11.3  2.3 6.9  0.6 2.8  0.2 20.9  2.7 10.6 0.8 
200
1
 11.8  1.3 6.1  1.2 2.7  1.1 20.6  3.2 12.8  3.9 
600 14.3  3.5 8.8  1.9 3.5  1.5 26.4  1.4 13.2  1.3 
600
1
 16.6  1.1 7.9  1.7 3.5  1.6 27.9  2.5 10.4  0.8 
1000 21.9  5.3 8.5  2.2 3.7  1.2 34.1  8.0 8.7  2.0 
1000
1
 20.7  3.7 8.5  1.9 3.5  1.5 32.8  6.6 10.1  1.9 
DTPA Dose 
(mg/kg) 
Urine (%) Feces (%) Cage 
Wash 
(%) 
Total Decorporation 
(%) 
Liver Burden 
(%) 
14 22.2  2.8 12.1  2.0 4.4  1.2 38.7  4.5 6.1  0.7 
1
Fasted Condition; other groups allowed access to food ad libitum 
 
 
 
Table 5.10 Mean ( SD) 241Am Decorporation 7 Days after IM Contamination in Female 
SD Rats: Treatment with a Single Oral Dose of C2E2 24 h after Contamination 
 
C2E2 Dose 
(mg/kg) 
Urine (%) Feces (%) Cage 
Wash (%) 
Total 
Decorporation (%) 
Liver Burden 
(%) 
0 4.7  1.0 4.9  1.0 1.6  0.5 11.2  2.1 21.4  2.5 
200 6.7  1.5 5.9  0.8 1.8  0.5 14.4  0.7 17.7  2.1 
200
1
 8.4  1.3 4.7  2.1 1.3  0.3 14.3  3.2 20.9  3.5 
600
2
 13.1  0.4 8.4  1.7 2.1  1.0 23.6  2.3 19.1  5.4 
600
1
 14.3  2.9 7.3  1.5 2.6  0.8 24.2  3.3 18.9  2.3 
1000
3
 14.8  1.3 7.7  2.4 3.1  0.1 25.7  3.5 15.7  0.9 
1000
1
 19.8  3.9 7.1  1.3 4.5  0.7 31.3  5.5 13.7  3.1 
DTPA Dose 
(mg/kg) 
Urine (%) Feces (%) Cage 
Wash (%) 
Total 
Decorporation (%) 
Liver Burden 
(%) 
14 22.1  2.6 10.3  1.7 3.6  0.8 36.1  4.6 12.3  1.2 
1
Fasted Condition; other groups allowed access to food ad libitum 
2
Group size = 3 
3
Group size = 2 
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Table 5.11 Percentage increase in 
241
Am decorporation over control, after treatment with 
single doses of orally-administered C2E2 or C2E5. Dosing began 1 day after contamination 
and continued the study was terminated after 7 days. n = 4 for all groups 
 
 
41
Am Decorporation (% of Administered Dose) 
Drug Dose (mg/kg) C2E5 C2E2 
40 18.3 % - 
100 108.5 % - 
200 160.5 % 37.2 % 
600 - 93.7 % 
1000 - 131.8 % 
 
 
Table 5.12 Total 
241
Am decorporation, represented as percent of the administered 
241
Am 
dose, after treatment with increasing doses of orally-administered C2E2 or C2E5. Daily 
dosing began 1 day after contamination and continued for a total of 7 days. n = 4 for C2E5 
and n=6-8 for C2E2 groups. 
 
 
41
Am Decorporation (% of Administered Dose) 
Drug Dose (mg/kg) C2E5 C2E2 
0 7.1  1.4 12.9  2.1 
40 8.4  1.0 - 
100 14.8  4.2  - 
200 18.5  4.4 17.7  2.0 
600 - 25.0  1.9 
1000 - 29.9  6.2 
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CHAPTER VI 
 
ORALLY ADMINISTERED DTPA DI-ETHYL ESTER FOR DECORPORATION 
OF 
241
AM: EFFICACY IN A DOG INHALATION-CONTAMINATION MODEL AND 
SAFETY ASSESSMENT IN DOGS 
 
6.1 Introduction 
This increasing terrorist threat has spurred the development of radionuclide 
decorporation agents for treatment of individuals contaminated with various radioactive 
materials, notably isotopes of the transuranic elements Am, Pu and Cm. In 2004, pentetate 
calcium trisodium injection (Ca-DTPA) and pentetate zinc trisodium injection (Zn-DTPA) 
received FDA approval for the treatment of internal contamination with these actinides and 
were subsequently included in the Strategic National Stockpile for use in the event of mass 
contamination. While Ca- and Zn-DTPA injections have been shown to be efficacious in 
treating contaminated individuals, they require administration by a skilled professional via 
either intravenous injection or via nebulization. These are not practical methods of 
administration in a mass casualty situation 
   This problem is particularly acute as early access to treatment improves 
decorporation efficacy by minimizing tissue deposition of the radioactive material. The loss 
of efficacy caused by treatment delay cannot be overcome by increasing the cumulative
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dose
144
. Therefore, there is a need to develop DTPA formulations that can be self-
administered and rapidly distributed to a large population. 
However, DTPA is known to have poor oral bioavailability (~3%) primarily because 
its charge and hydrophilicity cause permeability-limited absorption
145
. Esterification is often 
used to overcome barriers in drug delivery such as poor solubility
87
 or absorption
146
. The 
carboxylic acids present on DTPA provide multiple sites for esterification that we 
hypothesized could be used for prodrug formation to overcome the permeability-limited 
absorption. 
Lipophilic promoieties have previously been added to DTPA or 
triethylenetetraminehexaacetic acid (TTHA) in order to enhance chelation of intracellular 
radionuclides, however no studies previously focused on their use as prodrugs for oral 
bioavailability enhancement
88, 90, 147
. The DTPA ligands were not orally administered and 
although the TTHA ligands were given orally, the research focused on the long-term removal 
of radionuclides from intracellular deposition sites. None of the polycarboxylic acid ligands 
investigated were more effective or less toxic than Ca-DTPA and most of the research was 
abandoned
148
.  
Therefore with a focus on bioavalibility enhancement, a series of DTPA esters were 
synthesized, and two promising candidates emerged following evaluation of their physical-
chemical properties and permeability characteristics. These were the penta-ethyl and di-ethyl 
esters of DTPA, referred to as C2E5 and C2E2, respectively. C2E5 was shown to effectively 
decorporate 
241
Am in a wound-contamination animal model
94-95
, but its unfavorable 
pharmaceutical properties and concerns related to its hepatotoxicity caused us to focus our 
efforts on C2E2. 
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Here we report the decorporation efficacy of C2E2 following a single dose to beagle 
dogs contaminated via inhalation of americium. The toxicity of C2E2 was determined both in 
vitro using classical genotoxicity endpoints and in vivo by evaluation of both the acute and 
ten day maximum tolerated doses in beagle dogs.  
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6.2 Materials and Methods 
6.2.1 General 
Americium-241 was obtained from the Department of Energy as a nitrate complex 
stock solution. An aliquot of the stock solution was taken to dryness on a medium 
temperature hotplate and reconstituted in 0.25 M nitric acid to yield a final activity of 7.44 
MBq/mL (201.1 µCi/mL) as determined by gamma pulse height analysis. C2E2 was 
prepared by first synthesizing DTPA bis-anhydride followed by its subsequent reflux with 
ethanol as previously described
90
 (Yield - 85%, Purity – 97.7%). 
The general procedures for animal care and housing were conducted in accordance 
with the National Research Council for the Care and Use of Laboratory Animals and the 
Animal Welfare Standards. All procedures and protocols used in animal studies were 
reviewed and approved by the Institutional Animal Care and Use Committee of Covance 
Laboratories Inc. or Lovelace Respiratory Research Institute and were performed in 
AAALAC accredited facilities. 
 
6.2.2 Beagle Inhalation Contamination Model for 
241
Am 
Inhalation contamination was performed in a method similar to that previously 
described
138
. The beagles were fasted, sedated (acepromazine i.m.; 0.05 mg/kg.) and 
anesthetized with Isoflurate (5%) prior to exposure to 
241
Am. A muzzle was fixed to the dog 
and placed into an exposure plenum where a mixture of oxygen and isoflurane was 
continually flowing and monitored. Aerosols were generated from the 
241
Am-nitrate solution 
(pH - 0.74) using a Hospitak nebulizer (Unomedical Inc. McAllen, Tx, USA). The aerosol 
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was dried by transiting through a tube furnace operating at 70–80°C to minimize the amount 
of acid present. Oxygen was maintained at 45-55 % and isoflurane was delivered as needed 
(2-3 % in oxygen). Aerosol samples were collected on Pallflex Fiberfilm filters and analyzed 
for 
241
Am content. Dogs were exposed to an 
241
Am aerosol atmosphere of 42.7 ± 8.3 kBq/L 
(1.16 ± 0.22 µCi/L) for 8 minutes. The particle size of the aerosol was determined to be 0.63 
µm Activity Median Aerodynamic Diameter (AMAD) with a geometric standard deviation 
(GSD) of 1.72, with each dog receiving an average of 111 kBq (3 μCi) of 241Am. 
 
6.2.3 Single Dose Efficacy of C2E2 in Beagle Dogs 
The efficacy for decorporation of 
241
Am by C2E2 was evaluated in beagle dogs (n = 
4/sex/dose) approximately 13 months of age (8.8 ± 1.2 kg). The dogs were acclimatized to 
metabolic cages 24 hours prior to 
241
Am administration. Dogs were fasted overnight prior to 
treatment. Twenty-four hours after contamination, C2E2 solutions were administered by oral 
gavage. Dogs received either DI water (vehicle control) or C2E2 at 100, 300 or 500 mg/kg. 
C2E2 was dissolved in DI water on each day of dosing and dogs were administered between 
33-52 mL of solution to achieve the desired dosage. Urine and feces were collected daily for 
analysis of radioactivity. Fourteen days after contamination the dogs were euthanized and 
necropsied. The liver, spleen, kidneys, lungs and both femurs were among the tissues 
collected and analyzed for radioactivity. Samples were thermally and chemically processed, 
placed into 20-mL scintillation vials and the gamma pulse height from 
241
Am was analyzed 
in a gamma counter (2480 Wizard
2 
Gamma Counter, Perkin Elmer, Waltham, MA, USA). 
Statistical analyses to evaluate the pattern of recovered doses were conducted by one-
way analysis of variance (ANOVA). For each sample, differences between untreated controls 
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and treated groups were assessed with individual F-tests based on the ANOVA’s pooled 
estimate of underlying variance between dogs. 
 
6.2.4 Acute Maximum Tolerated Dose of C2E2 in Dogs 
Four beagles (Covance Research Products Inc.), (n = 2/sex/dose), 8 to 10 months old 
were housed individually in stainless steel cages. The dogs were acclimatized to the 
conditions at least two weeks prior to the study: ad libitum access to water and food for 6 
hours per day in a controlled environment with lighting on a 12-h light/dark cycle. Prior to 
dosing, the dogs were fasted overnight and food was returned 2 hours after dosing. The same 
dogs were used for each consecutive dose level with a minimum 7-day washout period 
between dose escalations. The initial dose of C2E2 administered was 100 mg/kg with 
subsequent escalating doses (300 or 750 mg/kg) based on clinical observations and clinical 
pathology results of the previous dose. C2E2 solutions were prepared by dissolving in DI 
water to a concentration that allowed each dog to receive 8.3 mL/kg of dosing solution by 
oral gavage. In addition, the effect of food on toxicity was examined at a single dose level of 
300 mg/kg under fed conditions.  
Detailed observations were performed at 1, 2 and 4 hours post-dose and then twice 
daily. Blood was collected from the jugular vein pre-dose and at 0.5, 1, 2, 4, 6, 8, 12 and 24 
hours for toxicokinetic analysis and approximately 48 hours post-dose for standard 
hematology and clinical chemistry analyses as well as trace element analyses. Toxicokinetic 
analyses for C2E2, the mono ethyl-ester of DTPA (C2E1) and DTPA were performed using 
WinNonlin Professional Edition (Pharsight Corporation, Version 5.2). 
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6.2.5 Ten-Day Oral Dose Range Finding Study of C2E2 in Dogs 
Twenty beagles (Covance Research Products Inc.), (n = 2/sex/dose), 7 to 9 months 
old (8.4 – 11.4 kg) were housed individually in stainless steel cages. C2E2 doses of 0, 60, 
200, 400, and 600 mg/kg/day for 10 days in fasted dogs were selected based on the results of 
the oral acute maximum tolerated dose study. Animals were fasted overnight prior to dosing 
and food was returned approximately 3 hours after completion of dosing. Water was 
provided ad libitum. Cageside observations were performed at 1, 2 and 4 hours post-dose and 
detailed observations were performed during the predose phase, and prior to dosing on days 1 
and 6. As in the single dose study, blood was collected from the jugular vein pre-dose and at 
0.5, 1, 2, 4, 6, 8, 12 and 24 hours for toxicokinetic analysis and predose, day 6 and at 
sacrifice (day 11) for standard hematology and clinical chemistry analyses. 
 
6.2.6 Genotoxicity of C2E2  
A reverse mutation assay in Salmonella typhimurium and Escherichia coli (Ames 
test), a chromosomal aberration assay in Chinese hamster ovary (CHO) cells and an in vivo 
rat bone marrow micronucleus assay were performed in accordance with standards 
established by ICH S2(R1)
149
. The Ames test was conducted with Salmonella histidine 
auxotrophs TA98, TA100, TA1535, and TA1537 and the E. Coli tryptophan auxotroph 
WP2uvrA, using a plate incorporation procedure as previously described
150, 151
. C2E2 was 
evaluated at doses of 5 to 5000 µg/plate with or without rat liver homogenate metabolic 
activation (Aroclor-induced Sprague-Dawley rat liver S9, NADP and Glucose-6-phosphate). 
Positive and vehicle controls were concurrently evaluated, and triplicate plates were used for 
all samples. Positive controls included, 2-nitrofluorene, sodium azide, ICR-191, 4-
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nitroquinoline-N-oxide, benzo[a]pyrene and 2-aminoanthracene. Dose concentration was 
confirmed by high-performance liquid chromatography (HPLC). C2E2 was considered to 
have produced a positive response if a dose-dependent increase in revertant frequency was 
≥2.0-fold vehicle control values for strains TA98, TA100, and WP2uvrA, or ≥3.0-fold 
vehicle control values for strains TA1535 and TA1537. 
The chromosomal aberration assay was performed in a CHO cell line derived from an 
ovarian biopsy of a female Chinese hamster (CHO-WBL). C2E2 was prepared in cell culture 
grade water, and stocks were prepared by serial dilution in vehicle so that all treatments were 
administered into 10 mL cultures in a volume of 10%. Treatment periods continued for 3 
hours with or without metabolic activation, or for approximately 20 hours without metabolic 
activation. Solutions containing C2E2 ranging from 7 to 500 μg/mL were prepared and 
concentrations were confirmed by HPLC. Visual observations of cultures for general cell 
health and confluence were made prior to termination. Mitomycin C (1.5 µM for the 3-hour 
treatment, and 0.6 µM for the 20-hour treatment) were used as positive controls for the 
assays without metabolic activation (rat liver S9, NADPH and isocitric acid) and 
cyclophosphamide (19 µM) in the assay with metabolic activation. At culture termination, 
viable cells were counted and population doubling was calculated for measurement of 
cytotoxicity to support selection of dose levels for aberration analysis. For each 
concentration, 1000 cells were assessed for toxicity and at least 200 cells in metaphase were 
scored and tabulated for aberrations. To control bias, slides were identified by an abbreviated 
code unknown to the scorer. Statistical analysis employed a Cochran-Armitage test for linear 
trend and Fisher's Exact Test to compare the percentage of cells with aberrations in treated 
cells to the results obtained for the vehicle controls. 
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The in vitro micronucleus test was performed in male Sprague Dawley rats. C2E2 
was formulated in cell culture grade water vehicle and the dose volume for all treatment 
groups was 20 mL/kg. Male rats were administered vehicle control or C2E2 at 500, 1000, or 
2000 mg/kg/day for two days separated by approximately 24 hours. The 2000 mg/kg high 
dose is the limit dose for this assay recommended by ICH S2(R1) guidance. A positive 
control group received a single 60 mg/kg cyclophosphamide treatment on the second day of 
dosing. Animals were observed at least twice daily for toxic signs and/or mortality. Bone 
marrow was extracted approximately 24 hours after the last treatment in all groups and at 
least 2000 polychromatic erythrocytes (PCEs) per animal were analyzed for the frequency of 
micronuclei. Cytotoxicity was assessed by scoring the number of PCEs and normochromatic 
erythrocytes (NCEs) observed while scoring at least 500 erythrocytes per animal. 
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6.3 Results 
 
6.3.1 Single Dose Efficacy of C2E2 in Beagle Dogs 
When radionuclide exposure is conducted via the inhaled route, fractional recoveries 
cannot be calculated; therefore, the actual administered activity of 
241
Am must be calculated. 
This is determined based on aerosol concentration samples as well as physiological and 
radiochemical measurement data. The estimated mean delivered 
241
Am activity was 
calculated to be 102.5 and 95.5 kBq (2.77 and 2.58 µCi) for female and male dogs, 
respectively. 
 Statistically significant increases in 
241
Am elimination over control were observed in 
all treatment groups with the highest dose (500 mg/kg) producing significant increases in 
decorporation over the 300 mg/kg dose (p<0.01). As shown in Figure 6.1, urinary excretion 
of 
241
Am increased in a dose-dependent manner, which persisted for the duration of the 
study. Urinary excretion was 8-fold higher than control for 100 and 300 mg/kg doses and 13-
fold higher at 500 mg/kg. Fecal elimination showed modest enhancement over control with 
all dose levels for three days after treatment before returning to control levels. Treatment 
with doses ≥ 300 mg/kg resulted in a 50 % increase in fecal elimination of 241Am, 
significantly higher than control (p<0.05). 
 In addition to evaluating enhancements in urine and fecal 
241
Am elimination, 
assessing the ability of a decorporation agent to prevent uptake of 
241
Am into body tissues, 
particularly the liver, kidney and bone, is important. Significant reductions in liver, kidney 
and lung 
241
Am burden were observed at all dose levels (p<0.05). Figure 6.2 demonstrates 
that a dose-dependent decrease in tissue burden was only observed in both liver and lung 
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tissues. At 500 mg/kg there was >65% decrease in liver and spleen 
241
Am burden, >50% 
decrease in kidney and lung burden and >30% decrease in total 
241
Am bone content 
compared to untreated controls. 
 
6.3.2 Acute Maximum Tolerated Dose of C2E2 in Dogs 
Beagle dogs received single C2E2 doses of 100, 300 or 750 mg/kg under fasted 
conditions and 300 mg/kg under fed conditions. In some cases, transient emesis, excessive 
salivation and fecal abnormalities occurred that did not affect the overall health of the dog 
and, therefore, were not considered adverse. C2E2 administered at ≤ 300 mg/kg had no 
significant effects on clinical pathology test results. Two days after administration of 750 
mg/kg, two dogs exhibited increased alanine and aspartate aminotransferase (ALT and AST) 
activities indicating hepatocellular injury, though this did not uniformly affect all dogs. As 
evident in Table 6.1, systemic exposure to C2E2 (AUC0-24) generally increased in a dose 
proportional manner, and there was no greater than a 2-fold difference in mean C2E2 Cmax 
and AUC0-24 values between sexes. A reduction in C2E2 exposure was observed under fed 
conditions compared to the fasted state. Specifically, CMax and AUC0-24 values were at least 
22-fold and 7-fold lower, respectively, in fed dogs. Under fed conditions the fraction of 
C2E2 metabolized to C2E1 doubled but was only responsible for 2 % of the total exposure. 
Overall, a single dose of C2E2 by oral gavage to male and female dogs at escalating doses 
resulted in minimal, non-adverse clinical observations at all dose levels, and the maximum 
tolerated dose was identified as 750 mg/kg. 
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6.3.3 Ten Day Oral Dose Range Finding Study of C2E2 in Dogs 
Daily administration of C2E2 to beagle dogs by oral gavage for 10 days at doses of 
60, 200, 400 and 600 mg/kg/day resulted in the early sacrifice of one male in both the 400 
and 600 mg/kg/day groups due to weight loss and declining health. Clinical pathology 
identified hepatocellular necrosis as the cause of toxicity in these dogs. Due to these early 
sacrifices the doses ≥ 400 mg/kg/day exceed the maximum tolerated dose. Exposure to C2E2 
increased with increasing dose and no accumulation was observed after administration of 
multiple doses. As in the acute maximum tolerated dose study, transient emesis and/or fecal 
abnormalities occurred in dogs receiving doses ≥ 200 mg/kg/day. In animals that survived 
until necroscopy, mild to moderate (1.0 - 3.6 x control) increased AST activity was observed 
on day 6 at doses ≥ 600 mg/kg/day. Mildly to markedly (6.8 - 90 x control) increased ALT 
activity was observed on days 6 and 11 in animals receiving doses ≥ 400 mg/kg/day. The 
increases in AST and ALT levels were associated with microscopic evidence of liver injury 
and considered adverse. Tubule cell necrosis was present in one female in both the 400 and 
600 mg/kg/day groups. This was not noted in the males at terminal sacrifice but was noted in 
both males sacrificed early. The liver and kidney were identified as the target organs of 
toxicity at ≥ 400 mg/kg/day. Based on these findings, an NOAEL of 200 mg/kg/day for 10 
days of oral dosing in beagles was established. 
 
6.3.4 Genotoxicity of C2E2 
C2E2 was evaluated for its potential to induce reverse mutations at the histidine locus 
of Salmonella typhimurium and at the tryptophan locus of E. coli in the Ames test and for its 
ability to cause chromosome aberrations in CHO cells. These in vitro tests are required by the 
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FDA for all small molecule drugs prior to their use in human clinical safety trials. 
Additionally, an in vivo rat bone marrow micronucleus test was performed to evaluate C2E2 
for clastogenic activity and/or disruption of the mitotic apparatus by detecting micronuclei in 
PCEs. 
The mutagenicity of C2E2 was evaluated in five bacterial tester strains at doses from 
5 to 5000 µg/plate in the presence and absence of S9 activation. Compared to vehicle 
controls, reductions in the mean numbers of revertant colonies, indicative of C2E2 treatment-
related toxicity, was noted at the 5000 µg/plate level in TA100, TA1535, TA1537 and 
WP2uvrA under conditions without S9 and at ≥ 500 µg/plate in TA1535, TA1537 and 
WP2uvrA under conditions with S9. There were no relevant increases in the number of 
revertant colonies observed at any dose level with any strain in the absence or presence of S9 
metabolic activation (Table 6.2). All vehicle and positive control values were within 
acceptable ranges. These results indicate that C2E2 was not mutagenic in the Ames assay for 
bacterial gene mutation up to 5000 µg/plate in the presence and absence of metabolic 
activation. 
In the chromosome aberration assays after 3-hour exposure, either with or without 
metabolic activation, no cytotoxicity was observed as evident by no dose-related reductions 
in cell counts or calculated population doublings compared to the concurrent vehicle control. 
All vehicle and positive controls were in acceptable ranges. Chromosomal aberrations were 
analyzed from the cultures treated with 245, 350 and 500 μg/mL of C2E2 and there were no 
statistically significant increases in the number of cells with chromosomal aberrations, 
polyploidy, or endoreduplication.  
For the 20-hour test chromosomal analysis, cytotoxicity was observed.  Based on 
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mitotic indices, the 6.92, 9.89 and 14.1 μg/mL dose levels were selected for aberration 
analysis. The 14.1 μg/mL dose level produced a 53% reduction in mitotic index compared to 
the concurrent vehicle control. Chromosomal analyses again showed that there were no 
biologically relevant or statistically significant increases in the number of cells with 
aberrations observed at any dose level examined. Therefore, C2E2 was determined to be 
negative for the induction of chromosomal aberrations with and without S9 when tested up to 
cytotoxicity-limiting dose levels and the 500 μg/mL limit dose for this assay. 
During the in vivo micronucleus test, one animal from the 2000 mg/kg/day group  
was noted to have audible respiration and hypoactive behavior on day 2. No other adverse 
signs of clinical toxicity were observed in any other C2E2 treated animal. There were no 
statistically significant decreases in the C2E2 treatment group PCE:NCE ratios compared to 
the vehicle control value indicating an absence of treatment-related bone marrow 
cytotoxicity. The male rat vehicle control values had micronucleated PCE means of 0.05 ± 
0.6% and the positive control, cyclophosphamide, induced statistically significant increases 
in micronucleated PCEs (2.14 ± 0.60%). Thus, it was concluded that there were no 
statistically significant or treatment-related increases in micronucleated PCEs at any C2E2 
dose level examined. 
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Table 6.1 Systemic C2E2 exposure following oral administration of single escalating 
doses in dogs (n = 2/sex).  
Dose Level 
(mg/kg/day) 
Sex Cmax 
(ng/mL) 
AUC0-24 
(ng.hr/mL) 
100 M 39900 91950 
 F 30700 79780 
300 M 74650 230600 
 F 108800 263100 
750 M 267000 530400 
 F 245500 498900 
300* M 3335 32860 
 F 3555 25930 
*Indicates dosed under fed conditions 
 
  
Table 6.2 C2E2 Mutagenicity in Bacterial Strains of the Ames Test 
Mean ± SD revertant colonies/plate 
Dose 
(µg/plate) 
TA98 TA100 TA1535 TA1537 WP2uvrA TA98 TA100 TA1535 TA1537 WP2uvrA 
 Without S9 With S9 
0 12.3  3.2 90.7  8.6 10.0  1.0 7.3  3.2 11.7  1.2 22.0  1.7 101.0  5.0 7.0  1.0 8.3  2.5 14.7  4.7 
5.00 11.0  2.6 97.7  11.0 9.7  1.5 4.7  2.3 11.3  0.6 19.0  2.6 112.0  19.5 7.7  2.9 11.3  1.5 15.0  2.6 
16.0 10.3  4.0 94.3  12.7 9.7  2.5 5.3  3.5 15.0  2.6 16.7  3.5 126.7  21.5 7.3  3.2 5.3  1.5 13.7  4.0 
50.0 14.0  2.0 103.7  7.8 9.3  2.3 4.0  2.0 10.3  2.1 20.7  8.0 93.0  9.8 10.0  0.0 5.7  1.2 14.7  4.0 
160 12.0  1.0 65.0  9.5 9.3  1.2 4.0  3.6 8.7  2.1 18.0  4.6 94.0  10.8 9.3  2.1 6.7  3.1 12.7  3.8 
500 12.7  1.5 94.7  21.6 7.3  5.0 2.7  1.2 13.7  1.2 21.0  4.4 83.3   12.0 7.0  2.6 4.3  0.6* 8.7  4.7* 
1,600 9.3  3.1 72.0  6.2 7.3  3.5 8.3  5.7 11.3  1.0 21.0  2.6 88.7  11.7 8.3  2.1 5.0  1.7* 6.7  1.5* 
5,000 10.0  4.6 23.7  17.6* 1.7  0.6* 2.7  2.1* 3.3  1.2* 15.3  3.1 77.0  15.1 4.3  2.5* 4.0  3.6* 5.0  1.0* 
(Errors indicate the standard deviation (SD) for n=3, *Reduction in the number of reverant colonies compared to control) 
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Figure 6.1 Daily urinary excretion after a single oral administration of C2E2 to dogs 24 
hours after inhalation contamination with 
241
Am nitrate. 
 
 
 
 
Figure 6.2 Percent of respirable 
241
Am dose remaining in lung (A), liver (B), total bone 
(C) and kidney (D) in dogs administered different doses of C2E2 at 24 h after inhalation 
contamination with 
241
Am nitrate (*p<0.05 against control group, **p<0.01 against control 
group).  
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6.4 Discussion 
Although there has been much research investigating the decorporation of radioactive 
actinides, DTPA remains the agent of choice for elimination enhancement of internalized 
americium, plutonium and curium. Recently there has been a focus on the development of 
novel orally active chelators and improved formulations to overcome the shortcomings of 
DTPA. Tablets containing DTPA and permeation enhancers increased oral DTPA absorption 
from 5 to 12% in rats
119
. Another approach involves the development of an orally 
administered DTPA nanoparticle formulation. Preclinical studies of this oral ‘NanoDTPA’™ 
capsule formulation demonstrated favorable pharmacokinetic and safety profiles in rodent 
and dog models
105
. Radionuclide decorporation efficacy was also demonstrated with a 
transdermally administered formulation of the DTPA penta-ethyl ester prodrug (C2E5), 
however, toxicological assessment was not conducted
96-97
. 
In this work we detail the development of an orally bioavailable ester of DTPA for 
use in radiological emergencies. For medical countermeasure development programs where 
efficacy can only be demonstrated in animal models, particular emphasis is placed on the 
appropriateness of the models used. Here we have demonstrated that orally administered 
C2E2 enhances urinary and fecal elimination of 
241
Am from beagle dogs in a model that was 
designed to mimic a realistic response to a mass casualty contamination. Specifically, the 
inhalation route of contamination was selected based on the most likely scenario for 
contamination of a large number of people, the species used was selected for the similarity of 
its 
241
Am biokinetics to humans, and a 24-h delay before treatment was used to approximate 
the time at which the initial response treatment would commence. The clearance of 
radioactive particles from the lungs following inhalation exposure is a complex and species-
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dependent process
141
. Particle clearance can occur by a mechanical process (e.g. 
muccocilliary action) or by the dissolution and subsequent absorption of the radionuclide into 
the systemic circulation. For moderately soluble materials, such as most americium salts, 
mechanical removal is strongly species-dependent whereas dissolution-absorption is species-
independent
140
. The rate of particle clearance in dogs and monkeys are a better 
approximation of human clearance than rodents
141
. For these non-rodent species, human 
241
Am biokinetics in other compartments are better approximated in dogs
148
, hence their use 
in the present study. 
The elimination of 
241
Am was significantly increased over controls in all treatment 
groups. Americium was predominantly eliminated by C2E2 in the urine, although 
statistically significant increases in fecal elimination were observed in the mid and high dose 
groups. This is in contrast to other studies performed with more lipophilic (C22) 
polyaminocarboxylic acids, where the predominant elimination was fecal via the biliary 
pathway
152
. This difference may be attributed to a smaller increase in lipophilicity generated 
by addition of ethyl esters rather than longer alkyl chain promoieties. The inhalation 
contamination model may also mask some of the fecal elimination effects due to the high 
percentage of activity (27%) cleared from the lung in control animals via mucocillary 
clearance.  
As efficacy cannot ethically be tested in human volunteers, proposed radionuclide 
decorporation agents need to comply with the Animal Rule (21 CFR 314.600)
153
 for efficacy 
determination before receiving approval for use in humans. The studies described herein 
were performed as the initial steps to meet regulatory requirements to demonstrate that C2E2 
is safe for first–in-human studies and efficacious for studies performed under the Animal 
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Rule. Dose escalating toxicity studies were conducted to evaluate the acute toxicity of C2E2 
and the data was used to support dose level selection for subsequent repeat-dose toxicity 
testing. The NOAEL established in dogs indicates that large doses of C2E2 are well 
tolerated. Administration of C2E2 with food resulted in a reduction in systemic exposure; 
this is an important factor that must be considered in the design of human clinical trials. In 
dogs, the liver was identified as a target organ of toxicity due to elevation of ALT and AST 
levels after a single dose of 750 mg/kg and at ≥ 400 mg/kg after 10 daily doses. At high 
doses or after multiple injections, DTPA is also associated with liver and kidney toxicity
154.
 
As with DTPA, the rapid excretion of C2E2 in the urine, may explain some of the 
nephrotoxicity. On occasion oral administration of C2E2 at doses ≥ 200 mg/kg/day resulted 
in transient emesis. Emesis in future studies may be minimized by formulating C2E2 in 
enteric coated tablets that, although may delay release, will help to minimize loss of drug and 
further increase bioavailability.
 
 
The maximum tolerated dose of 750 mg/kg is seven fold higher than the lowest 
effective single dose tested, though upon repeat dosing the NOAEL was determined to be 
200 mg/kg/day. Although only twice as high as the lowest effective single dose, it is 
presumed that lower repeat doses would be required to achieve the same effect. The 
therapeutic index is determined by the ratio of a drug’s ED50 and LD50. Unlike traditional 
diseases in which the ED50 is measured by a quantal effect, the goal in decorporation therapy 
is to maximize radionuclide removal and the effect is measured on a continuous scale. As 
with DTPA, the retention of 
241
Am is inversely related to dose; though each doubling of dose 
results in a diminishing return in efficacy
71
. Consequently a balance must be struck between 
decorporation efficacy and toxicity. In order to maximize the therapeutic window and 
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maintain efficacy, a modified dose regimen could be used, in which a high initial dose is 
given followed by lower daily doses.  
A comprehensive assessment of the genotoxic potential of the drug is required to 
obtain regulatory approval for human clinical trials. As no single test is capable of detecting 
all of the genotoxic mechanisms relevant to carcinogenicity, a standardized battery approach 
is recommended by ICH
149
. These tests were completed as part of this study and the results 
indicate that C2E2 is not mutagenic or clastogenic.  
As with DTPA, repeated dosing with C2E2 is expected to further enhance the 
elimination of 
241
Am. Extended daily treatment will enable chelation of radionuclides that 
continue to translocate from the lung into the systemic circulation. Besides providing ease of 
access to treatment, the oral formulation is advantageous for long-term treatment because 
repeated intravenous injections are avoided. The efficacy and acute toxicity of C2E2 in rats 
and multiple dose toxicity over 28 days in both species are currently being investigated. 
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6.5 Conclusion 
Single doses of C2E2 administered orally to dogs 24 hours after contamination by 
inhalation of 
241
Am nitrate significantly increased the urinary elimination and reduced the 
tissue burden of 
241
Am. The toxicity of acute oral doses of C2E2 was evaluated in dogs, and 
NOAELs were identified. C2E2 is neither mutagenic or clastogenic, based on the Ames test, 
chromosome aberration assay and micronucleus test data. Thus, this DTPA analog appears to 
be an effective orally-administered medical countermeasure for treating individuals 
contaminated with transuranic elements. Based on these studies as well as preliminary acute 
and genetic toxicity testing, C2E2 is a promising candidate for inclusion in the Strategic 
National Stockpile.  
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CHAPTER VII 
 
PERSPECTIVE AND CONCLUSIONS 
 
7.1 Discussion 
Since transuranic elements were first discovered research has been conducted to 
understand their distribution
37
 and health effects after internalization while simultaneously 
methods to enhance elimination were developed incase of accidental contamination
33
. Due to 
differences in each radionuclides physiochemical properties, pharmacokinetics and atomic 
structure the most efficient therapies are specific to each radionuclide
63
. For elimination of 
plutonium and americium, IV DTPA is the only FDA approved treatment available
58
. 
Although effective, IV therapy is not suited for use during a mass contamination scenario. 
Following the success of DTPA a number of approaches were investigated in hope of further 
increase radionuclide elimination. As DTPA resulted improved efficacy over EDTA addition 
of a further ethylene bridge produced triethylenetetramine hexaacetic acid (TTHA)
155
. TTHA 
had higher metal binding affinities though this did not translate to improved efficacy
156
. 
Esterified DTPA was also utilized in hope of improving plutonium decorporation from 
tissues however due to limited efficacy and toxicity this approach was abandoned
90
. 
In 2005 the NIH and NIAID evaluated the ability to respond to a number of terrorist 
threats and recognized that there was an unmet need for oral decorporation agents
98
. This led 
to the funding of three approaches for the development of an oral alternative to DTPA, 
including SRI International (Menlo Park, CA), Nanotherapeutics Incorporated (Alachua, FL) 
and the lab of Dr. Jay at the University of Kentucky
106
. 
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 Under the BCS, DTPA is can be categorized as a class III compound. Traditionally 
for such compounds permeability can be enhanced through the use of efflux inhibitors, 
formulation approaches or prodrugs. The oral bioavailability of DTPA is limited due to its 
charge. Masking the charge through prodrug formation results in permeability enhancement 
and this approach was shown to be effective with the DTPA-pentaethyl ester, C2E5
95
 and 
with partially esterified TTHA analogues
157
. However the increased lipophilicity of these 
compounds resulted in toxicity. This is likely due to increased cellular absorption and 
chelation of essential metals
88
. Formation of a partially esterified DTPA molecule, such as 
C2E2, lowers the net charge while increasing lipophilicity. The log D values for C2E5, C2E2 
and DTPA were 2.4
94
, -2.1 and -2.9
117
, respectively. Although only modestly enhanced over 
DTPA, bioavailability was improved from 3
110
 to 29 % in rats, higher than either competing 
product as discussed later. 
 One of the major concerns with the use of prodrugs is their stability
158
. Limited 
hydrolysis was observed in simulated fluids and so both esters on C2E2 will remain intact 
prior to absorption. Ideally once absorbed the esters should be metabolized to reveal the 
parent compound DTPA. Unfortunately this was not the case for C2E2, however as six 
chelation sites were available the chelation of americium was preserved. Thus, C2E2 is itself 
an active molecule and cannot be considered a prodrug, though any ester liberation in the 
plasma will yield a more effective chelator. 
The ionization constants determined for C2E2 are similar to other bi-functionalized 
DTPA analogues
130
. Due to the presence of three acid and three basic groups with pKas 
spanning the pH range, C2E2 will always be ionized, except for pH 2.7 where the net charge 
is neutral and a fraction of the compound will be unionized. The six coordination sites, allow 
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C2E2 maintain the ability to chelate americium albeit at lower concentrations than DTPA. 
The Log K value for americium binding is 19.6, this is similar to that of EDTA (log K 
18.2
135
). 
Although differences in radionuclide binding to plasma proteins had previously been 
recognized
34
, the effect on DTPA concentrations required for chelation was only recently 
investigated
119
. As efficacy must be demonstrated in animal models these differences can 
help to select the appropriate species. In the present work the americium nitrate salt was used 
in place of citrate to ensure consistency across in vitro and in vivo data. Differences were 
noted between the binding of americium citrate and nitrate salts by DTPA. These differences 
could stem from the higher association of citrate for americium than nitrate (Log K 8.6 vs 
1.8). The nitrate salt may bind to transferrin more readily increasing the concentration of 
DTPA required compared with the citrate salt. The in vitro binding data shows that the dog 
model is the most appropriate for establishing efficacy of C2E2 in humans as although 
efficacy may be slightly overestimated when using the dog model, the difference is much 
smaller than the underestimation observed in rats. In rats a 5-fold increase in C2E2 is 
required to achieve the same effect as in humans, where as only a 2-fold increase is required 
for DTPA. This means that the rat model unfairly discriminates against C2E2 compared to 
DTPA when used to predict human doses. Furthermore the difference in glomerular filtration 
rate (GFR) between species causes further underestimation of efficacy in the rat model. The 
dog GFR is similar to humans but still high, any differences in binding efficacy may be more 
than compensated for due to increased exposure. While the dog model offers a better 
representation of efficacy in humans, investigations in rats still have value especially when 
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compared to DTPA. The rats also offer a cost effective way to evaluate different dosing 
regimens, prior to conducting expensive dog decorporation studies.  
 The approaches of Nanotherapeutics and SRI are based on enhanced DTPA 
formulations. Briefly, Nanotherapeutics has prepared nanoDTPA by micronizing DTPA and 
zinc acetate (approximately 2:1 ratio) in a jet mill until a size of < 100 microns was obtained. 
Enteric-coated capsules were then filled with 470 mg of the micronized powder (300 mg 
DTPA)
159
. Similarly, SRI has formulated DTPA into enteric coated capsules containing a 
permeation enhancer that caused bioavailability to increase to 12 % in rats
119
.  
The efficacy of C2E2 in rats has been established after administration of both single 
and multiple doses. Maximum decorporation was seen after administration of 10 daily doses 
of 600 mg/kg with 50.1 and 43.9 % of the injected dose eliminated over 12 days for both 
male and female rats, respectively. Under all conditions tested the efficacy of C2E2 was 
lower than that achieved with DTPA, though as the duration of therapy increases the efficacy 
gap is reduced. In rats five daily 600 mg/kg doses of C2E2 were as effective as a single IV 
DTPA administration in lowering total decorporation, though liver and skeletal burdens were 
not as effectively reduced. As the majority of people contaminated with americium are given 
a single dose of DTPA
160
, a short oral course of C2E2 could be used as alternative treatment. 
The DTPA controls used during the experiments conducted at UNC were given as bolus 
injections as appose to infusions, the high Cmax associated with these injections may be the 
reason for the high liver burden reductions and increase in americium elimination via the 
fecal route seen with DTPA treatments.  
For C2E2 greater efficacy is seen in dogs than rats. Single doses of 100 mg/kg led to 
significant increases in total decorporation over control. There was no DTPA control for this 
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study and the all published DTPA data uses multiple injections. There is also no comparable 
data for the efficacy of competing products in either rats or dogs as IV contamination models 
and different durations were used during efficacy studies limiting the accuracy of 
comparisons. However, the pharmacokinetics of NanoDTPA and the toxicity of both 
competing products have been reported. A Nanotherapeutics pharmacokinetic study in male 
dogs, showed that when given orally a Zn-DTPA solution has a bioavailability of 3 %. The 
NanoDTPA formulation increased oral DTPA exposure 1.5-3 fold (based on AUC0-24)
105
 
however the doses were 3-6 times larger, consequently the formulation reduced 
bioavailability to 1.5 % in dogs.  
 The toxicity of DTPA is relatively low and large cumulative doses (580 g) have 
safely been administered to humans
161
. The target organs for DTPA toxicity are the kidneys, 
liver and GI tract, though doses 200 fold higher than those used in humans were required to 
observe these toxicities
160
. As the NanoDTPA product is mainly composed of DTPA its 
toxicity was low with 700 mg/day/dog (~70 mg/kg/day) doses tolerated for 14 days with no 
adverse effects observed aside from emesis. The maximum tolerated dose for the SRI product 
was 7560 mg/day and the NOAEL 1325 mg/kg/day in dogs and 1000 mg/kg/day (highest 
dose tested) in rats for 7 daily doses
119
. Again emesis was noted in dogs and there were no 
significant toxicological findings, confirming the low toxicity of DTPA. The disadvantage of 
using permeation enhancers is that absorption of ingested radionuclides may be increased in 
contaminated individuals. Also for those heavily contaminated the gastrointestinal mucosal 
may be damaged by radiation and so further disruption by permeation enhances is a concern. 
 The NOAELs were identified as 800 and 200 mg/kg/day in rats and dogs, 
respectively after 10 daily administrations. These are lower than those obtained for the DTPA 
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products, though this was expected as C2E2’s bioavailability and consequently exposure is 
higher. Previous studies with lipophilic chelators have also shown that toxicity increases in 
proportion to the number of esters
90
. However, the NOAELs determined for C2E2 are higher 
than the doses likely to be recommended for treatment in humans.  
 Although successful at enhancing decorporation of americium a variety of 
radionuclides may be responsible for contamination and those that occur with multiple 
radionuclides the hydroxypyridinonate (HOPO) group of compounds are favorable. These 
chelators have been designed to chelate a wide range of radionuclides with high affinity
162
. 
However, to achieve enhanced chelation oral absorption was not a priority and the 
compounds have poor oral bioavailability in rats (<5 %)
163
. The efficacy of two of these 
compounds 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) for decorporation of 
238
Pu, 
241
Am and 
233
U(VI)O2 has been demonstrated in mice after i.p and oral administration with 
promising results
164
. The NOAELs for 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) are 
also above their presumed target oral efficacy doses. Although additional work is needed, the 
information currently available for these two HOPO agents highlights their potential as 
alternatives to intravenous DTPA therapy. However, their high molecular weight and likely 
complex metabolic profile may add challenges to their regulatory approval.  
 This work has demonstrated the efficacy of C2E2 for oral decontamination of 
americium. Only a handful of experiments must be conducted prior to submission of an 
investigational new drug (IND) application. Protein binding data in the species used for 
repeated dose toxicity studies should be evaluated
165
 and the remaining safety pharmacology 
studies to assess cardiovascular, CNS and respiratory effects must be completed. Lastly the 
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manual patch clamp hERG assay for assessment of drug interactions with the hERG 
potassium channel and QT prolongation. 
 Assessing the binding affinity of C2E2 for these metals in plasma may lead to 
additional indications enabling turnover of stock in the national stockpile. In addition to 
transuranic elements other than Am, such as Pu and Cm, radioisotopes of non-transuranic 
elements (
60
Co) and non-radioactive metals associated with metal overload syndromes (Pb, 
Fe) should be assessed. The binding constants for EDTA can be used as a guide to determine 
those metals for which C2E2 is likely to have a high affinity.  
For BCS III compounds such as DTPA chemical modification is the most successful 
method of overcoming permeation-limited bioavailability. Though successful the C2E2 
molecule could be further optimize to maximize absorption while retaining the ability to 
chelate 
241
Am. Increasing the length of the ester promoeities may result in further 
enhancement in absorption as seen with partial esterified triethylenetetraminepentaacetic 
acids
91
, though with increased permeation toxicity is likely to increase. A balance must 
therefore be struck between ester length, affinity for the metal, and toxicity. Ultimately the 
ideal prodrug for DTPA would have all the carboxylic acids masked as with C2E5 and after 
absorption would be completely metabolized to DTPA. For traditional pro-drugs with one or 
two carboxylic acids there are a diverse set of alcohols and phenols available for conjugation 
allowing absorption and enzymatic conversion to be tailored
166
. Although the ethyl esters 
proved to be stable in vivo, utilization of alternative groups may result in more complete 
liberation. Investigation into the reason C2E5 ester hydrolysis slows after reaching liberation 
of the first two esters and is ineffective for C2E2, may aid in the design of more effective 
DTPA prodrugs in the future. 
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 Although less effective for BCS class III compounds than class II, further 
improvements in absorption could be obtained through formulation
167
. Permeation enhancers 
are commonly for poorly permeable compounds but are not ideal for decorporation products. 
Either a gastro-retentive drug delivery system that prolongs the residence time in the stomach 
such as floating tablets
168
 or a muccoadhesive system
169
, which can increase local 
concentrations at the intestinal mucosal membrane, may help to increase absorption of C2E2. 
 
7.2 Closing Remarks 
There is currently no treatment available in the strategic national stockpile enabling fast 
and efficient administration in the event of a mass contamination scenario involving the 
radionuclides of americium, plutonium and curium. Although effective, IV administration of 
DTPA requires health care professionals and is therefore not amenable to a mass casualty 
situation where any delay in treatment resulting in lower efficacy. On the contrary an oral 
chelation agent such as C2E2 can be rapidly distributed and administered limiting tissue 
disposition of internalized radionuclides. This doctoral research demonstrates that C2E2 is an 
effective orally administered medical countermeasure with low toxicity. Providing the human 
pharmacokinetics follow a similar trend as that seen with DTPA, C2E2 is a promising 
alternative for treating individuals contaminated with transuranic elements. 
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APPENDIX I 
 
PHARMACOKINETIC PHARMACODYNAMIC MODEL OF C2E2 AND 
PREDICTION OF MRSD IN HUMANS 
 
Introduction 
The effectiveness of a drug depends on the relationship between the administered 
dose, the resulting drug concentration in the body and the pharmacological effect caused by 
these concentrations
170
. These properties are described by both the pharmacokinetics and 
pharmacodynamics of the drug. Pharmacokinetics defines the concentration time profile of a 
drug obtained from a particular dose and is based on absorption, distribution, metabolism and 
excretion. Pharmacodynamics describes the magnitude of the drugs effect relative to its 
concentration. A mathematical model that encompasses both the pharmacokinetics and 
pharmacodynamics (PK-PD model) can be used to determine the dose required to produce a 
specific response
171
. Due to the inability to assess the clinic efficacy of decorporation agents 
in humans the development of a PK-PD model is of particular importance in supporting 
selection of an effective human dose and must be used in order to meet the fourth 
requirement of the FDA animal rule
100
.  
To enable prediction of the human dose, the pharmacokinetics must be determined in 
both animals and humans. The pharmacokinetics of C2E2 has been investigated in both
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Sprague-Dawley rats (Chapter V) and beagle dogs (Chapter VI). Without human 
pharmacokinetic data it is not possible to select an effective dose, however using in vitro 
data, animal pharmacokinetic parameters and efficacy results an estimation can be made 
based on similarities with DTPA.  
For C2E2, chelation of americium is achieved in a similar fashion as with DTPA. 
Target concentrations of DTPA were based on animal efficacy data. Americium 
decorporation is inversely related to DTPA dose and above concentrations of 30 µmol/kg 
(11.8 mg/kg) large increases in dose are required to gain additional efficacy in beagles
71
. 
Molar DTPA levels in plasma far exceed those of americium and recently target 
concentrations were determined in vitro using a competitive binding method
119
. Through use 
of this in vitro data it is possible to establish species differences in target concentrations and 
combined with pharmacokinetic data determine relative durations of action from a single 
dose. In chapter III the target plasma concentrations for C2E2 were identified and when 
combined with the pharmacokinetic data described in chapters V and VI can help guide dose 
selection. As with all new drugs human pharmacokinetics and toxicity must be determined in 
a phase I clinical trial. Prior to conducting a phase I trial it is important to determine the first-
in-human (FIH) dose
172
. There are many methods used for prediction of the FIH dose
173
, 
however current FDA guidance suggests that the maximum recommended starting dose 
(MRSD) should be calculated from NOAELs determined during animal toxicity studies
174
. 
The phase I trial is especially important for radionuclide decorporation agents as the 
pharmacokinetics established will help guide dose selection in place of formal efficacy trials.  
Below the efficacious human dose is estimated and the MRSD is also calculated based on 
animal toxicity data described in Chapters V and VI.  
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Pharmacokinetic and Pharmacodynamic Models 
The data obtained from rat and beagle toxicokinetic studies is presented in Tables A.4-10. 
For each dose area under the curve (AUC) values were determined using a two-compartment 
model. The results of the divided dose study in rats suggest that decorporation efficacy is 
dependent on cumulative AUC rather than Cmax. Thus to enable efficacy prediction from a 
particular dosing regimen, the percentage decorporation was modeled against cumulative 
AUCs for each dose administered for each species using the following equation: 
E =
Emax ×C
EC50 +C
 
There are several limitations to this approach. For rats both single and multiple dose 
studies have been conducted. The duration of the single and multiple dose studies were 
different, so there is potential for additional decorporation to occur over the extra time. In 
order to limit this effect the data was corrected for untreated decorporation using the control 
groups for each study. The majority of the multiple dose studies in rats were performed at 
doses of 600 mg/kg for which there is no PK data. Therefore, AUCs for the 600 mg/kg dose 
were calculated by normalizing the data obtained from the 200, 400, 800 and 2000 mg/kg 
doses (Tables A.4 – A.7) to 600 mg/kg (Table A.8) and calculating the median concentration 
by sex. The normalization process is based on the assumption that there is a linear 
relationship between dose and plasma concentration. For C2E2 this is not always the case 
however the differences are not consistent between doses and a superior alternative was not 
found. 
There is limited data for dogs with efficacy studies only conducted using three single 
doses, though a pharmacodynamic model was created using the available data (Figure A.2). 
In order to improve the prediction of human response more data is required in beagles. Due 
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to the increased exposure observed in dogs, efficacy of smaller doses should be assessed to 
further characterize the lower range of the pharmacodynamic curve. As cumulative AUC is a 
good indicator of efficacy a multiple dose study in dogs may not be required, as the exposure 
may be similar to that established with the high single dose.  
Both the PK tables and pharmacodynamic models demonstrate that higher AUCs are 
obtained in dogs with a single oral administration of 100 mg/kg achieving similar exposure to 
5 daily 600 mg/kg doses in rats. As expected, based on the in vitro binding data, C2E2 causes 
a greater enhancement decorporation in dogs for any given cumulative AUC compared to 
that in rats. The increase in exposure and resulting efficacy are also likely due to differences 
in the pharmacokinetics of C2E2 across species. The pharmacokinetic behavior of C2E2 is 
similar to DTPA with elimination best modeled using a 2-compartment model. For DTPA 
elimination is inversely related to body size. This is due to differences in renal clearance, 
with both EDTA and DTPA metal complexes eliminated in a similar fashion to insulin, 
where the glomerular filtration rates are 5.9, 3.8 and 1.3 for rat, dog and humans, 
respectively
116
. As the same trend is seen with C2E2 it is expected that human doses are 
likely to be lower than those required in beagles. As renal clearance is inversely proportional 
to AUC a dose that is 1/3 that of the beagle dose may be expected to produce a similar 
exposure providing the bioavailability is constant between species. Based on the data 
obtained and similarities between C2E2 and DTPA, human efficacy may be observed at 
single doses in the range of 30-40 mg/kg (67 µmol/kg) with higher efficacy observed with 
larger or repeated dosage.  
In contrast, efficacy with IV DTPA can be observed at doses as low as 1 mg/kg (3 
µmol/kg)
71
. The selection of a 30 mg/kg efficacious dose can also be supported by in vitro 
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binding data. If the bioavailability in beagles is similar to that in rats (~30%) the oral dose is 
equivalent to a 20 µmol/kg IV dose. Furthermore, in beagles a five-fold increase in C2E2 
plasma concentration is required to achieve the same chelation effect as DTPA to achieve the 
same effect. Multiplying the lowest DTPA concentration by both of these factors results in a 
starting dose similar to that obtained from efficacy data. 
 
Selection of MRSD for Human Dosing 
 In order to select a human starting dose the NOAELs from animal toxicity studies 
must be known. This relates to the highest dose level that does not produce a significant 
increase in adverse effects in comparison to control. Toxicity studies with C2E2 identified 
the single dose NOAELs as 2000 and 750 mg/kg in rats and dogs, respectively. The 10-day 
NOAELs were lower at 800 and 200 mg/kg/day for rats and dogs, respectively, and will be 
used to calculate the human equivalent dose (HED). 
 Toxic doses have been shown to scale in relation to body surface area. Typically 
conversion to body surface area is based on the weight of animals used within the study 
however body surface area conversion factors (BSA-CF) outlined by the FDA can be used to 
provide reasonable estimates of the HED. For C2E2 the NOAELs are 129 and 111 mg/kg 
when normalized to body surface area. The HED established from the beagle model should 
be selected as the value is more conservative and because the pharmacokinetics are more 
predictive of human response for similar drugs such as EDTA and DTPA. 
Finally a safety factor is applied to the HED to allow for variation in scaling and 
minimize the probability of the initial dose being toxic. For C2E2 the standard safety factor 
of 10 should be applied so that the MRSD is 11 mg/kg. However, as this dose is only three 
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fold lower than the estimated lowest efficacious dose and exposure in humans is likely to be 
higher than expected due to decreased glomerular filtration rate it may be necessary to further 
lower the MRSD to 1 mg/kg. 
 Although estimations of both the human efficacious dose and the MRSD can be made 
from the data presented, further beagle studies would help to improve confidence. 
Ultimately, human pharmacokinetic data is required to determine the optimal dose and 
regimen. 
  
  
168 
Table A.1 Summary of Pharmacokinetic and Efficacy Data for Male Sprague Dawley 
Rats 
Dose  # of 
Doses 
Study 
Duration 
Cumulative 
AUC 
Control 
Decorporation 
(%) 
Total 
Decorporation 
(%) 
Decorporation 
Increase (%) 
200 1 7 3764 14.6 20.9 6.3 
600 1 7 13288 14.6 26.4 11.8 
600 5 12 68735 23.4 44.1 20.7 
600 5 OD 12 68735 17.7 39.7 22 
600 5 BD 12 68735 17.7 43.6 25.9 
600 10 12 137470 23.4 50.1 26.7 
  
Table A.2.  Summary of Pharmacokinetic and Efficacy Data for Female Sprague Dawley 
Rats 
Dose  # of 
Doses 
Study 
Duration 
Cumulative 
AUC 
Control 
Decorporation 
(%) 
Total 
Decorporation 
(%) 
Decorporation 
Increase (%) 
200 1 7 4011 11.2 14.4 3.2 
600 1 7 18307 11.2 23.6 12.4 
200 7 12 28077 15.3 32.3 17 
600 5 12 91535 20.1 38.1 18 
600 5 OD 12 91535 15.9 28.9 13 
300 5 BD 12 91535 15.9 34.8 18.9 
600 10 12 183070 20.1 43.9 23.8 
 
 
Table A.3 Summary of Pharmacokinetic and Efficacy Data for Beagle Dog (Male and 
Female Combined). 
Dose  # of 
Doses 
Study 
Duration 
Cumulative 
AUC 
Control 
Decorporation 
(%) 
Total 
Decorporation 
(%) 
Decorporation 
Increase (%) 
100 1 7 85865 29.24 54.13 24.89 
300 1 7 246279 29.24 63.78 34.54 
500 1 7 640563 29.24 72.16 42.92 
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Figure A.1 Prediction of increase in decorporation over control from cumulative AUC in 
rats 
 
Figure A.2 Prediction of increase in decorporation over control from cumulative AUC in 
dogs 
 
 
  
EC50 = 15,490 ng∙hr/mL 
Emax = 24.75 % 
EC50 = 83,274 ng∙hr/mL 
Emax = 47.79 % 
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Table A.4 C2E2 plasma concentrations following administration of ten oral doses of 200 
mg/kg in both male and female rats. 
Male Female 
ID Day Time C2E2 Conc. ID Day Time C2E2 Conc. 
B29700 1 0.25 1140 B29752 1 0.25 888 
B29701 1 0.25 462 B29753 1 0.25 1000 
B29702 1 0.25 889 B29754 1 0.25 830 
B29703 1 1 740 B29755 1 1 550 
B29704 1 1 1340 B29756 1 1 580 
B29705 1 1 492 B29757 1 1 615 
B29700 1 3 357 B29752 1 3 196 
B29701 1 3 294 B29753 1 3 347 
B29702 1 3 461 B29754 1 3 215 
B29703 1 6 134 B29755 1 6 BQL < 100 ng/ml 
B29704 1 6 BQL < 100 ng/ml B29756 1 6 BQL < 100 ng/ml 
B29705 1 6 167 B29757 1 6 BQL < 100 ng/ml 
B29700 1 12 BQL < 100 ng/ml B29752 1 12 242 
B29701 1 12 137 B29753 1 12 149 
B29702 1 12 127 B29754 1 12 BQL < 100 ng/ml 
B29703 1 24 BQL < 100 ng/ml B29755 1 24 BQL < 100 ng/ml 
B29704 1 24 BQL < 100 ng/ml B29756 1 24 BQL < 100 ng/ml 
B29705 1 24 BQL < 100 ng/ml B29757 1 24 BQL < 100 ng/ml 
B29700 10 0.25 6590 B29752 10 0.25 856 
B29701 10 0.25 1050 B29753 10 0.25 5640 
B29702 10 0.25 1250 B29754 10 0.25 1820 
B29703 10 1 663 B29755 10 1 639 
B29704 10 1 507 B29756 10 1 602 
B29705 10 1 468 B29757 10 1 1330 
B29700 10 3 277 B29752 10 3 228 
B29701 10 3 347 B29753 10 3 203 
B29702 10 3 332 B29754 10 3 246 
B29703 10 6 119 B29755 10 6 BQL < 100 ng/ml 
B29704 10 6 104 B29756 10 6 BQL < 100 ng/ml 
B29705 10 6 135 B29757 10 6 104 
B29700 10 12 BQL < 100 ng/ml B29752 10 12 134 
B29701 10 12 464 B29753 10 12 BQL < 100 ng/ml 
B29702 10 12 112 B29754 10 12 166 
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Table A.5 C2E2 plasma concentrations following administration of ten oral doses of 400 
mg/kg in both male and female rats. 
Male Female 
ID Day Time C2E2 Conc. ID Day Time C2E2 Conc. 
B29700 1 0.25 1350 B29752 1 0.25 2580 
B29701 1 0.25 1150 B29753 1 0.25 47600 
B29702 1 0.25 2960 B29754 1 0.25 2270 
B29703 1 1 1160 B29755 1 1 3290 
B29704 1 1 912 B29756 1 1 2130 
B29705 1 1 1490 B29757 1 1 9490 
B29700 1 3 915 B29752 1 3 226 
B29701 1 3 607 B29753 1 3 1740 
B29702 1 3 686 B29754 1 3 592 
B29703 1 6 150 B29755 1 6 243 
B29704 1 6 204 B29756 1 6 154 
B29705 1 6 196 B29757 1 6 387 
B29700 1 12 147 B29752 1 12 162 
B29701 1 12 118 B29753 1 12 396 
B29702 1 12 201 B29754 1 12 224 
B29703 1 24 BQL < 100 ng/ml B29755 1 24 213 
B29704 1 24 208 B29756 1 24 144 
B29705 1 24 362 B29757 1 24 BQL < 100 ng/ml 
B29700 10 0.25 1020 B29752 10 0.25 3670 
B29701 10 0.25 1730 B29753 10 0.25 7280 
B29702 10 0.25 1890 B29754 10 0.25 8000 
B29703 10 1 1200 B29755 10 1 4040 
B29704 10 1 957 B29756 10 1 3280 
B29705 10 1 1650 B29757 10 1 2060 
B29700 10 3 512 B29752 10 3 410 
B29701 10 3 819 B29753 10 3 567 
B29702 10 3 779 B29754 10 3 731 
B29703 10 6 266 B29755 10 6 167 
B29704 10 6 321 B29756 10 6 199 
B29705 10 6 264 B29757 10 6 185 
B29700 10 12 145 B29752 10 12 160 
B29701 10 12 370 B29753 10 12 199 
B29702 10 12 172 B29754 10 12 189 
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Table A.6 C2E2 plasma concentrations following administration of ten oral doses of 800 
mg/kg in both male and female rats. 
Male Female 
ID Day Time C2E2 Conc. ID Day Time C2E2 Conc. 
B29711 1 0.25 5110 B29763 1 0.25 12500 
B29712 1 0.25 3670 B29764 1 0.25 19500 
B29713 1 0.25 4020 B29765 1 0.25 9140 
B29714 1 1 4670 B29766 1 1 16000 
B29715 1 1 6710 B29767 1 1 14000 
B29716 1 1 5640 B29768 1 1 14300 
B29711 1 3 2650 B29763 1 3 1900 
B29712 1 3 989 B29764 1 3 4190 
B29713 1 3 955 B29765 1 3 1290 
B29714 1 6 478 B29766 1 6 419 
B29715 1 6 589 B29767 1 6 459 
B29716 1 6 322 B29768 1 6 280 
B29711 1 12 219 B29763 1 12 226 
B29712 1 12 210 B29764 1 12 191 
B29713 1 12 251 B29765 1 12 179 
B29714 1 24 112 B29766 1 24 167 
B29715 1 24 106 B29767 1 24 280 
B29716 1 24 BQL < 100 ng/ml B29768 1 24 141 
B29711 10 0.25 46800 B29763 10 0.25 33700 
B29712 10 0.25 3880 B29764 10 0.25 32300 
B29713 10 0.25 5250 B29765 10 0.25 5040 
B29714 10 1 6770 B29766 10 1 2900 
B29715 10 1 12100 B29767 10 1 3940 
B29716 10 1 7360 B29768 10 1 8320 
B29711 10 3 3930 B29763 10 3 2460 
B29712 10 3 3210 B29764 10 3 1150 
B29713 10 3 1980 B29765 10 3 1920 
B29714 10 6 561 B29766 10 6 428 
B29715 10 6 744 B29767 10 6 407 
B29716 10 6 328 B29768 10 6 358 
B29711 10 12 393 B29763 10 12 296 
B29712 10 12 314 B29764 10 12 260 
B29713 10 12 275 B29765 10 12 208 
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Table A.7 C2E2 plasma concentrations following administration of a single oral dose of 
2000 mg/kg in both male and female rats. 
Male Female 
ID Day Time C2E2 Conc. ID Day Time C2E2 Conc. 
B29711 1 0.25 32900 B29763 1 0.25 25700 
B29712 1 0.25 15500 B29764 1 0.25 51300 
B29713 1 0.25 21600 B29765 1 0.25 52000 
B29714 1 1 25100 B29766 1 1 37400 
B29715 1 1 18600 B29767 1 1 19000 
B29716 1 1 28600 B29768 1 1 17300 
B29711 1 3 15000 B29763 1 3 43300 
B29712 1 3 14100 B29764 1 3 16500 
B29713 1 3 5160 B29765 1 3 13900 
B29714 1 6 1360 B29766 1 6 1170 
B29715 1 6 1960 B29767 1 6 3300 
B29716 1 6 989 B29768 1 6 1410 
B29711 1 12 592 B29763 1 12 2440 
B29712 1 12 1200 B29764 1 12 710 
B29713 1 12 653 B29765 1 12 601 
B29714 1 24 1420 B29766 1 24 467 
B29715 1 24 1350 B29767 1 24 383 
B29716 1 24 683 B29768 1 24 303 
 
Table A.8 C2E2 plasma concentrations calculated for a 600 mg/kg dose of C2E2 in rats. 
Data represents the median normalized plasma concentrations from 200, 400, 800 and 2000 
mg/kg doses in Tables 6.4 – 6.7.  
Male Female 
Time C2E2 Conc. Time C2E2 Conc. 
0.25 3150 0.25 7710 
1 2235 1 3990 
3 1169 3 968 
6 398 6 313 
12 236 12 243 
24 84 24 133 
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Table A.9 C2E2 plasma concentrations following administration of a single oral dose of 
100 mg/kg in both male and female dogs. 
Male Female 
ID Time C2E2 Conc. ID Time C2E2 Conc. 
H04377 0.5 11800 H04379 0.5 12500 
H04378 0.5 32200 H04380 0.5 35100 
H04377 1 27900 H04379 1 18100 
H04378 1 51900 H04380 1 41300 
H04377 2 14400 H04379 2 20100 
H04378 2 30300 H04380 2 23700 
H04377 4 3520 H04379 4 2940 
H04378 4 6380 H04380 4 5490 
H04377 6 833 H04379 6 654 
H04378 6 2110 H04380 6 926 
H04377 8 337 H04379 8 377 
H04378 8 580 H04380 8 325 
H04377 12 BQL < 100 ng/ml H04379 12 BQL < 100 ng/ml 
H04378 12 141 H04380 12 284 
H04377 24 BQL < 100 ng/ml H04379 24 BQL < 100 ng/ml 
H04378 24 BQL < 100 ng/ml H04380 24 BQL < 100 ng/ml 
 
 
Table A.10 C2E2 plasma concentrations following administration of a single oral dose of 
300 mg/kg in both male and female dogs. 
Male Female 
ID Time C2E2 Conc. ID Time C2E2 Conc. 
H04377 0.5 16700 H04379 0.5 34400 
H04378 0.5 90100 H04380 0.5 86100 
H04377 1 23300 H04379 1 79600 
H04378 1 126000 H04380 1 138000 
H04377 2 21800 H04379 2 59700 
H04378 2 122000 H04380 2 93400 
H04377 4 5110 H04379 4 7090 
H04378 4 21700 H04380 4 21200 
H04377 6 1140 H04379 6 854 
H04378 6 4150 H04380 6 4050 
H04377 8 393 H04379 8 204 
H04378 8 1190 H04380 8 947 
H04377 12 238 H04379 12 129 
H04378 12 990 H04380 12 180 
H04377 24 BQL < 100 ng/ml H04379 24 BQL < 100 ng/ml 
H04378 24 223 H04380 24 123 
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Table A.11 C2E2 plasma concentrations calculated for a 500 mg/kg dose of C2E2 in 
dogs.  
Male Female 
ID Time C2E2 Conc. ID Time C2E2 Conc. 
H04377 0.5 83500 H04377 0.5 192000 
H04378 0.5 199000 H04378 0.5 106000 
H04377 1 78200 H04377 1 179000 
H04378 1 285000 H04378 1 345000 
H04377 2 113000 H04377 2 184000 
H04378 2 171000 H04378 2 359000 
H04377 4 24600 H04377 4 19800 
H04378 4 24700 H04378 4 76800 
H04377 6 3280 H04377 6 1770 
H04378 6 3900 H04378 6 9280 
H04377 8 785 H04377 8 344 
H04378 8 1130 H04378 8 2140 
H04377 12 1360 H04377 12 BQL < 100 ng/ml 
H04378 12 281 H04378 12 657 
H04377 24 BQL < 100 ng/ml H04377 24 BQL < 100 ng/ml 
H04378 24 160 H04378 24 189 
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